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6Aim of the thesis
Viruses with oncogenic or oncomodulatory properties are known agents of onco-
genesis. Human Cytomegalovirus (HCMV) infection has been associated with sev-
eral cancers, such as colon cancer and glioblastomas. At least one of the HCMV-en-
coded viral G-protein coupled receptors (vGPCRs), US28, has been shown, strongly 
dependent on the cellular context, to induce proliferative and anti-apoptotic signal-
ing. The other vGPCRs; UL33, UL78, and US27 are not as well described, although 
UL33 has been demonstrated to display constitutive signaling. Multiple signaling 
pathways are engaged by US28, and the proliferative behavior is the result of the 
integration of these pathways. This thesis aims to gain more understanding of the 
molecular mechanisms by which HCMV-encoded GPCRs induce this proliferative 
phenotype. 
First, the signal transduction pathways activated by US28, involving the Janus ki-
nase/Signal transducer and activator of transcription (JAK/STAT)-axis and interleu-
kin-6 (IL-6) induced activation of STAT3 have been investigated in detail (Chapter 3). 
Next, the nature of the IL-6/STAT3 positive feedback loop was investigated using a 
systems biology approach (Chapter 4).  In Chapter 5, US28-induced non-canonical 
signaling through the b-catenin pathway is explored. An characterization of  the 
signalosome in Chapter 6 has resulted in a proposed model that may explain the 
mechanism by which US28 induces Tcf/Lef activation.  One of the other vGPCRs, 
UL33, also displays constitutive signaling and its potential for proliferative signaling 
is explored in Chapter 7. 
Understanding the molecular mechanism by which HCMV exerts its oncomodula-
tory effects, is key to further understand the fundamental mechanisms in tumor 
biology. This holds true, especially for the first steps in transformation and the role 
that aberrant signaling may play in it. Furthermore, the complex nature of US28-in-
duced signaling clearly highlights the importance of a systems biology approach to 
understand the interplay between the different induced pathways.
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Introduction to virally encoded GPCRs
Adapted from:
Herpesvirus-encoded GPCRs rewire cellular signaling
Erik Slinger, Ellen Langemeijer, Marco Siderius, Henry F. Vischer, Martine J. Smit.
Molecular and Cellular Endocrinology, 2010
Leiden/Amsterdam Center for Drug Research, Division of Medicinal Chemistry, Fac-
ulty of Sciences, VU University Amsterdam, De Boelelaan 1083, 1081 HV Amster-
dam, the Netherlands.
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Figure 1. Models showing examples of the different modes of signaling by GPCRs. Signaling through Gαq  results 
in activation of phosphotadyl-inositol-3-kinase (PI3K). Subsequently, PLC is activated which results in activation 
of Ca2+ stores which activates the transcription factors (eg. NFAT). Activation of Gαi inhibits adenylate cyclase 
(AC) which lowers cyclic-adenosine-mono-phosphate (cAMP) levels. In contrast, Gαs induces AC activation, 
increasing cAMP levels. Signaling through Gα12/13 results into activation of RhoA via RhoGEF. Finally, G-protein 
independent signaling via β-arrestin involves scaffolding of the kinases MKK4, JNK3, and Ask1 on β-arrestin.
1.1 G-protein coupled receptors Human and viral chemokine receptors
G-protein coupled receptors (GPCRs) constitute a diverse family of membrane 
receptors which can be activated by ligands varying from light (as in rhodopsin) to 
proteins (e.g. the chemokine receptors). Despite being activated by such a variety 
of ligands, these receptors show a high degree of structure similarity. The GPCR 
superfamily can be divided into 3 major groups (1). The family A receptors, the 
largest family, contains the Rhodopsin-like GPCRs which are named after their 
prototypical receptor. The chemokine receptors belong to this family. The Secretin-
like GPCRs constitute the family B receptors, which are often regulated by peptide 
ligands. The glucagon receptor is a member from this family. Finally, there are 
the family C GPCRs which includes the metabotropic glutamate receptors, GABAB 
receptors, and the taste receptors amongst others. The GPCRs constitute the most 
abundant family of signaling proteins encoded by the human genome (2). Because 
of their importance in cellular signaling and relative ease of access, the GPCRs have 
been an important drug target for the last decades with over 30% the currently 
marketed drugs targeting a GPCR (3).
Almost all GPCRs are composed of 7 transmembrane (TM) domains, and generally 
couple to hetero-trimeric G-proteins resulting in a plethora of cellular responses 
to receptor activation (4). GPCRs contain a number of conserved sites that are 
necessary for GPCR functionality. For example, the DRY motif located in TM3 
controls coupling of the receptor to G-proteins. Mutations in these residues can 
result in constitutive activity (eg. VRY for the chemokine receptor CXCR2 (5)). 
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1Conversely, other mutations can render a constitutive active receptor inactive (eg. DAY for US28 (6)). The G-proteins are composed of three constituents; the α, β, and 
γ subunits, of which the α subunit is the most variable and determines for a great 
part downstream signaling. However, the β and γ subunits were found to modulate 
downstream signaling. Figure 1 shows several different signaling pathways being 
activated by different Gα subunits: Gαq, Gαs, Gα12/13 and Gαi. For example, Gαq 
signaling typically activates phospholipase C b (PLCβ) signaling which in turn will 
activate Ca2+ signaling which then culminates in the activation of Nuclear Factor 
of Activated T-cells (NFAT). On the other hand, signaling via Gαi typically inhibits 
adenylyl cyclase which subsequently results in reduced cyclic-adenosine-mono-
phosphate (cAMP) levels. In contrast, Gαs signaling is translated in increased 
activation of adenylyl cyclase. Finally, signaling via Gα12/13 results in activation of 
RhoGEF, subsequently leading to RhoA activation and further downstream signaling. 
Once the receptor has been activated by a ligand, G-protein coupled receptor 
kinases (GRK) phosphorylate serine residues in the C-terminal tail. Upon C-tail 
phosphorylation, signaling through the G-proteins ceases. Subsequently, β-arrestins 
may bind to the phosphorylated GPCR and interact with clathrin and AP2, driving 
GPCR internalization into endosomes where the receptor is either recycled to the 
plasma membrane or degraded in lysosomes (7).
While most receptors are thought to activate only one pathway at a time this is not 
necessarily the case. It is possible for a GPCR to simultaneously activate multiple 
pathways resulting in GPCR-mediated promiscuous signaling. Furthermore, 
while GPCRs typically only signal upon binding of an agonist, some GPCRs show 
constitutive activity. Virally encoded GPCRs are especially known to display such 
behavior. In recent years another aspect of GPCR signaling has become apparent, 
G-protein independent signaling. In this type of GPCR-mediated signaling β-arrestin 
acts as a scaffold for Mitogen-activated protein kinases (MAPK) which then results 
in activation of c-Jun N-terminal kinase 3 (JNK3) (8). Another novel concept in 
GPCR signaling is ligand-directed signaling, where different ligands yield different 
responses upon binding to the receptor. Other names have been suggested for 
this behavior, including functional selectivity, biased agonism, agonist-directed 
trafficking, or protean agonism (9).
1.2 The chemokines and chemokine receptors
The mammalian chemokine (the name is derived from chemotactic cytokines) 
signaling system is composed of small protein ligands (the chemokines with a size 
around 8-10 kD) that bind and activate chemokine receptors. Together, chemokines 
and chemokine receptors are important mediators of the immune system. 
Chemokine nomenclature is based on conserved cysteine motifs and the chemokine 
family can be subdivided into 4 families, the CCL, CXCL, XCL and CX3CL. In this system, 
the chemokines themselves are noted with a ‘L’ at the end and the receptors with 
a ‘R’ at the end.  As some chemokines activate multiple chemokine receptors the 
chemokine / chemokine receptor system is believed to be promiscuous (Figure 2). 
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Figure 2. Schematic depiction of the 
chemokine/chemokine receptor system. 
Shown in blue are the different CXC-receptors 
with their respective ligands. Depicted in 
green are the CC-receptors and corresponding 
ligands. Finally, the viral receptors that are 
discussed in this review are shown in red with 
their ligands (if known). The XC-receptor and 
CX3C-receptor are also shown in yellow and 
orange, respectively.
The superfamily of chemokines is currently composed of at least 46 members, the 
majority of which belongs to either the CCL or the CXCL family. The XCL and CX3CL 
families only have two and one member, respectively (10).
The main function of chemokines, as the name suggests, is to attract cells to sites of 
inflammation. The different chemokines bind different kinds of cells, as each type of 
cell expresses distinct subsets of chemokine receptors. The CCL chemokines attract 
a variety of cells from the immune system, whereas the CXC chemokines mainly 
attract neutrophils and lymphocytes. Furthermore, the CXC chemokines possess 
angiomodulatory activity. The combination of these angiomodulatory properties 
and their homing response renders the CXC chemokines to be of special interest 
in tumor growth as well as in metastasis. Notably, in breast cancer, the combined 
effects of e.g. CXCR4 and CXCL12 are of importance for tumor development (11). 
Chemokine receptors are not only expressed in leukocytes, but are also present 
on cells that are of a non-hematopoietic origin such as endothelial cells and 
neurons (12). Furthermore, several of the CXC receptors have been reported to be 
associated with several tumors (9). This is not unexpected considering the observed 
angiomodulatory properties of some of the CXC chemokines described above. 
Mammalian viruses have evolved multiple strategies to evade or subvert the host’s 
immune system. Members of the Herpesviridae family are particularly successful 
in this respect, with some of them capable of achieving life-long infections in up to 
90% of the general population. To be able to do this, several host genes have been 
‘hijacked’ in the course of evolution by these viruses. This ‘hijacked’ genetic material 
includes genes encoding chemokines and chemokine receptors. The receptors and 
chemokines thus obtained have been severely modified and optimized for the virus’s 
own benefit. Furthermore, these receptors often exhibit unique characteristics, 
such as receptors that show promiscuous binding of ligands and constitutive 
activity. The last years some of these vGPCRs have shown to be involved in virus-
associated pathologies, by ‘rewiring’ the cellular signaling network, not only in the 
11
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1
Figure 3. Methods by which the different viruses take over cellular signaling. Showing from the left to the right; 
ORF74 activating IL-6 transcription in a PI3K and Akt dependent manner. BILF1 displays constitutive Gαi signaling 
and downregulates PKR and MHC1. When forming dimers with endogenous chemokine receptors it may show 
negative binding cooperativity
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cells expressing vGPCRs but also affecting neighboring cells by inducing secretion 
of different signaling factors. Examples of such signaling pathway subversions by 
vGPCRs are described in this thesis, and are also shown in Figure 3.
1.3 Kaposi Sarcoma associated herpes virus (KSHV) 
KSHV or HHV8 is a γ-herpesvirus that was first identified in AIDS patients in the 
1980’s, when frequent occurrences of the usually rare Kaposi sarcoma (KS) were 
reported (13). The virus is endemic in Africa, with infection rates of over 50% in 
Central Africa, whilst infection rates in the rest of the world are much lower 
(between 0.2% and 10%). Currently three different variants of KS are recognized. 
Classic KS occurs mainly in Mediterranean men over the age of 50, and the lesions 
do not typically spread beyond the extremities. Endemic KS is common in particular 
parts of Africa. In Uganda, for example, KS accounts for up to 9% of the cancers. 
Finally, there is AIDS-associated KS, which was found initially predominantly in 
AIDS-affected patients, a particularly aggressive and often fatal variant of KS. In all 
the variants KS is characterized by highly vascularized lesions (14). Moreover, KHSV 
is found in nearly 100% of tumor isolates from patients. KSHV is also associated with 
primary effusion lymphoma and multicentric Castleman disease (15, 16).
The double stranded DNA genome of KSHV encodes 84 open-reading frames (17) 
and 12 microRNAs (miRNAs) (18). Open-reading frame 74 encodes a vGPCR, also 
referred to as ORF74. ORF74 is a close homologue of CXCR2 and binds multiple 
chemokines, particularly those of the CXC family, which is indicative for a role in 
the avoidance of the host immune system by KSHV. In addition, ORF74 displays 
12
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constitutive activity, which has been correlated with oncogenesis in vitro and in 
vivo (19, 20). Furthermore, transgenic mice expressing ORF74 develop KS-like 
lesions (21, 22). Host cell signal transduction pathways activated by ORF74 include 
MAPKs, PLC, phosphoinositide-3-kinase (PI3K), and Akt (23). ORF74 has also been 
shown to activate NF-κB via PI3K and Akt. Moreover, the activation of NF-κB by 
ORF74 is accompanied by the release of inflammatory cytokines (24).  The CXCL8 
and CXCL1 chemokines act as (partial) agonists for ORF74 (25). In contrast, CXCL10 
and CXCL12 act as inverse agonists (26, 27). Furthermore, ORF74 induces IL-6 
release in infected cells, in the aforementioned manner via NF-κB. Subsequently, 
IL-6 triggers VEGF production both in a paracrine as well as autocrine manner (24). 
Moreover, KSHV encodes a viral IL-6 homologue (vIL-6) that may further strengthen 
inflammatory responses in the infected cells (28). Increased IL-6 levels induced by 
ORF74 produce an inflammatory environment that has been shown to promote 
transformation of cells and formation of tumors (29). IL-6 secretion and subsequent 
para- or autocrine activation of the JAK/STAT axis are thought to play an important 
role in these processes (30, 31). Interestingly, stimulation of cells neighboring the 
IL-6 producing cells may also induce an epigenetic switch, turning a transient event 
into a permanent change in phenotype of the affected cells, which has recently 
been described by Iliopoulos et al. (32) in a breast cancer model.
Only a small amount of the tumor cells in KS is actually KSHV positive in early KS. In 
later stages of the disease, more than 90% of the tumor cells are KSHV positive (16). 
In the latter case, only a small subset actually displays a gene expression profile 
typical for the lytic phase, including ORF74 expression (33). Although ORF74 is 
not the only oncogenic determinant in KSHV, this observation is striking. A small 
number of ORF74 expressing cells can alter the behavior of the surrounding tumor 
cells via paracrine signaling by inducing the production of factors like IL-6. Such 
a feed-forward mechanism creates an inflammatory environment that may be an 
important factor in KSHV related cancers. Indeed, for many cancers an inflammatory 
milieu promotes tumor development, and such tumor-associated inflammation may 
also invoke feed-forward mechanisms (34). However, the molecular mechanism 
how ORF74 accomplishes this, remains to be elucidated.
1.4 Epstein-Barr Virus (EBV)
EBV or HHV4 is another lymphotropic virus involved in proliferative diseases. This 
γ-herpesvirus was first identified in the 1960’s. It infects over 90% of humans and 
persists during lifetime. Infection with EBV usually occurs by contact with oral 
secretions, causing infectious mononucleosis, also known as kissing disease. The 
virus replicates in cells in the oropharynx. B cells in the oropharynx are the primary 
site of infection and resting memory B cells are thought to be the site of persistence 
of EBV within the body. Shedding of EBV from the oropharynx is abolished in 
patients treated with acyclovir, whereas the number of EBV infected B cells in the 
circulation remains the same as before treatment (35).
13
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1EBV-related diseases are B cell- and epithelial cell-specific diseases, namely Burkitt’s lymphoma, Hodgkin’s lymphoma and nasopharyngeal carcinoma (36). All 
these diseases are particularly common in immune-suppressed patients like HIV-
infected patients and recipients of organ or bone marrow transplants. Immune-
compromised patients have impaired T-cell immunity and are unable to control the 
proliferation of EBV-infected B cells. EBV may play a pathogenic role in several other 
lymphoproliferative diseases and tumors in which EBV DNA or proteins have been 
detected as well.
The EBV genome consists of a linear DNA molecule that encodes approximately 
94 ORFs or viral proteins. During viral replication, these proteins are important for 
regulation of the expression of viral genes, replicating viral DNA, forming structural 
components of the virion, and modulating the host immune response. Of the almost 
100 viral genes that are expressed during replication, a small subset is expressed 
in latently infected B cells in vitro. Two types of non-translated RNA, six nuclear 
proteins, and two membrane proteins are expressed in these latently infected B 
cells (37). 
Like KSHV, the EBV genome also contains a single viral GPCR, BILF1, a gene 
specifically expressed in the lytic phase of the viral replication cycle. BILF1 presents 
(low) homology to chemokine receptor CXCR4, a chemokine receptor known to 
be involved in many cancers (11). In contrast with ORF74 from KSHV, BILF1 does 
not seem to display oncogenic properties in vitro (unpublished observations Smit 
et al). Attempts that were undertaken so far to deorphanize BILF1 have not been 
successful. However, downstream signaling by BILF1 can be studied as this receptor, 
like other vGPCRs, signals in a constitutive manner through Gai (38, 39). It has been 
suggested that EBV may use BILF1 to control Gai-activated pathways during viral 
lytic replication, thereby affecting disease progression (38). 
The function of BILF1 has also been examined in the context of immune evasion. 
Expression of BILF1 constitutively inhibits the phosphorylation of RNA-dependent 
protein kinase (PKR) (39). Upon viral infection, PKR is phosphorylated and activated, 
causing the overall cellular translational machinery to stop, thereby prohibiting viral 
replication (40). This mechanism serves to prevent viral spreading by elimination of 
the infected cells. Thus, the inhibition of PKR by BILF1 may help EBV by preventing a 
cellular antiviral response. Moreover, Zuo et al. showed recently that BILF1 reduces 
the levels of MHC class I at the cell surface of epithelial and melanoma cells (41). 
Targeting these molecules for lysosomal degradation, results in impaired recognition 
by immune T cells. Together with two other EBV lytic cycle genes BGLF5 and BNLF2A, 
BILF1 is the third gene in a group that cooperates to interfere with MHC class I 
antigen processing. This underscores the importance of the need for EBV to be able 
to evade CD8+ T cell responses during the lytic replication cycle. The effect on MHC 
class I degradation is independent of constitutive BILF1 signaling functions and the 
molecular mechanisms are distinct. It involves physical association of BILF1 with 
MHC class I molecules, an increased turnover from the cell surface, and enhanced 
degradation via lysosomal proteases (41). 
14
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In addition to the above mentioned immune-escape mechanisms, viral GPCRs may 
also affect the properties of human receptors by means of receptor oligomerization 
and/or cross-talk between downstream signaling pathways. GPCR proteins 
can physically interact, thereby modifying intracellular signaling and cellular 
functions (42). B lymphocyte migration and function is controlled by chemokines, 
acting on their cognate receptors. Using bioluminescence resonance energy 
transfer (BRET), time-resolved fluorescence resonance energy transfer (trFRET) 
and co-immunoprecipitation techniques, we recently have shown that BILF1 
heterodimerizes with various chemokine receptors endogenously expressed in B 
lymphocytes. The oligomerization of BILF1 with chemokine receptors involved in 
B lymphocyte migration may change the receptors responsiveness to chemokines, 
resulting in altered homing and homeostasis of infected B lymphocytes. This might 
be an essential step for EBV dissemination or in EBV-induced pathogenesis in general 
(43). Negative binding cooperativity of both cognate chemokines and small drug-like 
compounds has been shown for CCR2/CCR5 and CCR2/CXCR4 chemokine receptor 
heterodimers (44). Since BILF1 is still an orphan GPCR, such binding cooperativity 
cannot be investigated at this moment. On the other hand, the active conformation 
of the constitutive active BILF1 may affect the function of partnering receptors in a 
hetero-oligomer, as previously shown for other GPCR dimers (45). As BILF1 seems to 
play a role in preventing the immune system from clearing the virus from the body, 
this may present an extra venue that can be targeted in treatment of EBV infection. 
Furthermore, a study by Kledal et al. has shown that BILF1 may display oncogenic 
signaling (46), which suggests a possible role for BILF1 in the development of EBV-
related cancers.
1.5 Human Cytomegalovirus (HCMV)
Another member of the Herpesviridae family and β-herpesvirus subfamily is 
HCMV (HHV-5). HCMV is widely present among the general population, with up to 
90% of the individuals harboring a latent infection (47). While HCMV infection is 
asymptomatic in immune-competent individuals, it can cause severe pathologies in 
immune-compromised patients (48). HCMV infection during pregnancy can result 
in aberrant development of the unborn child resulting in, for example, hearing loss 
(49, 50). Furthermore, HCMV infection has been correlated to several pathologies, 
such as arthrosclerosis (51).
HCMV proteins, DNA, and mRNA have been detected in multiple tumors that, 
together with epidemiological data, suggest a role for HCMV in cancer (52, 53). 
Furthermore, HCMV preferably infects cancer cells (54). However, unlike KSHV and 
EBV, HCMV is not considered an oncogenic virus and it is unlikely that HCMV by itself 
can act as an oncogenic factor. Alternatively, HCMV may have an oncomodulatory 
role, to catalyze an oncogenic process that has already been initiated.
The HCMV genome is the largest of any human virus known thus far, being 236 kb 
in size. The genome can be divided into two parts, a long and short part named 
UL and US, respectively. Also, a number of miRNAs have been found to be present 
15
Introduction to vGPCRs
1on the HCMV genome (55). In contrast with KSHV, the HCMV genome encodes four vGPCRs: US27, US28, UL33, and UL78. All of these genes encode chemokine 
receptor homologues, indicating that they were most likely pirated from the 
human -or another mammalian- genome at some point during evolution (56, 57). 
Homologues of UL33 and UL78 are conserved throughout the β-herpesvirus family, 
whereas homologues of US28 and US27 have been identified only in primate CMVs 
closely related to HCMV. Furthermore, two chemokines have been pirated from the 
human genome, vCXC1 and vCXC2 (58). 
Only US28 has been shown to bind to chemokines, and has been most intensively 
studied. US28 binds promiscuously to several different members of the CC family, 
including CCL5 and CCL2, and also binds CX3CL1. Upon binding of chemokines, 
US28 is rapidly internalized, reflecting a possible function as a chemokine sink in 
the viral life cycle (59). Like ORF74 and BILF1, US28 displays constitutive signaling, 
activating PLCβ and NF-κB (60) as well as NFAT and CREB (61) via Gαq and Gαi. 
The constitutive signaling through CREB has been found to play a role in the 
regulation of the viral genome, specifically by stimulating the immediate-early 
gene promoter (62). Signaling via Gα12 results in SMC migration (63). Interestingly, 
US28 has been shown to possess tumorigenic properties when expressed in a NIH-
3T3 murine fibroblast cell line, upregulating VEGF production and Cyclin D1. In a 
mouse xenograft model, tumors were formed when US28 expressing NIH-3T3 cells 
were injected (64). Further investigation revealed that release of PGE2 via US28-
induced NF-κB activation of COX2 results in the activation of VEGF and Cyclin D1. 
This signaling cascade can be perturbed using pharmacological inhibitors of COX2 
(eg. Celecoxib) (65). These data suggest a role of US28 in HCMV-related cancers that 
may be reminiscent of ORF74’s role in KSHV, with the important distinction that 
HCMV, and thus US28, are probably not direct causative agents. However, as stated 
above, US28 most likely has an oncomodulatory role. This is strongly suggested 
by the observations that in many cell lines prolonged US28 expression results in 
apoptosis (66), indicating an interference of US28 in critical signaling pathways 
which, depending on cellular context results in either proliferation or apoptosis. 
It remains to be seen whether US28 also induces a local environmental change 
reminiscent of ORF74, but the US28-induced release of PGE2 and IL-6 suggests such 
a possibility. The fact that NF-κB is activated by US28 supports this notion, since NF-
κB is known to induce the secretion of inflammatory factors. 
Another vGPCR encoded by HCMV is UL33, which has been shown to signal in a 
constitutive manner via Gαq, Gαi, and Gαs (67). UL33’s mouse homologue M33 has 
a function in viral dissemination within the host. Interestingly, a ΔM33 MCMV (viral 
strain lacking expression of M33) strain can be complemented with UL33, which 
suggests that UL33 may serve a role in the HCMV life-cycle (68). Supporting such 
a role for UL33 in HCMV is the presence of UL33 on the virion itself (69). Although 
US28 has never been detected in the viral envelope, there are indications that 
this is also the case. For instance, the rhesus macaque CMV homologue RhUS28.5 
has been found in the viral envelope (70). Furthermore, the envelope proteins gB 
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and gH have been found to co-localize with US28 (71). In Chapter 7 we show that 
infected cells bind CCL5 directly after infection, well before any US28 has been 
synthesized from the viral genome. Presence of vGPCRs on the viral particle likely 
enhances binding to target cells, considering that US28 recognizes the membrane-
bound chemokine CX3CL1 (72). However, in experiments in vitro with viral strains 
lacking either US28 or UL33 (ΔUS28 and ΔUL33, respectively) no reduced infectivity 
was observed (73). Of note, in vitro there is no real necessity for viral dissemination 
and UL33 would not be necessary. The biochemical properties of the remaining 
two vGPCRs, US27 and UL78, remain thus far largely uncharacterized. US27 has 
been shown to localize on the plasma membrane as well as in endosomes (71). The 
mouse and rat homologues of UL78, M78 and R78 respectively, have been shown 
to contribute to efficient viral cell-cell spread (74, 75). Interestingly, UL33 and UL78 
have been shown to be able to form heterodimers with US28, which inhibits US28-
induced activation of NF-κB, while induction of inositol phosphate accumulation 
was not affected (76). 
It is clear that US28 and its constitutive activity may rewire cellular signaling and 
by this means play a potential role in HCMV-related pathologies. However, the 
exact signaling pathways involved still remain to be resolved. This will be critical for 
further understanding of HCMV-mediated oncomodulatory effects. Since US28 and 
UL33 are expressed at different times during the viral cycle (77), their expression will 
most likely modulate distinct signaling pathways at different times post infection.
1.6 Conclusions
The chemokine system, responsible for immune responses and as such an important 
mediator of the mammalian defense system against invasion of pathogens, has 
been corrupted by several β-herpesviruses. These viruses have hijacked and 
subverted many of the components of the chemokine system, both the ligands as 
well as the receptors. Although the three herpesviruses described above all have 
hijacked chemokine receptors, the role these vGPCRs play in the viral life cycle 
and the impact they have on host cell’s signaling differs widely. Figure 3 depicts 
the different ways virus-encoded chemokine receptors take over signaling in 
their respective target cells. KSHV’s ORF74 induces NF-κB signaling via PI3K and 
its downstream kinase Akt, resulting in IL-6 release and the establishment of an 
inflammatory environment, beneficial for tumorigenesis. EBV’s BILF1 appears to be 
mainly involved in immune avoidance, which is demonstrated by both the hijacking 
and subversion of both the PKR and the MHC1 signaling pathways. In addition, 
BILF1 may act as a chemokine receptor scavenger, possibly modulating chemokine 
receptor affinity for their ligands by means of negative binding cooperativity. This 
is in contrast with ORF74 and US28, that both negatively influence the immune 
system by binding the chemokines themselves. The HCMV encoded vGPCR US28 
has been shown -at least in a specific cellular context- to be able to induce a 
proliferative phenotype. US28 may exert this effect by creating a pro-inflammatory 
microenvironment by activation of COX2 expression leading to PGE2 production. 
17
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1Furthermore, by modulating signaling through ROCK via Gα12, US28 is also able to promote smooth muscle cell migration. In cells without Gα12, US28 cannot induce 
migration further underlining the importance of cellular context.
In the cases described above, cellular signaling networks have been rewired to the 
benefit of the virus. In some cases radical alterations of cellular signaling can have 
unforeseen consequences and may result in or aggravate a transformed phenotype. 
To further understand the molecular basis behind the mechanisms described above 
we investigated signaling pathways induced by the HCMV-encoded GPCR US28. In 
this thesis two more US28-induced signaling pathways are described: STAT3 and 
β-catenin. Therefore a general background of these two pathways is given in the 
next chapter.
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2.1 Oncogenic signaling pathways
The development of cancer is dependent on the aberrant regulation of cell cycle 
regulation and apoptosis (1). Understanding the signaling pathways that govern 
growth, anti-growth and apoptosis is therefore paramount for understanding can-
cer development. In the case of this thesis we restricted ourselves to two different 
signaling pathways, JAK/STAT and β-catenin signaling. These two pathways came to 
our attention as a result of an angiogenesis array and a micro-array analysis, respec-
tively. Therefore, an introduction and more details about both pathways is given 
below. Additionally, VEGF signaling and regulation will be discussed.
2.2 The JAK/STAT axis
2.2.1 The JAK and STAT family proteins
The signal transducers and activators of transcription (STAT) are important media-
tors of growth factor and cytokine-directed signaling. There are 7 members of STAT 
family known to date, STAT1, STAT2, STAT3, STAT5A, STAT5B, and STAT6 (2). The dif-
ferent STATs, their ligands and some of their target genes are shown in Table 1. The 
receptors generally responsible for STAT activation are composed of multiple sub-
units. They consist of receptor subunits that actually bind to the ligand (eg. IL-6) and 
the gp130 subunit that interacts with Janus kinases (JAK).  Ligand binding results 
in receptor dimerization which results in activation of JAK which, in turn results in 
phosphorylation and dimerization of STAT (Figure 1). The resulting STAT-dimer sub-
sequently translocates to the nucleus where it engages its respective target genes. 
The receptor complex consist of, as mentioned above, multiple subunits which can 
form different functional receptors. For example, the IL-6 receptor complex is com-
posed of the IL-6-Receptor (IL-6R) and two gp130 subunits. The other receptors 
belonging to this family form a similar complex. They always contain the gp130 in 
combination with different ligand-recognizing subunits (3). However, activation of 
JAK/STAT is not limited to the cytokine receptors, as GPCRs can also directly acti-
Table 1. STAT protein family members with examples of their respective ligands and target genes.
STAT family member Ligands Target genes References
STAT1 IFNα,β, and γ Inflammatory and pro-apoptotic factors (eg. 
IL-12, caspases)
(1)
STAT2 IFNα and β Inflammatory and pro-apoptotic factors (eg. 
CD80)
(1)
STAT3 IL-5, IL-6, IL-10, IFNγ and 
LIF
Anti-apoptotic, proliferation inducing, an-
giogenic, and inflammatory. (eg. VEGF, Cy-
clin D1, IL-6)
(2-6)
STAT4 IL-12 and IL-23 IFNγ (1)
STAT5A/STAT5B IL-2, IL-7, IL-15, GM-CSF, 
IL-3, IL-5, and growth hor-
mones
Anti-apoptotic, proliferation inducing. (eg. 
Cyclin D2, BCL-XL)
(7)
STAT6 IL-4 and IL-13 Anti-apoptotic (eg. BCL-2) (1)
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vate the JAK/STAT axis. The chemokine receptor CXCR4 was shown to do just this. 
Upon stimulation with CXCL12, CXCR4 associates with JAKs within minutes, which 
then results in phosphorylation of STAT1, 2, and 3 (4). The JAK family encompasses 
four members; JAK1, JAK2, JAK3, and Tyk2. These proteins have a molecular mass 
between 120 and 140 kD. 
JAK1 
JAK1 first was identified in a PCR-based screening for novel kinases (5), and was 
shown to associate with IL-2 and IL-6 receptors. Other cytokine-mediated respons-
es for which JAK1 is critical are those triggered by interferon, IL-4, and IL-10. When a 
receptor is activated, the JAKs are recruited to the receptor and phosphorylate each 
other, a process that is also known as transphosphorylation. Of note, this can occur 
between two different JAKs (eg. JAK1 and JAK3). This was shown by Witthuhn et al. 
using the IL-2 receptor. They observed that using kinase-dead JAK1 and a wild-type 
JAK3 resulted in phosphorylation of JAK1 but not JAK3. However wild-type JAK1 
was not capable of phosphorylating kinase-dead JAK3 (6). This suggests that the 
transphosphorylation between different JAK-pairs may be time-dependent, requir-
ing one of the JAKs to be phosphorylated first (2). 
JAK2  
The second member of the JAK family is JAK2, which mediates response to IL-3, 
erythropoietin (Epo), and GMCSF among others. Being involved with erythropoi-
etin and GMCSF suggest an important role in hematopoiesis. This was confirmed 
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Figure 1. General structure of cytokine receptors and STAT-family proteins. (A) Shown are 7 conserved domains 
present in all proteins of the STAT-family: the amino-terminal (NH2), coiled-coil, DNA-binding domain (DBD), linker 
(LK), SH2, tyrosine phosphorylation site (in black with the phospho-group depicted in green), and the transcrip-
tional activation domain (TAD). (B) Model showing the basic layout of a cytokine receptor, using the IL-6 receptor 
as an example. The IL-6R subunit is the actual IL-6 sensing unit, while the gp130 subunits bind to JAK. Upon ligand 
binding the receptor complex recruits STAT3 which then becomes phosphorylated and dimerizes. Subsequently the 
STAT3-dimers translocate to the nucleus where they activate their target genes.
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with the generation of JAK2 knockout mice that die of anemia during embryogen-
esis. In the case of erythropoietin, the erythropoietin receptor (EpoR) recruits two 
JAK2 proteins upon activation which subsequently transphosphorylate each other. 
This was demonstrated using EpoR-dihydrofolate reductase (DHFR) chimeras that 
resulted in a receptor that only had DHFR functionality when the two parts of the 
enzyme were in close proximity. Using fluorescently labeled methotraxate, which 
binds to DHFR, the conformational change of the EpoR upon binding Epo resulted 
in fluorescence (7).
JAK3  
The third member, JAK3, is an important mediator of IL-2 signaling. The IL-2-recep-
tor is composed of 3 chains, a, b, and g. JAK3 interacts exclusively with the g-chain. 
The g-chain is also a key component of other receptors, such as IL-4, IL-7, IL-9, IL-
15, and IL-21 (2). In contrast to JAK1 and JAK2, where knockout mice die during 
embryogenesis, JAK3 knockout mice are viable. However, these mice display im-
mune deficiencies. Interestingly, human mutations in JAK3 have been described, 
and these cases show severe combined immune deficiency  (SCID). Individuals with 
mutated JAK3 completely lack T-cells and NK-cells leaving them effectively without 
a functioning immune system (8).
Tyk2  
The fourth and last member of the JAK kinases is Tyk2. This kinase interacts with 
receptors responding to interferon (IFN) type I cytokines, as well as cytokines from 
the IL-6, IL-10, IL-12, and IL-23 families (2). Unlike the other JAKs, Tyk2 knockout 
mice do not show a pronounced phenotype, other than a slight defect in interfer-
on-α and β response (9). Humans exhibiting mutations in Tyk2 show a somewhat 
more severe phenotype with increased susceptibility to viral, bacterial, and fungal 
infections (10). 
The STAT proteins have a size of about 80 kD, and contain seven conserved domains 
shown in Figure 5A. An example of cytokine receptor composition (in this case the 
IL-6 receptor with STAT3) is shown in Figure 5B.  The SH2 domain of these proteins 
is of special interest, as this domain is critical for the formation of dimers. Upon 
phosphorylation the SH2 domain binds to the phosphorylated tyrosine of another 
STAT molecule, resulting in the formation of an anti-parallel dimer (2, 11). Activated 
STAT dimers typically bind to GAS sites (TTTCCNGGAAA), STAT1-STAT2 heterodimers 
are an exception and bind to ISRE (AGTTTN3TTTCC) sites instead. 
STAT1  
The first STAT protein to be identified, and was first discovered as an ISRE binding 
factor. STAT1 is mainly involved in IFN signaling, being activated by IFNα, β, γ, λ, and 
ω. Two splice variants of STAT1 exist, a full length STAT1α of 91 kD, and a truncated 
isoform STAT1β having a molecular mass of 84 kD (12). Tyrosine phosphorylation of 
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Y701 is essential for dimerization. 
STAT1 is an important factor in the immune system, having a key role in the defense 
against bacterial and viral infection. STAT1 is generally thought of as an anti-prolif-
erative and pro-apoptotic factor, as evidenced by the inhibition of cell growth (13) 
and induction of caspase expression (14). Moreover, induction of apoptosis by IL-21 
is dependent on STAT1, involving STAT1 target genes such as BIK, NIP3, and HARA-
KIRI (15). Also, STAT1 potentiates p53 activity, either by inhibiting Mdm2 expression 
(16) or by promoting p53 activation (17). This, and data from experiments showing 
increased tumor incidence in STAT1 knock-out mice, as well as the observation that 
STAT1 expression is diminished in several cancers (18, 19), cause STAT1 to be regard-
ed as a tumor suppressor.
Interestingly, STAT1 was shown to be activated by the EBV protein LMP1 in Burkitt’s 
lymphoma. This STAT1-activation is indirect, driven by constitutive NF-κB activation 
by LMP1 resulting in the induction of IFNs that subsequently activate STAT1 (20, 
21). However, it is not entirely clear how STAT1 is exactly involved in EBV-associated 
cancers.
STAT2  
The largest STAT protein, with a size of 113 kD, it is also the most mysterious one. 
While STAT2 has been shown to be essential for IFNα and β signaling, the existence 
of STAT2 homo-dimers remains to be demonstrated (2). Thus far, STAT2 has only 
been shown to possess transcriptional activity when forming a hetero-dimer with 
STAT1 (2). Consequently, it shares quite a lot of the signaling characteristics (e.g. 
target genes, receptors) with STAT1. However, in contrast with STAT1 and the other 
STAT proteins, except for STAT6, STAT2 does not possess a serine phosphorylation 
site (22).
Despite the large overlap with STAT1-associated signaling, STAT2 appears to have 
a specific signaling role, as was shown by analysis of STAT2 genetic polymorphisms 
in humans which indicate that STAT2 may play a role in the development of asth-
ma (23). Furthermore, the HCMV protein immediate early gene 1 (pUL123) inhibits 
STAT2-mediated IFN signaling (24), further indicating a key role for STAT2 in IFN 
signaling.
STAT3  
Originally, STAT3 was identified as the down-stream effector of IL-6 (25). However, 
since its first identification STAT3 has been recognized to mediate signaling for a 
wide variety of ligands. Among the activating ligands are the IL-6 and IL-10 cytokine 
families, as well as IFNγ (26, 27).  Dimerization is controlled by phosphorylation of 
Y705. It also features a serine phosphorylation at S727 (22). Like STAT1, STAT3 is dif-
ferentially phosphorylated depending on the upstream receptor, thyroid stimulating 
hormone (TSH), for example, induces both Y705 and S727 phosphorylation, while 
IFNγ results in Y705 phosphorylation but not in S727 phosphorylation (28). In the 
case of TSH, the S727 phosphorylation is associated with STAT3 inactivation. Serine 
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phosphorylation of STAT3 is not as well defined as it is for STAT1. Nevertheless, stud-
ies have shown that stimulating the TrkA receptor with nerve growth factor (NGF) 
induces STAT3 phosphorylation at S727 but not at Y705. Interestingly, despite being 
only phosphorylated at S727, STAT3 still displays DNA binding (29). Moreover, con-
stitutively active mutant TrkA, which acts as an oncogene, still induces STAT3 phos-
phorylation at S727. In both cases, serine phosphorylation of STAT3 is mediated by 
p44/p42 as was demonstrated by treating cells with the MEK1/2 inhibitor U0126, 
which inhibited STAT3 phosphorylation at S727 (29, 30). Serine phosphorylation 
of STAT3 does not appear to be only function as a transcriptional activator, it also 
serves to target STAT3 to a role in the cell’s metabolism. Reconstitution experiments 
in murine STAT3-/- pro-B cells showed that STAT3 is required for full mitochondrial 
activity. Moreover, the S727 phosphorylation was shown to be critical for this func-
tion, while the Y705 phosphorylation was not required. Co-immunoprecipitation 
experiments indicated that STAT3 is present inside the mitochondria existing in both 
mitochondrial protein complex I and II (31). 
Mutants of STAT3 that display constitutive activity have been found in solid tumors 
and lymphomas (32, 33). As mentioned above, target genes of STAT3 include genes 
that promote proliferation, such as the Cyclin D1 gene. Another important feature 
that highlights STAT3’s importance in cancer development is its control over VEGF 
expression. In multiple cases, STAT3 directly drives VEGF expression (34). For exam-
ple, STAT3 activation promotes brain metastasis of melanoma, which is accompa-
nied by STAT3 driven VEGF expression (35). 
Interestingly, expression of IL-6 is induced by STAT3 activation (36), which allows for 
a positive feedback loop, which is an interesting possibility considering the possibil-
ity of induction of IL-6 production by viruses like HMCV (37) or KSHV (38) with the 
latter even producing a viral variant of IL-6 (39). STAT3’s propensity towards prolifer-
ation and survival can be explained by the role that inflammation is thought to have 
in cancer development. Moreover, mitochondrial STAT3 has an important function 
in regulating cellular respiration (31), and has been shown to support Ras depen-
dent transformation (40). As mentioned earlier, an inflammatory environment may 
provide an environment that promotes transformation and survival of transformed 
cells. For example, liver cancer often arises from chronic hepatitis (41), and stomach 
cancer is strongly associated with chronic gastritis (42). 
STAT4  
Originally STAT4 was discovered via its homology with STAT1. STAT4 is a 86 kD pro-
tein, which plays a critical role in IL-12 and IL-23 signaling. IL-12 signaling through 
STAT4 is key for differentiation of lymphocytes into Th1 cells (2). Furthermore, STAT4 
also mediates activation of NK cells by IL-12. An important STAT4 target gene is IFNγ.
Like STAT1 and STAT3, STAT4 is also phosphorylated both on tyrosine (Y694) and 
serine (S722) residues. Phosphorylation of S722 is required for STAT4-induced IFNγ 
production, and is mediated by p38 (43). Because of the role of IL-12 and IL-23 in 
immune-modulation STAT4 is mainly associated with auto-immune diseases and al-
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lergies (44, 45), although there may also be a role for STAT4 in tumor development 
as IL-23 is over-expressed in various human cancers (46).
STAT5a and STAT5b  
These two STATs are actually tandem genes that both show high homology to Dro-
sphila STAT (dSTAT). Together with STAT3, STAT5a and 5b are the closest homologues 
to this primordial STAT. The different mammalian STATs are thought to have evolved 
from a single STAT by gene duplication, of which STAT5a and 5b are the most recent 
examples (47). Consequently, both STAT5 isoforms mediate signaling for a variety of 
ligands and as such display a diverse functionality ranging from lymphoid develop-
ment (48) and hematopoeisis (49) to lactogenesis (50) and growth (51).
Like most of the other STAT proteins, both STAT5a and STAT5b undergo serine phos-
phorylation (S726 and S731, respectively) separately from tyrosine phosphoryla-
tion (Y694 and Y699, respectively). While STAT5a and STAT5b show high sequence 
similarity and are largely functionally redundant, they possess different signaling 
capabilities. For example, STAT5a mediates prolactin signaling, while STAT5b is re-
sponsible for transducing signaling upon stimulation with growth hormone (2, 50). 
Consistent with these signaling differences, STAT5 serine phosphorylation also dif-
fers for the two isoforms. STAT5a phosphorylation at S726, is controlling STAT5a 
activity upon stimulation with prolactin (52). On the other hand, S731 phosphoryla-
tion of STAT5b is associated with EGF signaling (53).
Both 5a and the 5b isoforms are associated with several cancers, which is consistent 
with their role in development and proliferation. Breast cancer cells require STAT5a 
for anchorage-independent growth and survival, while suppressing cell motility as 
was shown by overexpression of constitutive active STAT5a and knockdown exper-
iment using siRNA. In contrast, nor overexpression of constitutive active STAT5b or 
downregulating expression with siRNA, showed any significant change in survival 
and proliferation or motility (54). While STAT5b may not play an important role in 
breast cancer, there are indications that it has a role in supporting renewal of leuke-
mia stem cells (55). Also, both isoforms have been shown to be required for survival 
and growth of prostate cancer cells, although STAT5b appeared to be more import-
ant in this case of survival as was demonstrated with siRNA experiments (56).
STAT6  
The final member of the STAT-proteins, STAT6, is a 94 kD protein transducing signals 
for IL-4 and IL-13. It is involved in T-cell differentiation as well as regulating B-cell 
proliferation and maturation. IL-4 and IL-13 are related proteins, and this is reflect-
ed by sharing of receptor components (57). According to the role that IL-13 plays in 
the defense against parasites, mice that are deficient for STAT6 are rendered more 
susceptible to infection of the parasite Mesocestoides corti. Furthermore, IL-13 is 
also reported to have an inhibitory effect on cancer surveillance. The latter was 
shown using a recurrent-tumor model in transgenic mice that were deficient in ei-
ther STAT6, IL-4, IL-13 or IL-4Rα. In this model the mice that did not express STAT6, 
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IL-13 or the IL-4Rα were more resistant against tumor recurrence, while the IL-4 
knockout mice did not gain any resistance against tumor formation (58).
Interestingly, both EBV and KSHV influence STAT6 signaling. In the case of EBV STAT6 
signaling is hijacked to drive LMP-1 expression. Either IL-4 or IL-13 are capable of 
inducing LMP-1 expression, even in the absence of EBNA-2 which is normally re-
quired for LMP-1 expression (59). The KSHV encoded protein LANA inhibits STAT6 
transcriptional activity by preventing IL-4-induced STAT6 phosphorylation at Y641, 
effectively blocking B-cell activation (60).
2.2.1 Regulation of STAT mediated signaling
Normally, signaling by STAT-proteins, characterized by both a rapid onset and decay, 
is a transient event. As described earlier, STATs translocate to the nucleus upon ac-
tivation, which already starts within minutes after stimulating the cell with a ligand. 
However, within a few hours after stimulation the STAT proteins will have been ex-
pelled from the nucleus. Negative regulation of signaling through the JAK/STAT axis 
can be subdivided into three main categories.
Phosphatases 
Phosphorylation of STATs is essential for dimerization and signaling, and conse-
quently phosphatases are an important mechanism of downregulation. STAT de-
phosphorylation is governed by multiple phosphatases, among which are SHP-2 
and TC-PTP (61).
Regulation by nuclear import/export 
STAT dimers are quite large, consisting of 2 ~80 kD subunits, while nuclear ac-
cumulation is rapid. Considering that only ions and proteins smaller than 40 kD 
can enter nucleus freely (62), it follows that this is an active process and is there-
fore subject to regulation. The transcriptional activity of the STAT proteins is 
controlled by subcellular localization and until the cell is stimulated with a li-
gand, the balance is towards nuclear export. However, when the cells are stim-
ulated by a ligand, the balance rapidly shifts towards nuclear import and then 
as the signal decays, again towards nuclear export. To this end the STATs con-
tain multiple nuclear export sequences (NES), as well as nuclear localization 
sequences (NLS). This also means that the total amount of STATs does not real-
ly change in the cell upon activation, but rather their subcellular localization. 
The SOCS protein family 
The family of Suppressor Of Cytokine Signaling (SOCS) proteins are essential com-
ponents of immune regulation, as excessive or untimely activation of inflammatory 
pathways can result in auto-immunity, chronic inflammation or even septic shock. 
An example of the latter is the strong induction of cytokines by lipopolysaccharide 
(LPS), from Gram-negative bacteria (63). The SOCS proteins are defined by the pres-
ence of a conserved SOCS box domain in the C-terminus. The SOCS box functions as 
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a binding site for E3 ligase which targets for ubiquitin-induced degradation. Another 
conserved domain, is the SH2 binding domain. The SH2 binding domain recognizes 
tyrosine phosphorylation within specific motifs (64). For example, SOCS1 recogniz-
es activated JAKs and down-regulates signaling by the JAK/STAT axis (65). Other 
SOCS-proteins that can down-regulate JAK/STAT signaling are SOCS3 (66), SOCS4, 
and SOCS5 (67).
The mechanisms described above are responsible for the correct signaling, and 
considering the potential for an out of control positive feedback loop (eg. IL-6 and 
STAT3) the need for tight regulation is clear.
While STAT3 activation normally is tightly controlled via the mechanisms described 
above, in a transformed cellular background parts of this control can be lost. For 
example, epigenetic silencing of SOCS3 has been correlated to prostate cancer ag-
gressiveness (68). Furthermore, overexpression of SOCS3 in human non-small cell 
lung cancer cells resulted in growth inhibition and increased sensitivity to radiation 
(68). Cells with an impairment of SOCS3 functionality may more likely evoke a det-
rimental IL-6 positive feedback-loop that was mentioned before. 
In the context of oncomodulatory viruses conditional activation of positive feed-
back loops may have interesting implications. A virally infected cell itself does not 
need to be transformed, as viral proteins can elicit secretion of factors that can 
affect cells in a paracrine fashion. In such a case only a small fraction of a tumor 
needs to express the protein in question as is seen in KSHV (69) and for US28 (70).
It is clear that the STAT proteins have a pivotal role in controlling cell survival, prolif-
eration, and apoptosis. Therefore, it is not surprising that many of the STAT proteins 
are involved in cancer development be it as an oncogen or in the role of a tumor 
suppressor. In this light, subversion of STAT signaling by some of the viruses dis-
cussed earlier has the potential of instigating an oncomodulatory effect, especially 
considering the possibility of paracrine signaling and the initiation of positive feed-
back loops. 
2.4 Wnt/β-catenin signaling
Another pathway that is activated by US28 is the Wnt/β-catenin pathway.
The Wnt signaling pathway is an evolutionary conserved pathway that is present in 
virtually all multicellular creatures. Even the most simple multicellular organisms, 
the placozoans, possess a functional Wnt signaling pathway (71). As such, Wnt sig-
naling is a key component in the development of many organisms, and was also 
first discovered as an important factor in Drosphila melanogaster development. 
Consistent with the complex nature of Wnt signaling, there are many Wnt ligands. 
Moreover, signal transduction triggered by Wnt is accomplished via complex signal-
ing routes. Wnt ligands typically initiate signaling by binding to Frizzled receptors, 
which are GPCRs, as shown in Figure 2, although other receptors also have been de-
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scribed. The canonical Wnt/Frizzled pathway utilizes the transcription factor β-cat-
enin, which is normally degraded by the destruction complex (72). Subsequently, 
free β-catenin activates genes regulated by Tcf/Lef, such as Cyclin D1 (73) and VEGF 
(74). Following their key role in development, which requires precise control of cell 
proliferation, survival, and apoptosis, aberrant Wnt signaling has been associated 
with cancer development in humans, in particular colon cancer (75-77).
The Wnt ligands
To date, 19 different Wnt proteins have been identified. Considering that they are 
secreted, these glycoproteins have a relative large size, with a molecular mass of 
around 40 kD. The different human Wnt ligands are listed in Table 2, with their char-
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Figure 2. Model showing canonical Wnt signaling. Upon activation by a Wnt ligand Frizzled and LRP5/6 desta-
bilize the destruction complex that is composed of Axin, APC and GSK3β that normally targets the transcription 
factor β-catenin for proteosomal destruction. The destruction complex is inhibited by recruitment of Axin by the 
activated receptor complex, as well as inhibition of GSK3β activity via G-protein mediated activation of Akt. The 
free non-phosphorylated β-catenin can then translocate to the nucleus and together with Tcf/Lef activate its target 
genes. An example of non-canonical signaling is signaling via RhoA which then activates the kinases ROCK and JNK. 
Both ROCK and JNK can subsequently induce cytoskeletal rearrangements, and JNK also activates the transcription 
factor c-JUN which, together with AP1, can activate target genes.
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acteristics and, if known, associated diseases. The first mammalian Wnt ligand to be 
purified, because of its relatively efficient expression, was the murine homolog of 
Wnt3a (101).  Analysis revealed that Wnt3a is post-translationally N-glycosylated. 
In addition these proteins also undergo lipidations, like palmitoylations and acyla-
tions, which are thought to attribute to the general poor solubility displayed by Wnt 
proteins (93). Mutations to these residues result in impaired secretion and reten-
tion in the endoplasmic reticulum (S209 acylation) or reduced signaling capability 
(C77) (102). These observations, coupled with studies performed on the D. mela-
nogaster Wnt homolog wingless (Wg) instigated the hypothesis that Wnt proteins 
may be secreted linked to lipoprotein particles. Studies on Wg and its homolog in 
the nematode Caenorhabditis elegans, EGL-20, have resulted in a detailed under-
standing of Wnt biogenesis and secretion, displayed in Figure 3. The membrane 
protein Porcupine, which may possess acyltransferase activity, has been proposed 
to perform some of the acylations on Wnt (102, 103). 
Experiments performed on C. elegans identified a protein complex called the ret-
romer complex as an important mediator for Wnt signaling in Wnt producing cells. 
Using RNAi screening, a homolog of the yeast retromer subunit Vps35p was shown 
Table 2. The different Wnt ligands with their putative glycosylation sites and their respective associated dis-
eases
Wnt ligand Size (aa) Glycosylation sites Associated disease Refer-
ences
Wnt1 370 N29, N316, N346, N359 Breast cancer (79-81)
Wnt2 360 N295 Malignant glioma (82-85)
Wnt2b 391 N117, N283 Leukemia (86)
Wnt3 355 N90, N301 Tetra-amelia (87)
Wnt3a 352 N87, N298 Melanoma (88)
Wnt4 351 N88, N297 SERKAL syndrome and Müllerian-duct re-
gression
(89, 90)
Wnt5a 380 N114, N120, N312, N326 Pancreatic cancer (91, 92)
Wnt5b 359 N93, N99, N291, N305 Type 2 diabetes (93)
Wnt6 365 N86, N311 N/A
Wnt7a 349 N83, N127, N295 Fuhrmann syndrome (94)
Wnt7b 349 N83, N127, N295 N/A
Wnt8a 351 N103, N262, N281 N/A
Wnt8b 351 N103, N259 Gastric cancer (95)
Wnt9a 365 N103 N/A
Wnt9b 357 N99 N/A
Wnt10a 417 N106, N363 Odonto-onycho-dermal dysplasia (96, 97)
Wnt10b 389 N93, N335 Obesity, Split-hand/foot malformation (98, 99)
Wnt11 354 N40, N90, N160, N300, 
N304
Hepatocellular carcinoma (100)
Wnt16 365 N143, N189, N311 Leukemia (101)
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to be essential for EGL-20 mediated patterning in C. elegans development. Further-
more, C. elegans EGL-20 null mutants display a similar phenotype as Vps35 defi-
cient mutants, indicating a similar role in signaling. Further experiments showed 
that both in C. elegans as well as in mammalian cells Vps35 homologs are critical 
for Wnt ligand secretion (104). The retromer complex is composed of five subunits 
and is a mediator of protein trafficking between the endosomal compartment and 
the Golgi apparatus. Another protein that was determined to be indispensable for 
Wnt secretion is Wntless (Wls), Wls is a transmembrane protein that is localized to 
the Golgi and the plasma membrane and it can bind to the acylated residues of Wnt 
ligands, targeting it to the plasma membrane for secretion. Furthermore, the ret-
romer complex has a key role in recruiting Wls from endosomes to the Golgi (105). 
However, while this proposed model is elegant, it must be noted that all this data 
has been gathered for Wnt3a and its homologs. Caution is necessary for extrapolat-
ing these characteristics onto the other Wnt ligands, considering that they differ in 
the extent in amount of lipidation. Moreover, there is at least one Wnt ligand that 
does neither require Porcupine nor Wls for secretion (106).
As is shown in Table 2, the Wnt ligands mostly have a critical role in development 
and mutations in the ligands are usually associated with severe birth defects, like 
Tetra-amelia or Fuhrmann syndrome (86, 93). Up- or down-regulation of several of 
these ligands is associated with multiple cancers.
 Although there is clearly a specific role for each Wnt ligand, exactly which pathway 
is engaged by a Wnt ligand is not completely clear. Based on biological assays a sub-
division between canonical (ligands that primarily engage the canonical signal path-
way) and non-canonical (ligands that primarily signal via non-canonical pathways) 
ligands was made. In this subdivision Wnt1, Wnt3a, and both Wnt8s are considered 
canonical ligands, while Wnt5a and Wnt11 are thought of mainly activating non-ca-
nonical pathways. However, this classification of Wnt ligands is somewhat artificial 
as Wnt signaling is dependent on the cellular context. For example, Wnt5a activates 
Figure 3. Schematic represen-
tation detailing the currently 
proposed model for Wnt ligand 
biogenesis and secretion. Newly 
synthesized Wnt post-transla-
tionally modified in the endo-
plasmatic reticulum (ER), which 
among others, entails acylation 
by Porcupine. Subsequently, the 
acylated Wnt is recognized by 
Wntless. Wntless targets vesicles 
containing Wnt to the plasma 
membrane, where Wnt is secret-
ed into the extra-cellular milieu. 
The Wnt ligand then presumably 
clusters together into lipopar-
ticles. The retromer complex is 
responsible for recruiting Wntless 
from endosomes.
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canonical β-catenin signaling when the receptor Frizzled-5 is present (107). More-
over, Wnt5a and Wnt11 have been shown to form dimers that can induce β-catenin 
activation (108). These findings show that the Wnt ligands cannot be easily qualified 
as canonical or non-canonical.
The Frizzled receptors  
The cognate receptors for the Wnt ligands are 7 trans-membrane receptors, that 
share a similar structure with the GPCRs, which together form the family of Frizzled 
receptors. The Frizzled receptor family contains 11 members which are listed in 
Table 3. Because the Wnt ligands  are poorly soluble, and dependence on cellular 
context, the pharmacology of most of the receptors and their ligands are ill defined. 
In some cases the cell-type on which the receptor is present determines whether 
a Wnt ligand acts as an agonist or antagonist. Although this fits with the complex 
role these receptors play in development and embryogenesis, it also indicates that 
these receptors and their ligands have a complex interplay with each other. GPCR 
signaling in general can be complicated by their ability to form dimers. Frizzled re-
ceptors are no exception and to this and has been at least one report of a Frizzled 
receptor forming dimers (123).
Although the Frizzled receptors share the 7 trans-membrane architecture with the 
rest of the GPCRs, they constitute an unconventional class of GPCRs. The Frizzled 
receptors exhibit signaling characteristics that are unconventional among the GP-
CRs. For example, signaling through Disheveled/b-catenin is unique for this class of 
receptors (124). The smoothened receptor shares the structure of the other Friz-
zled receptors, but unlike the other receptors of this family, it does not appear to 
recognize a Wnt ligand. Instead it binds to protein ligands from the Hedgehog family 
that serve a similar role in body development as the Wnt ligands do. Smoothened 
Table 3. The Frizzled receptor family, with their respective ligands and mutant phenotype
Receptor name Size (aa) Wnt ligand Mutant phenotype References
Frizzled-1 647 Wnt1, 2, 3a, 5a, 7b N/A (110, 111)
Frizzled-2 565 Wnt5a N/A (112)
Frizzled-3 666 Wnt3a N/A (113)
Frizzled-4 537 Wnt1, 2, 3a Criswick-Schepens syn-
drome
(114-116)
Frizzled-5 585 Wnt5a N/A (108)
Frizzled-6 706 Wnt4 N/A (117)
Frizzled-7 574 Wnt3 Loss of embryonic stem 
cell self-renewal
(118, 119)
Frizzled-8 694 Wnt3a, 5a, 5b, 9b N/A (120)
Frizzled-9 591 Wnt2 N/A (121)
Frizzled-10 581 Wnt1, 8 N/A (122)
Smoothened 787 No known Wnt ligand. 
Binds Hedgehog instead
N/A (123)
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can signal via both Gαi and Gα12/13 (125, 126). 
Another set of receptors that play a pivotal in Wnt signaling are LRP5 and 6. These 
receptors form a complex together with Frizzled en Wnt. Subsequently LRP5/6 
are phosphorylated by the kinases CK1 and GSK3β (127). The phosphorylation of 
LRP5/6 creates a docking site for Axin, which is a critical component of the destruc-
tion complex (Figure 6). Other receptors that bind Wnt are structurally unrelated 
to the Frizzled receptors; the single transmembrane receptors from the Ryk and 
Ror families. Both these receptors seem to engage non-canonical signaling. The Ryk 
proteins have been reported to transduce signaling through the kinase Src in D. 
melanogaster (128). Experiments performed with mice deficient for the Ror family 
member Ror2, have shown that Ror2 signaling involves Rho-GTPases, and, further 
downstream, JNK (129).
The Frizzled receptors do not exclusively bind Wnt ligands, a multitude of other 
factors have been described. For example, a small family of ligands known as the 
R-spondins have been shown to activate canonical signaling via the Frizzled recep-
tors (130).
Key component of Wnt-signaling: β-catenin  
The transcriptional regulator β-catenin has a pivotal role in Wnt signaling. It is a 88 
kD protein, it is characterized by the presence of so-called armadillo repeats, which 
are named after the D. melanogaster β-catenin homolog Armadillo. As mentioned 
before, β-catenin is normally rendered inactive by the destruction complex. The 
destruction complex is composed of four proteins, besides β-catenin itself: Adeno-
matous Polyposis Coli (APC), Axin CK1, and GSK3β. These four proteins all perform 
a different role in β-catenin regulation, as is shown in Figure 6. While APC and Axin 
act as a scaffold, CK1 kinases and GSK3β phosphorylate β-catenin (CK1 phosphor-
ylates at S45, and GSK3β at S33, S37, and T41), targeting it for ubiquitination, and 
subsequent proteasomal degredation. Highlighting β-catenin’s role as a powerful 
regulator of cell proliferation and survival, mutations in APC and Axin are associated 
with the development of cancer. Mutations in APC are known to be associated with 
cancer, especially colon cancer, with familial adenomateous polyposis as an import-
ant risk factor for developing colon cancer. Mutations in Axin, on the other hand, 
are associated with several other cancers, such as liver cancer and medullablasto-
ma. Stabilizing mutations in β-catenin have also been described to promote onco-
genesis, which is understandable, considering the importance of phosphorylation 
for regulating β-catenin abundance.
Activation of β-catenin is mediated by destabilizing the destruction complex, in-
creasing levels of cytoplasmic non-phosphorylated β-catenin. The free β-catenin 
subsequently translocates to the nucleus where it can transcriptionally activate ex-
pression of its target genes (eg. Cyclin D1). Disruption of the destruction complex is 
of key importance for activation of β-catenin. However, the exact molecular mech-
anisms triggering this event are not fully understood. There are currently three 
proposed models, starting with a model which involves Axin binding Disheveled 
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resulting in a conformational change in Axin disrupting the complex thus freeing 
β-catenin. In the second model, LRP5/6 are the main mediators of destruction com-
plex inhibition, by binding to Axin which subsequently results in disruption of the 
destruction complex. Finally, the last model entails inhibition of GSK3β, preventing 
β-catenin phosphorylation (131). These three possible models are not mutually ex-
clusive, and quite possibly happen in concert.
It is important to note that there are alternative pathways besides the canonical 
signaling of Frizzled receptors through β-catenin. For example, Frizzled can also sig-
nal via other pathways such as JNK and ROCK (Figure 6). Conversely, other GPCRs 
may activate β-catenin via alternative signaling routes. For example, stimulation of 
the EP2 and EP4 receptors with PGE2 results in the stablization and activation of 
β-catenin. In the case of the EP2 receptor this is effected by signaling via Gas and, 
further downstream, PKA which results in inhibition of GSK3b (132). The EP4 recep-
tor achieves b-catenin activation by PI3K dependent inhibition of GSK3b, a process 
which is dependent on Gaq activation (133). Additionally, Gas has been reported to 
be able to bind with the RGS domain of Axin, which also facilitates binding of APC to 
Axin (134, 135). This results in a loss of binding of GSK3b to Axin. In contrast to Gas, 
Gai is not capable of binding to Axin (134). 
The existence of these different pathways means that care must be taken when an-
alyzing b-catenin signaling, since autocrine and paracrine signaling through either 
the canonical or one of the non-canonical pathways may also signal at the same 
time through the same pathway.
2.5 VEGF signaling
α β
-2362 -1
PRE PRE PREERE AP-1 AP-1HIF STAT3 LXR Sp1
Sp3
Sp1
Sp3
AP-2 Egr
Figure 4. Architecture of the human VEGF promoter region. The response elements are indicated in differently 
colored shapes. The promoter region is approximately 2.5 kb in size. The different elements, and examples of 
stimuli are listed below:
Element Activated by Location
PRE Polycomb -1865/-1860, -716/-711, +679/+684
ERE Estrogen -1525/-1514
AP-1 Activating protein 1 -1168/-1015, +418/+425
HIF-1 Hypoxia-inducible factor -975/-968
STAT3 IL-6/Oncostatin -848/-850
LXR Liver-X receptor response element -317-302
Sp1/Sp3 Retinoic acid, TNFa -238/-233, -94/-89, -84/-79, -73/-68, -57/-52
AP-2 Activating protein 2 -79/-72
Egr Early growth response -77/-70
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Vascular endothelial growth factor (VEGF) is an important angiogenic factor, that 
specifically acts on endothelial cells. Currently, there are five VEGF isoforms known 
that are expressed from a single gene through alternative splicing. The VEGF gene 
constitutes 8 exons and the coding sequence is approximately 14 kb in size. The 
VEGF promoter region contains multiple consensus sites which tend to be well 
conserved between different species (Figure 4). The promoter region contains re-
sponse elements for Sp1/Sp3, AP-2, Egr-1, STAT3, and HIF1 (136). The presence of 
multiple response elements allows for signal integration from multiple pathways. 
For example, induction of VEGF expression in chronic myeloid leukemia (CML) is 
achieved through activation of Erk, JAK/STAT and PI3-kinase signaling (137). Factors 
that induce signaling through these pathways include TNF-a, PDGF, IL-1b, IL-6, Inter-
feron a, estrogen, and retinoic acid.
A STAT3 response element is located between -848 and -840 of the human VEGF 
promoter. This predicted site was experimentally confirmed to be a STAT3 re-
sponse site by chromatin immunoprecipitation experiments (34). Furthermore, ex-
periments where a dominant negative form of STAT3 was expressed resulted in a 
down-regulation of VEGF promoter activity. Conversely, a constitutive active form 
of STAT3 up-regulates VEGF promoter activity (138). In the context of cancer, STAT3 
activation by Oncostatin  and IL-6 has been shown to be an essential factor in the 
pathogenesis of glioblastoma (139) and cervical cancer (140). In both cases VEGF 
expression is induced by either ligand through the JAK/STAT axis.
Regulation of VEGF expression is controlled by multiple signaling pathways, and be-
cause of that complex. Many tumors exist in an inflammatory micro-environment. 
The presence of response elements that are associated with inflammatory signaling 
(e.g. Sp1/Sp3, STAT3, Liver-X-receptor, AP-1, AP-2) indicates that the presence of 
inflammation can induce VEGF production.
There are three VEGF receptors, VEGFR-1, VEGFR-2, and VEGFR-3. These receptors 
are all tyrosine kinase receptors and members of the PDGF receptor family. Re-
flecting their critical role in vasculogenesis, knock-out mice for any one of these 
receptors are not viable and die at different stages of embryonic development (141-
143). Upon binding to their respective VEGF ligand, VEGF receptors homo- or het-
erodimerize which results in receptor kinase activity, (auto)phosphorylation and, 
ultimately, downstream signaling. Signaling through VEGFR-2 has been extensively 
studied and plays a pivotal role in endothelial cell migration, differentiation, and 
survival. Activation of VEGFR-2 results in signaling through PLCg. Subsequently, 
MAPK becomes activated, promoting endothelial cell proliferation (144). PLCg also 
triggers calcium release, which in turn activates PKC pathways (145). These two 
pathways ultimately induce NFAT and EGR-1. Both these transcription factors are 
involved in effecting the angiogenic response in endothelial cells (146).
2.6 Conclusions
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In this chapter several oncogenic signaling were discussed: STAT3, b-catenin, and 
VEGF. Although there are of course more oncogenic pathways, investigation of 
US28-induced proliferation described in this thesis found that the HCMV-encoded 
viral GCPRs US28 and UL33 constitutively activate STAT3 and b-catenin. The next 
chapters will describe the molecular mechanisms underlying activation of STAT3 
and b-catenin by US28 in particular.
Of course, oncogenic signaling in general encompasses more pathways than the 
two pathways mentioned above. Additionally, the possibility of interplay between 
the different pathways adds greatly to the complexity of oncogenic signaling. By 
reducing complexity using model systems (Chapter 3 and 5) and constructing math-
ematical models, as described in Chapter 4, that give good approximations of the 
‘real world’ we can learn a great deal about the nature of oncogenic signaling path-
ways in different settings.
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3.1 Abstract
US28 is a viral G protein-coupled receptor encoded by the human cytomegalovirus 
(HCMV). In addition to binding and internalizing chemokines, US28 constitutively 
activates signaling pathways linked to cell proliferation. Here, we show increased 
concentrations of vascular endothelial growth factor (VEGF) and interleukin (IL)-
6 in supernatants of US28-expressing NIH-3T3 cells. Increased IL-6 was associated 
with increased activation of the signal transducer and activator of transcription 3 
(STAT3), through upstream activation of the Janus activated kinase JAK1. We used 
conditioned growth medium, IL-6-neutralizing antibodies, an inhibitor of the IL-6 
receptor, and shRNA targeting IL-6 to show that US28 activates the IL-6-JAK1-STAT3 
signaling axis to elicit a  positive feedback loop. This loop is initiated in an US28-de-
pendent manner through activation of the NF-κB transcription factor and the con-
sequent production of IL-6. Treatment of cells with a specific inhibitor of STAT3 in-
hibited US28-dependent [3H]-thymidine incorporation and foci formation, further 
suggesting a key role for STAT3 in the US28-mediated proliferative phenotype. US28 
also elicits STAT3 activation and IL-6 secretion in HCMV-infected cells. Analysis of 
tumor specimens from glioblastoma patients demonstrates co-localization of US28 
and phosphorylated STAT3 in the vascular niche of  these tumors. Moreover, in-
creased phospho-STAT3 expression correlated with poor patient outcome. Taken 
together, US28 induces proliferation via a novel signaling pathway, by establishing 
a positive feedback loop via activation of the IL-6/STAT3 axis, which defines a novel 
pathway activated in HCMV-infected tumors.
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3
3.2 Introduction
Human cytomegalovirus (HCMV), a member of the family of β-herpesviruses, is 
widespread, persisting as a latent infection in up to 90% of the population (1). Al-
though HCMV is asymptomatic in immunocompetent individuals, it may cause such 
pathologies as pneumonitis, hepatitis, and retinitis in immunocompromised hosts 
(1). Furthermore, HCMV has been proposed to promote the development of colon 
cancer (2) and malignant glioma (3). HCMV has also been detected as an active 
infection in several forms of cancer, including prostate cancer, colon cancer, and 
malignant glioblastoma. However, the exact role of HCMV as a promoting factor in 
these tumors remains elusive. HCMV-encoded proteins are thought to drive these 
processes either directly, through activation or inhibition of cellular signaling path-
ways, or indirectly, through induction of autocrine and paracrine signaling. One of 
the HCMV-encoded proteins, known to induce a proliferative and angiogenic phe-
notype in vitro and in vivo, is the viral chemokine receptor US28 (4). 
The presence of four G protein-coupled receptors (GPCR) that are structurally sim-
ilar to human chemokine receptors in the HCMV genome--US28, US27, UL33, and 
UL78-- (5, 6) is intriguing. Chemokine receptors are involved in regulation of the 
immune system (7), and have also been implicated in various aspects of oncogen-
esis (8). The HCMV-encoded GPCR US28, which is structurally similar to the human 
chemokine receptor CCR1 (9), has been studied most extensively (10). US28 binds 
various chemokines, including: CCL2, CCL5, and CX3CL1 (11), and may thereby sup-
press the host immune response  (12). In addition, US28 also signals constitutively 
and shows G-protein promiscuity, traits that enable it to hijack the host cell’s signal-
ing machinery (13).
Like chemokine receptors, viral GPCRs appear to play a role in oncogenesis and 
tumor growth (14, 15). Transgenic mice expressing ORF74, the chemokine receptor 
encoded by Kaposi sarcoma-associated herpesvirus (KSHV), develop lesions resem-
bling Kaposi sarcoma (16). Similarly, US28 induces various oncogenic responses, 
including increased cyclin D1 and cyclooxygenase-2 (COX2) production, as well as 
that of vascular endothelial growth factor (VEGF), when expressed in NIH-3T3 fi-
broblasts (4, 17). Moreover, US28 enhances HCMV-induced VEGF promoter activity 
and COX2 expression in HCMV-infected cells (4, 17), and promotes tumor formation 
in a mouse xenograft model (4, 17).
To investigate the molecular mechanism by which US28 contributes to oncogenesis, 
we analyzed US28-induced release of angiogenic factors. We used an antibody ar-
ray that recognized different chemokines, growth factors, and cytokines to identify 
factors secreted by US28-expressing NIH-3T3 cells. US28 increased the production 
of interleukin (IL)-6, which is induced by HCMV infection  (18, 19) and has been 
implicated in oncogenesis (20, 21). In addition, we identified a key role for the IL-
6-STAT3 (signal transducer and activator of transcription 3) axis in US28-mediated 
proliferative signaling. Our data thus reveal a positive feedback loop initiated by 
US28 that is crucial for the proliferative phenotype shown by US28-expressing cells. 
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3.3 Results
3.3.1 US28 increases the secretion of IL-6 and VEGF 
NIH-3T3 cells stably expressing US28 display oncogenic properties (4, 17). For in-
stance, injection of US28-transformed NIH-3T3 cells into nude mice results in tu-
mor formation  (4). Because angiogenic factors are required for formation of large 
tumors (22), we assessed their secretion by US28-expressing NIH-3T3 cells. We an-
alyzed conditioned medium from US28-expressing NIH-3T3 cells and compared it 
to that from mock-transfected NIH-3T3 cells using a mouse antibody array for an-
giogenic factors. The array analysis showed a marked increase in both IL-6 (296% ± 
3%) and VEGF (271% ± 45%) in medium from the US28-expressing cells (Fig. 1); the 
latter finding was consistent with earlier observations  (4). Medium concentration 
of CCL2, a chemokine that binds US28, was decreased  (13% ± 2%) (11), whereas the 
medium concentration of CCL11 and CXCL4, which do not bind US28, was unaffect-
ed. Because IL-6 has been implicated in oncogenesis (22, 23), we investigated the 
role of IL-6 in US28-induced proliferative signaling.
3.3.2 US28 induces STAT3 phosphorylation and STAT3-driven transcriptional acti-
vation 
IL-6 binds to its cognate receptor, the IL-6 receptor, to activate STAT3 signaling (24); 
therefore, we assessed the phosphorylation status of STAT3. Consistent with the 
observed increase in IL-6 concentration in the supernatant of stably US28-transfect-
ed cells, STAT3 phosphorylation was markedly increased in US28-expressing cells, 
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Figure 1. Increased IL-6 and VEGF secretion in US28 transfected cells. Medium from NIH-3T3 cells stably transfect-
ed with US28 was compared with medium obtained from mock transfected cells. Excreted cytokines and growth 
factors were analyzed using an antibody array. The mean result of three separate experiments is shown as a per-
centage of protein levels in US28 expressing cells compared to mock transfected cells. CCL2 secretion is significantly 
downregulated in US28 expressing cells (***p < 0.001) whereas IL-6 and VEGF secretion are both significantly 
upregulated (**p < 0.01).
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compared to mock-transfected cells (Fig. 2A). In contrast, no STAT3 phosphorylation 
was observed in cells stably transfected with the US28-R129A mutant, which fails to 
couple to G proteins  (25). Furthermore, a luciferase-based reporter assay showed 
that STAT3-driven transcriptional activation was increased in HEK293T transiently 
transfected with a plasmid encoding US28, but not in mock- or US28-R129A-trans-
fected cells (Fig. 2B). The presence of US28 in transfected HEK293T (Fig. 2C), and 
NIH-3T3 (Fig. 2D) cells was verified using [125I]-CCL5 binding. 
3.3.3 JAK1 and NF-κB mediate US28-induced STAT3 signaling 
Next, we used specific inhibitors to identify components of the signaling pathway 
leading from US28 to STAT3 activation (26, 27). We performed these analyses both 
in transiently-transfected HEK293T cells, in which we assessed STAT3 activity using 
STAT3 reporter gene assays, and in NIH-3T3 cells stably transfected with US28, in 
which we determined STAT3 phosphorylation using Western blot analysis. Over-
night treatment with 10 μM Pyridone-6 (P6, a pan-JAK inhibitor) inhibited STAT3-de-
pendent reporter gene activity by 51.6% ±1.5% in HEK293T cells transfected with 
US28 (Fig. 3A). In contrast, overnight exposure to several other kinase inhibitors [10 
μM AG-490 (JAK2 inhibitor), PP-2 (Src inhibitor), or Tyrene CR-
4 (Abl inhibitor)] failed to affect STAT3 signaling. Signaling through the Gαo family of 
G proteins has been described to activate STAT3 (28). Therefore, we assessed the 
effects on US28-induced STAT3 signaling of treating cells with 100 ng/ml of the Gαi/o 
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Figure 2. Increased STAT3 activity in NIH-3T3 and HEK293T transfected with US28. (A) STAT3 phosphorylation 
levels are increased in NIH-3T3 stably transfected with US28, whereas in the G-protein uncoupled mutant US28-
R129A shows no increased STAT3 phosphorylation. (B) In HEK293T cells, STAT3-driven transcriptional activation 
is only observed when the US28 wild-type receptor is expressed (**p < 0.01 compared to mock). (C) [125I]-CCL5 
binding to US28, displacement with 10-7 M CX3CL1 in HEK293T (**p < 0.01 compared to mock). (D) [125I]-CCL5 
binding to US28 and US28 R129A, displacement with 10-7 M CX3CL1 in stably transfected NIH-3T3 (**p < 0.01 for 
both wild-type and US28 R129A compared to mock).
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inhibitor pertussis toxin (PTX) and observed no significant effect on STAT3 reporter 
gene activity (Fig. 3A).  Because IL-6 production is enhanced by the transcription 
factor nuclear factor kB (NF-κB) (29, 30), which is constitutively activated through 
both Gαq and Gβγ in cells expressing US28 (12), we treated cells with the NF-κB 
inhibitor BAY11-7082 (31, 32). BAY11-7082 reduced the transcriptional activation of 
reporter genes by STAT3 78.7% (±4.2%) (Fig. 3A). 
We also assessed the effects of the kinase inhibitors P6, AG-490, and Tyrene on 
STAT3 phosphorylation in US28-expressing NIH-3T3 cells treated for 30 minutes 
with 10 μM of each inhibitor. We observed a strong reduction of STAT3 phosphory-
lation only after treatment with P6 (Fig. 3B), implicating JAK1 in mediating US28-de-
pendent STAT3 phosphorylation. 
3.3.4 US28 activates the IL-6-STAT3 axis in a paracrine and autocrine fashion
To assess whether US28 directly or in a paracrine or autocrine fashion, via activa-
tion of NF-κB, induces increased IL-6 production, we investigated the importance of 
US28-mediated IL-6 release in STAT3 activation. We observed a marked increase in 
STAT3 phosphorylation as assessed by Western blot analysis  in mock- and US28-ex-
pressing NIH-3T3 cells treated with 10 ng/ml IL-6 (Fig. 4A). Moreover, conditioned 
medium from US28-expressing NIH-3T3 cells induced STAT3 phosphorylation 
in both mock- and US28-R129A-transfected cells (Fig. 4B), whereas incubation of 
US28-expressing NIH-3T3 cells with a neutralizing antibody to IL-6 attenuated STAT3 
phosphorylation (Fig. 4C). Treatment of US28-expressing NIH-3T3 cells with 10 μM 
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Figure 3. US28 induced STAT3 phosphorylation and transcriptional activaty is mediated by JAK1. (A) STAT3-driven 
transcriptional activation was inhibited by treatment with 10 µM of Pyridone 6 (P6, pan-JAK kinase inhibitor) (**p 
< 0.01 compared to vehicle treated), whereas similar concentrations AG-490 (JAK-2 inhibitor), PP-2 (Src inhibitor), 
and Tyrene CR-4 (Abl inhibitor) had little or no effect. 100 ng/ml pertussis toxin (PTX) had no effect on STAT3 activa-
tion. The NF-κB inhibitor BAY11-7082 reduced STAT3-dependent reporter gene activation approximately 80% (**p 
< 0.01 compared to vehicle). (B) NIH-3T3 cells stably transfected with US28 were treated for 30 minutes with the 
different kinase inhibitors. Only 10 µM P6 inhibited STAT3 phosphorylation (~6% compared to vehicle treated cells).
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3
Madindoline-A, which inhibits the formation of gp130 homodimers and thereby sig-
naling of the IL-6Rα-gp130 complex  (33), completely inhibited US28-induced STAT3 
phosphorylation (Fig. 4D). 
To investigate the involvement of IL-6 in the US28-induced activation of STAT3 in 
HEK293T cells, we expressed shIL-6, the shRNA targeting and downregulating IL-6 
(23), in conjunction with the STAT3 reporter gene. Co-transfection of shIL-6 com-
pletely abolished US28-induced STAT3 transcriptional activity, whereas expression 
of scrambled shRNA (shEmpty) did notaffect STAT3 transcriptional activity (Fig. 4E). 
In contrast, co-transfecting shIL-6 with a NFAT (nuclear factor of activated T cells) re-
porter gene did not significantly alter US28-induced NFAT signaling (Fig. 4F). These 
results indicate that, in both HEK293T and NIH-3T3 cells, US28 induces IL-6 release, 
resulting in STAT3 activation by way of the IL-6Rα-gp130 complex.
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Figure 4. US28 induces a positive feedback loop 
involving IL-6 signaling. (A) Incubation with 10 ng/
ml IL-6 for 10 or 30 min elicits STAT3 phosphoryla-
tion in both mock- (~2500% and ~1800% compared 
to 0 minutes, respectively) and US28-transfected 
(~450% and ~500% compared to 0 minutes, re-
spectively) NIH3T3 cells. (B) Conditioned medium 
from NIH-3T3 cells transfected with US28 induced 
STAT3 phosphorylation after a 90 minute incuba-
tion in both mock (~1300% compared to vehicle) 
and US28-R129A (~760% compared to vehicle) 
transfected NIH-3T3 cells. (C) Incubation with 1 
µg/ml IL-6 neutralizing antibody for 90 minutes de-
creased STAT3 phosphorylation in US28-expressing 
cells (20% compared to vehicle). (D) Overnight 
incubation with 10 µM of gp130 inhibitor Madin-
doline-A (MDL-A) also decreased STAT3 phosphor-
ylation in US28-expressing cells (~4% compared to 
vehicle). (E) HEK293T cells expressing US28 were 
co-transfected with different amounts of shIL-
6. At 100 ng shIL-6 / 106 cells STAT3-dependent 
transcriptional activation was reduced by almost 
50% (*p < 0.05 compared to transfection with 
shEmpty), and 400 ng shIL-6 per 106 cells abol-
ished STAT3-driven transcriptional activation (***p 
< 0.001 compared to transfection with shEmpty). 
(F) Co-transfection of shIL-6 failed to significantly 
alter NFAT reporter gene activation. Nuclear factor 
of activated T-cells (NFAT).
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3.3.5 STAT3 is involved in the US28-induced proliferative phenotype 
Next, we used inhibitors of STAT3 and JAK1 to determine whether IL-6-driven STAT3 
signaling was involved in the US28-mediated proliferative phenotype. The specific 
STAT3 inhibitor JSI-124  (34) inhibited US28-mediated STAT3 signaling in HEK293T 
cells (Fig. 5A) with an IC50 of approximately 500 nM. Next, we used a [
3H]-
thymidine incorporation assay to determine the effect of various inhibitors of the IL-
6-STAT3 pathway on the proliferation of mock- and US28-expressing NIH-3T3 cells. 
We found that treatment with either the STAT3 inhibitor JSI-124 or the JAK inhibitor 
P6 strongly reduced proliferation of US28-transfected cells (Fig. 5B). Because US28 
increases expression of the gene encoding VEGF (4), which in part is regulated by 
STAT3 (35), we examined whether IL-6 was involved in US28-mediated transcrip-
tional activation of the VEGF promoter. Co-expression of shIL-6 with US28 resulted 
in reduced US28-induced activation of the VEGF promoter (Fig. 5C). Furthermore, 
inhibition of STAT3 with JSI-124 partially inhibited US28-induced VEGF promoter 
activity (Fig. 5D). COX-2 has previously been shown also to mediate US28-induced 
VEGF-production (17); therefore we investigated whether combined inhibition of 
STAT3 and COX-2 with JSI-124 and Celecoxib had a synergistic effect. Indeed, treat-
ment with both inhibitors resulted in a 67.8% ± 4.2% reduction of VEGF promoter 
activation, compared to 35.1 ± 7.7 % and 48.1 ± 5.6 % reduction when treated with 
either JSI-124 or Celecoxib, respectively (Fig. 5D). In addition, the transforming po-
tential of US28 was inhibited by treatment with JSI-124, resulting in a 48% ± 4% and 
77% ± 8% reduction in number of foci when treated with 250 and 500 nM JSI-124, 
respectively, in a focus formation assay with NIH-3T3 cells (Fig. 5E).
3.3.6 HCMV infection results in STAT3 activation
To investigate the contribution of US28 to STAT3 activation during HCMV infection, 
we infected U373 MG (malignant glioblastomas) cells with HCMV Titan wild-type 
or a HCMV Titan ΔUS28 mutant at an multiplicity of infection (MOI ) of 2. The pres-
ence of US28 or lack thereof was confirmed with [125I]-CCL5 binding (Fig. 6A). The 
presence of US28 was further confirmed 24 hours post-infection by immunofluo-
rescence using an antibody targeting US28. Infected cells (green) were visualized by 
means of GFP incorporated in HCMV Titan and US28 is shown in red (Fig. 6C, panel 
I and II). As previously shown, US28 is predominantly found in the perinuclear re-
gion of infected cells (36).  In contrast, we did not detect any US28 in cells infected 
with HCMV Titan ΔUS28 (Fig. 6C, panel III and IV). We confirmed US28 functional-
ity by measuring the intracellular accumulation of inositol phosphate, as described 
before (4, 13). We observed increased inositol phosphate accumulation in HCMV 
Titan-infected cells, whereas cells infected with the ΔUS28 strain did not show ino-
sitol phosphate accumulation (Fig. 6B). 
Experiments using the STAT3 reporter gene showed increased STAT3 activity 48 
hours post-infection in cells infected with the HCMV Titan strain, but significantly 
less activity in cells infected with the HCMV TitanΔUS28 mutant strain (p<0.001) 
(Fig. 6D). Consistent with the reporter gene data, Western blot analysis of cells in-
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Figure 5. STAT3 plays a critical role in US28-induced proliferation. (A) The STAT3 inhibitor JSI-124 inhibited STAT3 
response element activation in HEK293T after a 24 hour incubation. (B) Over-night treatment with either JSI-124 or 
P6 inhibited DNA synthesis in NIH-3T3 cells expressing US28 (**p < 0.01 compared with vehicle). (C) Knock-down of 
IL-6 with 400 ng shIL-6  / 106 cells in HEK293T cells expressing US28 inhibits transcriptional activation of the VEGF 
promoter (**p < 0.01). (D) Treatment of HEK293T cells co-transfected with US28 and a reporter gene containing 
the VEGF promoter with either 500 nM JSI-124 or 25 µM Celecoxib partially inhibits transcriptional activation of 
the VEGF promoter , and treatment with both compounds simultaneously has a synergistic effect (***p < 0.001 and 
**p < 0.01 compared to single treatment with JSI-124 or Celecoxib, respectively) . (E) Inhibition of foci formation by 
US28-expressing NIH-3T3 cells by either 250 nM or 500 nM JSI-124 (**p < 0.01 compared to vehicle).
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Figure 6. STAT3 activation during HCMV infection is partly mediated by US28. (A) [125I]-CCL5 binding to US28 
on U373 MG cells 48 hours post-infection with HCMV Titan; cells infected with the wild-type virus showed CCL5 
binding, whereas those infected with ΔUS28 virus did not (*p < 0.05 compared to binding on HCMV Titan ∆US28). 
(B) Accumulation of inositol phosphate in U373 MG cells 48 hours post-infection with HCMV Titan; cells infected 
with the wild-type virus showed increased inositol phosphate accumulation compared to both mock- and ΔUS28 
mutant virus-infected cells (***p < 0.001 compared to HCMV Titan ∆US28). (C) Anti-US28 stains U373 MG cells 
infected with HCMV Titan show specific staining of US28 (Red) in panel I and II, where in panel II infected cells 
are shown in green using a GFP-tag incorporated in the viral genome. In panel III and IV the same staining is 
performed on cells infected with HCMV Titan ΔUS28 as a negative control; in panel IV infected cells are also 
shown in green using the same GFP-tag. (D) STAT3-dependent transcriptional activation by HCMV Titan in U373 
cells 48 hours post-infections with HCMV Titan, which is less prominent in the ΔUS28 mutant virus (***p < 0.001 
compared to the wild-type virus). (E) STAT3 phosphorylation in U373 MG cells 24 hours post-infection with HCMV 
Titan, STAT3 phosphorylation is induced more strongly upon infection with wild-type virus (~250% compared to 
mock) compared to HCMV Titan ΔUS28 (~130% compared to mock), staining with anti-IEA confirms viral infection 
in both samples. (F) HCMV infection induces IL-6 secretion in U373 MG in a US28-dependent fashion, IL-6 concen-
tration was measured 24 hours post-infection in serum starved cells (*p < 0.05). Human cytomegalovirus (HCMV), 
immediate early antigen (IEA), green fluorescent protein (GFP).
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3
fected with the HCMV Titan strain showed increased STAT3 phosphorylation, which 
was significantly greater than that in cells infected with the HCMV TitanΔUS28 mu-
tant strain (Fig. 6E). IL-6 concentration in the supernatant of HCMV-infected cells 24 
hours post-infection was increased by 182% ± 13.8% compared to mock, whereas 
no increase in IL-6 concentration was apparent in cells infected with the HCMV Ti-
tan ΔUS28 strain (Fig. 6F).
3.3.7 Primary glioblastoma tumors show presence of US28 and activated STAT3
Finally, we examined whether US28, STAT3 phosphorylation, and IL-6 could be de-
tected in primary tumor specimens from patients with malignant glioblastoma. We 
examined 21 different malignant glioblastoma specimens obtained from patients 
at debulking surgery, of which 20 were HCMV-positive and one HCMV-negative. 
The presence of HCMV was confirmed by staining with antibodies directed against 
US28 and HCMV immediate-early antigen (IEA) (Fig 7A and 7C). Cells containing 
US28 and showing STAT3 phosphorylation were mostly confined to the vascular 
wall, with a few cells scattered over the tumor. Double-staining with antibodies di-
rected against phospho-STAT3 and US28 revealed a similar pattern (Fig. 7B and 7E; 
cells with phospho-STAT3 in brown and cells with US28 cells in red). HCMV IEA was 
present in tumor cells, smooth muscle cells (identified using SMC α-actin (Fig. 7D), 
and endothelial cells (Fig. 7G). IL-6 was abundant in tumor cells close to the vessels 
in all tissue samples (Fig. 7F; US28 in brown and IL-6 in red). As shown in figure 7G, 
CD31, an angiogenic marker, was consistently detected in HCMV-positive glioblas-
toma specimens. We did not observe either HCMV IEA- or US28-stained cells in the 
HCMV-negative tumor (Fig. 7I). In this HCMV-negative tumor phospho-STAT3 abun-
dance was very low and only detected in <10% of the cells (Fig. 7J), in contrast with 
its abundance in HCMV-infected tumor samples.
The abundance of US28 and the extent of STAT3 phosphorylation differed among 
different individuals, allowing us to grade tumor samples accordingly and relate 
these values to patient outcome. Median overall survival (OS) and in patients (n=9) 
with <30% US28-positive cells in the tissue was 19.5 vs. 14.5 months in those 
 (n=12) with > 30% US28-positive cells, (p=0.7), and median time to tumor pro-
gression (TTP) was 12 vs. 6.5 months, p=0.28 (Table 1). Overall survival time and 
TTP were higher in patients (n=1) with <30% HCMV-IEA-positive cells (median OS: 
34 vs. 14.5 months, median TTP: 17 vs7 months) than in those (n=17) with >30% 
Table 1. Median overall survival and time to tumor progression in tumors with low (0-2) and high grade (3-5) 
US28, Phospho-STAT3, and HCMV-Immediate Early Antigen (IEA). (n = 21 patients per group). P-value was 
determined using the Log-rank (Mantel-Cox) test.
Overall survival (months) Time to tumor progression (months)
Grade 0 to 2 Grade 3 to 5 P Grade 0 to 2 Grade 3 to 5 P
US28 19.5 (n=9) 14.5 (n=12) >0.05 12 (n=9) 6.5 (n=12) >0.05
Phospho-STAT3 21 (n=14) 11.5 (n=7) <0.05 12 (n=14) 4.5 (n=7) <0.01
HCMV-IEA 34(n=1) 14.5 (n=20) - 17 (n=1) 7 (n=20) -
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Figure 7. HCMV-IEA, US28, and 
STAT3 phosphorylation in primary 
glioblastoma specimens. Repre-
sentative immunohistochemical 
stainings are shown. (A) Presence 
of US28 (brown). (B) Presence of 
phospho-STAT3 (Brown). (C) Pres-
ence of HCMV-IEA (brown). (D) Pres-
ence of SMC α-actin (brown). (E) 
Double staining of a primary brain 
tumor tissue sample with anti-US28 
(red) and phospho-STAT3 (brown) in 
cells lining a blood vessel. (F) Dou-
ble-staining for US28 (brown) and 
IL-6 (red). (G) Presence of CD31 in 
blood vessels. (H) Rabbit IgG served 
as an isotype control. (I) No US28 or 
(J) phospho-STAT-3 is apparent in tis-
sue from the HCMV negative patient. 
Bar, 50 µm. (K) Kaplan-Meyer analy-
sis showing decreased overall surviv-
al probability for individuals with a 
high grade of STAT3 phosphorylation 
in the primary tumor (p = 0.039) as 
well as a shorter time to tumor pro-
gression (p=0.0052).
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infected cells (Table 1). Patients (n=14) with <30% phospho-STAT3-positive cells sur-
vived significantly longer (median OS: 21 vs. 11.5 months, p=0.039 and median TTP: 
12 vs. 4.5, p=0.0052) than those (n=7) with >30% phospho-STAT3-positive cells in 
their tumor tissue (Table 1, Fig. 7K, L). The presence of US28 was related to STAT3 
phosphorylation (p=0.006) and STAT3 phosphorylation was related to the presence 
of IL-6 as determined by a Wald test (p=0.041).  Thus, although we analyzed only 
a limited number of samples, our data suggest that HCMV infection is related to 
STAT3 phosphorylation, IL-6 production and outcome for individuals with malignant 
glioblastomas.
3.4 Discussion
Convincing evidence has linked viral infection to several forms of cancer. For ex-
ample, Kaposi sarcoma-associated herpes virus (KSHV) and Human Papilloma virus 
(HPV) are considered the etiological agents of Kaposi sarcoma and cervical cancer, 
respectively (37, 38). HCMV proteins and DNA have been detected in several tu-
mors (39-42), but a causal relationship has yet to be demonstrated. Although HCMV 
is not considered an oncogenic virus like KSHV and HPV (43), accumulating evidence 
suggests that it may act as an oncomodulator (44). Furthermore, HCMV interferes 
with several key cellular signaling pathways, leading to enhanced tumor survival 
and angiogenesis, as well as alterations in cell motility and adhesion (45). 
Here, we identified a signaling pathway involving NF-κB and IL-6/STAT3 through 
which US28 induces cell proliferation. Analysis of a set of secreted growth factors, 
chemokines, and cytokines enabled us to confirm increased VEGF secretion by 
US28-expressing cells (4). Medium concentration of CCL2 was decreased, reflecting 
its sequestration by US28 (11). Notably, the concentration of IL-6 was increased in 
the medium of US28-expressing cells. IL-6 is a pro-inflammatory cytokine that in-
duces STAT3 phosphorylation by binding to its cognate receptor IL-6Rα and thereby 
activating the tyrosine kinase subunit of the IL-6 receptor, gp130 (24). Following 
IL-6 binding to IL-6Rα, the two gp130 subunits activate Janus kinases (JAKs), leading 
to activation of STAT3 and its target genes. IL-6 is a regulatory factor in melanoma, 
inhibiting proliferation, and may play a pivotal role in the switch from cellular se-
nescence to oncogenesis (23). Moreover, STAT3 is a transcriptional regulator known 
to show increased activity in solid tumors (46), as well as in lymphomas (47). Re-
cent studies have shown that constitutively active gp130 mutants are responsible 
for increased STAT3 phosphorylation in hepatocellular tumors (48). As such, IL-6 
and STAT3 are considered promising anti-cancer drug targets (49, 50), stimulating 
the clinical use of IL-6 neutralizing antibodies  (51) and the discovery of several 
STAT3 inhibitors (34, 52). The importance of IL-6 and STAT3 signaling in oncogen-
esis  (20, 21) led us to investigate the role of the IL-6-STAT3 axis in US28-mediated 
proliferative signaling. The rise in IL-6 production and secretion in US28-express-
ing cells was associated with increased activation of STAT3, through the upstream 
activation of JAK1. This increase was only apparent in cells transfected with US28 
and not in either mock-transfected cells or cells carrying the US28 mutant, US28-
58
US28 mediates proliferative signaling through IL-6/STAT3
R129A. Using conditioned growth medium, IL-6 neutralizing antibodies, an inhibitor 
of the IL-6 receptor, and shRNA targeting IL-6, we showed that US28 activates the 
IL-6-JAK1-STAT3 signaling axis. Because IL-6 itself  is transcriptionally activated by 
STAT3 (53), this creates a positive feedback loop. Both IL-6/STAT3 autocrine loops, 
as well as paracrine loops have been described in cancer cells (54, 55).  A com-
mon factor in both US28 and IL-6 signaling is NF-κB, which is activated in response 
to US28 signaling (13) and drives the transcription of IL-6  (29, 30, 56). We found 
that NF-κB signaling was crucial to US28-mediated STAT3 activation. Using the G 
protein-uncoupled US28-R129A mutant, we demonstrate that similarly to NF-kB 
constitutive signaling  (13), US28-induced STAT3 activation is G protein-dependent. 
Thus, a positive loop activating IL-6-JAK1-STAT3 is initiated in an US28-dependent 
manner through activation of NF-κB. Treatment of cells with the STAT3 inhibitor 
JSI-124 inhibited US28-induced [3H]-thymidine incorporation, VEGF promoter ac-
tivity, and foci formation, further demonstrating the relevance of the STAT3 path-
way to the US28-induced proliferative phenotype. We previously identified a role 
for COX-2 in US28-induced VEGF production (17); our experiments here indicate 
that US28-induced VEGF promoter activation is regulated by both STAT3 and COX-
2, suggesting that US28 acts as an oncomodulator through multiple mechanisms. 
We also observed increased STAT3 activity and IL-6 abundance in HCMV-infected 
U373 MG glioblastoma cells, both of which were attenuated in cells infected with a 
strain lacking US28. However, STAT3 activity was not fully abolished in cells infected 
with the ΔUS28 virus, suggesting that STAT3 activation is also promoted by other 
viral factors. Furthermore, HCMV-infected cells secrete large amounts of IL-5 (57), 
which activates STAT3 (58). The increased IL-6 production in HCMV-infected U373 
MG cells appears to depend on US28.  Increased IL-6 abundance and subsequent 
activation of the STAT3 axis have been reported in HCMV-infected HUVEC and U373 
MG cells (57, 59). Moreover, gliomas, and some cancer stem cells, require IL-6 and 
STAT3 for tumor growth and survival (60). The presence of US28 and of STAT3 phos-
phorylation in cells lining the blood vessels in primary glioblastoma tumors suggest 
that US28 may be involved in the formation and maintenance of these tumors in 
within the vascular niche. The IL-6 receptor has shown to be present in glioblasto-
mas and IL-6 triggers proliferation and migration in cerebral endothelial cells (61, 
62). The specific localization of these cells suggest that they may play a role in vas-
cularization of the tumor, particularly in light of our data showing IL-6-dependent 
VEGF secretion. Furthermore, IL-6 is known to induce expression of VEGF and other 
angiogenic factors in pulmonary hypertension (63). Moreover, increased IL-6 con-
centrations are associated with smooth muscle cell proliferation and VEGF release 
in human cerebrovascular smooth muscle cells (62). Cells expressing US28 may also 
influence neighboring cells in a paracrine manner, effectively reprogramming these 
cells to display a more malignant phenotype. This notion is further supported by 
our data on disease progression and patient survival.  Increased number of cells 
showing HCMV-IEA and STAT3 phosphorylation in the glioblastoma specimens was 
associated with a poor prognosis, with median overall survival and time to tumor 
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progression significantly reduced. A similar trend was observed for the presence 
of US28. The fact that US28 abundance correlated with the degree of STAT3 phos-
phorylation in the tumor specimen indicates a potentially important role for US28 
in glioblastoma: US28 and other viral factors that induce NF-kB signaling in infected 
cells may initiate a positive feedback loop activating the IL-6-STAT3 axis, thereby 
contributing to the severity of disease. 
We suggest the following model for US28-induced STAT3 activation and subse-
quent proliferative signaling (Fig. 8). Cells carrying US28 produce IL-6 by way of 
a G-protein-dependent pathway involving NF-κB. IL-6 binds to the IL-6Rα subunit, 
subsequently activating the gp130 subunits of the IL-6 receptor , eliciting tyrosine 
phosphorylation of STAT3 by JAK1. Phospho-STAT3 dimerizes and translocates to 
the nucleus, to regulate target genes, including proliferative and angiogenic factors 
such as Cyclin D1  (64) and VEGF (35), respectively. IL-6 itself is a STAT3 target gene 
(53), leading to creation of a positive feedback loop. Our observations imply that, 
in cells infected with HCMV, US28 initiates a pathway leading to secretion of IL-6 
and resulting in enhanced proliferative signaling in an autocrine feedback loop.  In 
addition, IL-6 stimulates STAT3 activation in neighboring uninfected cells through 
paracrine signaling. By locally altering cytokine concentrations, US28 may facilitate 
tumor progression and vascularization, thereby contributing to the oncomodulato-
ry properties of HCMV. Together, our data indicate that the HCMV-encoded chemo-
kine receptor US28 mediates proliferative signaling by establishing a positive feed-
back loop involving activation of the IL-6-STAT3 axis. Targeting the IL-6-STAT3 axis 
with inhibitors effectively inhibited US28-induced proliferative signaling and VEGF 
secretion; the IL-6-STAT3 axis may thus represent a target for anti-angiogenic thera-
py, and specifically for HCMV-related tumor formation.
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Figure 8. Model outlining the US28 positive feedback loop. (A) US28 activates STAT3 via autocrine stimulation 
initiated byinducing IL-6 production via the NF-κB pathway. IL-6 subsequently activates the IL-6 receptor which 
results in STAT3 phosphorylation and activation of its target genes (amongst others, VEGF). (B) IL-6 secreted by 
US28-expressing cells can also activate STAT3 in a paracrine fashion. In both cases IL-6 is a target gene of STAT3 and 
activation of the IL-6/STAT3 axis may result in a positive feedback loop. Arrows indicate direct interactions, dashed 
arrows indicate activation with intervening steps.
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3.5 Materials and methods
Materials and reagents
Antibodies directed against phospho-STAT3 (Tyr705) and STAT3 were purchased from Cell Sig-
naling Technology (Boston, MA, USA). Neutralizing antibody against murine IL-6 was from 
BD Biosciences (Franklin Lakes, NJ, USA). Secondary antibodies used in the immunofluores-
cence experiments were obtained from Invitrogen (Paisley, UK). Pyridone 6 (pan-JAK inhib-
itor), Tyrene CR-4 (Abl inhibitor), AG-490 (JAK2 inhibitor), JSI-124 (STAT3 inhibitor), BAY11-
7082 (NF-κB inhibitor) and PP-2 (Src inhibitor) were all purchased from Calbiochem (San 
Diego, CA, USA). Stocks were made in DMSO, except for JSI-124, which was dissolved in 
ethanol. The inhibitors were subsequently diluted in the culture medium. Madindoline-A 
was purchased from Alexis Biochemicals (Lausen, Switzerland). Tris base, pertussis toxin, 
and linear polyethylenimine (25 kD) were obtained from Sigma-Aldrich (St. Louis, MO); 
other chemicals were obtained from Applichem (Darmstadt, Germany). Recombinant hu-
man CCL5, human CX3CL1, and murine IL-6 were obtained from Peprotech (Rocky Hill, NJ, 
USA). Dulbecco’s Modified Eagle Medium (DMEM) was purchased from PAA Laboratories 
(Pasching, Austria). Fetal bovine serum was purchased from Integro (Zaanstad, The Nether-
lands), and bovine serum was purchased from Invitrogen. 
Cell culture
Human HEK293T, human U373 MG, and murine NIH-3T3 cells were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM) supplemented with 50 IU/ml penicillin, 50 μg/ml strep-
tomycin, and 10% fetal bovine, heat inactivated fetal bovine and bovine sera, respectively. 
Transient transfections of HEK293T cells were performed using the polyethylenimine meth-
od (65). Transient transfections of U373 cells were performed using the lipofectamine meth-
od (66). The HCMV Titan strain described in  (4) was used to infect U373 cells at an MOI of 
2. Stable clones of NIH-3T3 expressing US28 or US28 R129A mutant  (4) were kept under 
a selective pressure of 400 µg/ml neomycin in the culture medium to ensure homogenous 
receptor expression in the cells. Expression of US28 in HEK293T, U373 MG, and NIH-3T3 cells 
was confirmed using [125I]-CCL5 binding (specific binding was determined using CX3CL1 10-7 
M), as previously described (13).
Angiogenesis array
A mouse angiogenesis array (Raybiotech, Norcross, GA, USA) was used according to manu-
facturer’s instructions to determine relative amounts of cytokines and chemokines involved 
in angiogenesis.
Measurement of IL-6 concentration in culture medium
Il-6 concentrations in culture medium supernatant from serum-starved U373 MG cells were 
measured 24 hours post-infection with either HCMV Titan wild-type or HCMV Titan ∆US28. 
For the measurement the Human IL-6 Quantikine ELISA Kit from R&D Systems (Minneapolis, 
MN, USA) was employed according to manufacturer’s instructions.
Western-blot analysis
A Biorad (Hercules, CA) minigel system was used to perform SDS/PAGE, and a Biorad elec-
troblot system was used to transfer protein samples to a 0.45 μm nitrocellulose membrane. 
Cells were lysed in RIPA-buffer supplemented with α-complete protease inhibitor cocktail 
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from Hoffmann-La Roche (Basel, Switzerland), 1 mM PMSF, 1 mM NaVO4, and 1 mM NaF 
added. Samples were normalized using the BCA total protein determination kit obtained 
from Thermo Fisher Scientific (Rockford, IL, USA). Blots were quantified using ImageJ (Ras-
band, W.S., U. S. National Institutes of Health, Bethesda, Maryland, USA). Data shown is 
representative of three independent experiments.
Reporter gene analysis
The Ly6E STAT3-response element luciferase construct (28) was used for STAT3 activity mea-
surements. To determine STAT3 activity, 106 HEK293T cells were transfected with 625 ng 
Ly6E STAT3-response luciferase construct, with or without pcDEF3 containing a gene en-
coding HA-US28. U373 cells were transfected 24 hours before infection with 1300 ng STAT3 
reporter gene. When inhibitors were used, they were added immediately following trans-
fection. Total DNA amounts were kept constant by adding empty vector. Luciferase activity 
was measured 24 hours after transfection or 48 hours post-infection using a Victor2 multila-
bel platereader from Perkin-Elmer (Waltham, MA, USA). The NFAT reporter gene, pNFAT-luc 
was purchased from Stratagene (La Jolla, CA, USA). To measure VEGF promoter activation, 
the pGL2-VEGF-Luciferase construct, kindly provided by Dr. G. Pages (Institute of Signalling 
Development Biology and Cancer, Nice, France).
IL-6 knock-down
IL-6 knock-down experiments were performed with the pRS-puro-shIL-6 (GAACTTAT-
GTTGTTCTCTA) construct kindly provided by Dr. D. Peeper (Netherlands Cancer Institute, 
Amsterdam, the Netherlands) (23). For the knock-down, HEK293T cells were transiently 
transfected with shIL-6 and a STAT3, VEGF, or NFAT reporter gene. Luminescence measure-
ments were made 48 hours post-transfection. As a negative control pRS-puro expressing a 
nonsense sequence (CCAATGCTTTGATGCCAAA) was used.
[3H]-Thymidine incorporation
Cell proliferation in NIH-3T3 cells was measured using [3H]-thymidine incorporation. 
[6-3H]-Thymidine was obtained from GE Healthcare Life Sciences (Buckinghamshire, UK). 
Cells were serum-starved overnight before labeling in DMEM supplemented with 0.5% bo-
vine serum containing 1 μCi/ml [6-3H]-Thymidine together with inhibitors.
Focus formation assay
Focus formation potential of NIH-3T3 cells transfected with either US28 or empty vector was 
determined by seeding cells into a monolayer of native NIH-3T3 cells as previously described 
(4). Treatment with JSI-124 was initiated 48 hours after seeding. Medium containing JSI-124 
or vehicle was replaced every 48 hours. After 2 weeks the cells were washed 3 times with 
phosphate buffered saline (PBS) and subsequently fixed in cold methanol for 10 minutes. 
Following this the cells were stained with 0.4% Methylene Blue in H2O and the foci counted.
Inositol phosphate accumulation
U373 MG cells were labeled 48 hours post-infection in inositol-free DMEM supplemented 
with 2 µCi/ml myo-[2-3H]-inositol and incubated overnight. The cells were subsequently in-
cubated for 2 hours in DMEM with 10 mM LiCl added. The incubation was stopped with 10 
mM cold formic acid, and inositol phosphates were isolated by anion exchange chromatog-
raphy (Dowex AG1-X8 columns, Bio-Rad).
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Generation of a rabbit antiserum against US28
To generate polyclonal antisera, rabbits were immunized with a synthetic peptide correspond-
ing to the C-terminal 17 amino acids of the US28 protein (H2N-SSDTLSDEVCRVSQIIP-CO2H) 
coupled to keyhole limpet hemocyanin through the N-terminal amino group. The specificity 
of the antisera was assessed by immunoprecipitation followed by Western blot analysis and 
immunofluorescence (Fig. S1). Immunofluorescence was performed using Alexafluor568 
conjugated anti-rabbit to detect anti-US28, and subsequent imaging was done on an Olym-
pus FSX-100.
Patient Samples and Immunohistochemistry
Paraffin-embedded primary brain tumor specimens were obtained from one HCMV nega-
tive glioblastoma tumor and randomly from 20 GBM patients in our sample collection in the 
Biobank at the Karolinska University Hospital Sweden. Twelve of 21 patients received Te-
mozolomide and radiation; 2 patients received gammaknife treatment; 5 patients received 
CCNU and radiation; and 2 patients received only CCNU after debulking surgery. Tissue sec-
tions (6 μm thickness) were stained for HCMV-IEA, US28, phospho-STAT3, CD31, and IL-6 
using immunohistochemistry staining protocols as previously been described (67). Briefly, 
the sections were deparaffinized in xylene, rehydrated through an alcohol series, postfixed 
with 4% neutral buffered formalin, treated with pepsin (Biogenex, San Ramon, CA), and then 
incubated in citrate buffer (Biogenex). The sections were treated with 3% H2O2 (Sigma-Al-
drich) to inactivate endogenous peroxidase, avidin/biotin blocking kit (DakoCytomation, 
Glostrup, Denmark), was used in order to block endogenous biotin/avidin, and FC recep-
tor blocker (Innovex Biosciences) to block FC-R.  Finally, the tissue sections were treated 
with Background Buster (Innovex Biosciences). Incubation with primary antibodies against 
US28 (created by Alberto Fraile-Ramos), phospho-STAT3 (Cell Signaling), CD31 (Dako Cyto-
mation, Denmark), IL-6 (AbCam), Human cytomegalovirus-IEA (Chemicon, US), and Human 
cytomegalovirus-Late (Chemicon, US) was done overnight at 4°C. Antibodies against rabbit 
IgG (R&D Systems, Minneapolis, MN) and smooth muscle cells alpha actin (IgG2a, Dako) 
were used as isotype control. After incubation with primary antibodies, the sections were 
incubated with biotinylated anti-rabbit (Dako) or anti-mouse (Biogenex) antibodies. Finally, 
the antibodies were visualized using streptavidin-conjugated horseradish peroxidase and di-
aminobenzidine (Innovex Biosciences). For double-staining, the first staining was performed 
as described, and the second was performed using streptavidin-conjugated alkaline phos-
phatase (DakoCytomation) and FastRed (Dakocytomation). Hematoxylin (Sigma-Aldrich) 
was used for counterstaining and slides were mounted in permanent mounting medium 
(DakoCytomation).
The percentage number of cells expressing different factors in the tissue specimens were 
graded 1, 0-1+ to <10%; grade 2, >10% to 30%, grade 3, >30% to 50%, grade 4, >50 % to 70%, 
grade 5, >70%. This study was approved by the ethics committees at Karolinska Institutet.  
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Statistical analysis
All experiments were performed at least three times in triplicate. When comparisons be-
tween treated and vehicle-treated cells, or mock and infected cells were made, Student 
T-test was performed using the GraphPad Prism software (San Diego, CA, USA). Bars and 
error bars represent the mean and SEM, respectively. Median time to tumour progression 
(TTP) and survival were analyzed using Kaplan-Meier curves by using Long-rank (Man-
tel-Cox) test. Relationship between different stainings was determined using Wald statistics.
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4.1 Abstract
STAT3 signaling is an important mediator of cytokine signaling, and IL-6 in particular. 
In recent years it has become clear that STAT3 and IL-6 both play an important role 
in tumor biology. Recently, the virally encoded G-protein coupled receptor US28 has 
been shown to induce IL-6 production, which subsequently results in STAT3 activa-
tion. Furthermore, because STAT3 itself can also induce IL-6 expression there is the 
potential for establishing a positive feedback loop. In this study a systems biology 
approach was utilized to investigate the nature of US28-induced IL-6/STAT3 signal-
ing. A mathematical model was developed of the basic IL6-signaling circuitry and 
cell-to-cell signaling mechanisms. Experiments could qualitatively reproduce model 
predictions of the consequence of US28-induced IL-6 production and STAT3 acti-
vation. Moreover, the model reveals that US28 can provoke an IL-6/STAT3 positive 
feedback loop, which can cause a population of cells to concertedly switch in states. 
The data presented here, show that a systems biology approach may be of great 
help in understanding signaling pathways and to identify new therapeutic targets.
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4.2 Introduction
Human cytomegalovirus (HCMV) is a beta-herpesvirus establishing a latent infec-
tion of 30–70% (1) among residents in developed countries and up to 90% among 
residents of developing countries (2). HCMV infection has been proposed to pro-
mote the development of malignant glioma (3) and colon cancer (4). It has also 
been detected as an active infection in several cancer forms.
The genome of HCMV encodes four G-protein-coupled receptors (GPCR), which are 
homologous to human chemokine receptors (5, 6). Chemokine receptors are in-
volved in immune system regulation (7) and participate in oncogenesis (8). One of 
the HCMV encoded GPCRs is US28. The presence of US28 causes suppression of 
the host’ immune response against HCMV infection (9) and constitutively activates 
signaling pathways linked to proliferation (10, 11); mediated by IL6. HCVM-encoded 
viral GPCRs may play a role in oncogenesis and tumor growth. US28 is known to 
induce various oncogenic responses in vitro when expressed in NIH-3T3 fibroblasts. 
US28 is also capable of promoting tumor formation in mice (12).
To investigate the molecular mechanism by which US28 contributes to the progres-
sion of oncogenesis, we previously analyzed the US28-induced release of cytokines 
(11). Conditioned medium from US28-expressing NIH-3T3 cells was analyzed and 
compared to medium from mock-transfected NIH-3T3 cells. Analysis using an an-
tibody array showed that Interleukin-6 (IL-6) levels were significantly higher in the 
medium taken from US28 expressing cells. Further investigation showed that US28 
activates STAT3 signaling pathway in an indirect fashion. Furthermore, analysis 
of glioblastoma patients revealed localized expression of US28 around the blood 
vessels. In the aforementioned study US28-induced IL-6 secretion involved NF-κB. 
However, because STAT3 can also induce IL-6 expression (13), there is a potential 
for a positive feedback loop. This would imply that once cells have been exposed 
to certain IL-6 levels, they will be able to produce enough IL-6 in response to this 
stimulus to maintain signaling without an exogenous source of IL-6. 
To obtain a better understanding of this mechanism we first describe a single cell 
model for US28 induced IL-6 production and autocrine IL-6 signaling that includes 
simplified NF-kB and STAT3 signaling. In the second part we organize these single 
cell models on a lattice. By studying the conditions for IL-6 spreading and IL-6 in-
duced IL-6 synthesis on the lattice, we examined whether irreversible bistability of 
the single cell module is of key importance for the observed experimental behavior 
described in Chapter 3.
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Eactive = K An + Sn
ETSn
Figure 1. Schematic representation outlining the IL6 positive feedback loop. Two components, NF-κB and STAT3, 
influence the production rate of IL-6 (v1). v3 indicates the secretion rate and uptake rate of IL-6. v2 and v4 are the 
respective internal and external degradation rates of IL-6. The left graph gives a possible relation between US28 
and NF-kB and the right one the relation between IL6 and active STAT3. Internal IL-6 is denoted as IL-6I and IL-6E 
denotes the extracellular IL-6.
4.3 Results
4.3.1 Development of a single cell mathematical model with IL-6-induced IL-6   
 synthesis
The essential features of the biological model described in the introduction are il-
lustrated in Figure 1. The US28-induced IL-6 synthesis is mediated by NF-kB signal-
ing (11, 28). NF-kB induced transcription of IL-6 leads to the excretion of IL-6 protein 
in the extracellular fluid. In response to extracellular IL-6, STAT3 is phosphorylated. 
As mentioned before, STAT3 is a transcription factor regulating the il6 gene. IL-6 is 
degraded both internally and externally. The relation between the concentration 
of US28 and active NF-κB as well as the relation between the concentration of ex-
tracellular IL-6 (IL-6E) and phosphorylated STAT3 (STAT3P) is unknown. We model 
their relation with a Hill equation. This provides the steady state concentrations of 
STAT3P and active NF-κB based on the concentrations of US28 and IL-6E. The Hill 
equation used is noted below:
where n is the Hill coefficient, describing the steepness of the curve. S is the concen-
tration of activator and KA equals the activator concentration at which Eactive equals 
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Figure 2. Behavior of the Hill equation for 
different n. On the y-axis the active portion 
of E and on the x-axis the input strength 
(S). When n=1 the Hill equation behaves as 
a normal saturation curve, n>1 gives a sig-
moidal shaped relation.
Parameters: ET=1, KA=0.5.
dt
dIL6 I = k 1NFlB active + k 2STAT3 P - k 3 IL6 + k 5 IL6E
dt
dIL6E = - k 6 IL6E - k 5 IL6E + k 4 IL6E
NFlB active = K 1n1 + US28n1
E 1US28n1
STAT3P = K 2
n 2 + IL6E
n2
E 2 IL6E
n2
0.5 ET, where Eactive denotes the amount of activation of a factor (e.g. STAT3) and ET 
is a number that describes the level of activation by a stimulant (e.g. IL-6). When 
n=1, the Hill equation behaves as a normal saturation curve, n>1 gives sigmoidal 
behavior (Figure 2).
4.3.2 Analysis of the single cell model
The change of intracellular IL-6 (IL-6I) over time is the balance between production, 
degradation and transport of IL-6. For IL6E, the change over time is the result of 
transport and degradation. The differential equations for the model are:
Where kx denotes the rate constant for the step under consideration, k1-k4 are used 
to describe the rate constant for v1-v4 while k5 and k6 describe uptake and degrada-
tion of extracellular IL-6, respectively. 
Next the behavior of this model was investigated. In Figure 3A the rate of produc-
tion and degradation is plotted for three different values of US28 activity. In the 
model the degradation rate only depends on IL-6E and is therefore insensitive to 
changes in US28 activity. The sigmoidal nature of the production rate originates 
from the sigmoidal relation between IL-6E and STAT3P (E1=5, K1=3, n1=5). Due to 
the sigmoidality, the number of intersections between the rate of production and 
degradation varies with US28 activity. Each intersection between the two rates in-
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Figure 6. Schematic representation of the IL6 positive feedback loop in a multicellular context. The left hand of 
the figure corresponds to the single cell model, similar to Figure 6. On the right hand side a second cell is incor-
porated in the model. In this cell IL-6 production is not induced by US28, but rather by IL-6 originating from the 
neighboring cell.
Figure 3. (A) Production rates (blue solid 
lines) and degradation rate (red dashed 
line) as a function of IL6. The production 
rate depends on the activity of US28 
and is visualized for three different 
activities (US28activity=0, US28activ-
ity=1 US28activity=2). Stable steady 
state points are indicated in green and 
unstable steady state points in red. (B) 
Net rate of IL6 production as a function 
of IL6. The net rate of IL6 production is 
the difference between IL6 production 
and IL6 degradation. When the net rate 
of IL6 production is zero (production 
equals degradation) the system is at 
steady state. Parameters: k1=1, k2=1.2, 
k3=0.9, k4=10, k5=1, k6=0.9, E1=5, K1=3, 
n1=1, E2=5, K2=3, n2=5.
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Figure 4. The bifurcation diagram of the sin-
gle cell model shows the IL6 steady state 
concentration for different US28 activities. 
The solid lines represent stable steady states 
whereas the dotted line represents the unsta-
ble ones. For certain values of US28 activity 
the cell has two possible stable steady states, 
which one it occupies depends on the history 
of the cell, a process called hysteresis. The red 
dot indicates the critcal value of US28. If a cell 
has experienced an active US28 higher than 
US28critical in the past, the system will oc-
cupy the high steady state. Parameters: k1=1, 
k2=1.2, k3=0.9, k4=10, k5=1, k6=0.9, E1=5, K1=3, 
n1=1, E2=5, K2=3, n2=5.
0 = k 1NFlB active + k 2STAT3P - k 3 IL6 I - k 6 IL6E
dicates a steady state of the model. Different concentrations of the US28 receptor 
(higher US28 activity) can result in another number of steady state solutions.
The net rate of the system is plotted in Figure 3B. The steady state solutions are 
the crossings with the x-axis. There are regions for which the net-rate increases 
with IL-6 (d/dIL-6•dIL6/dt>0). A steady state situated in such a region is unstable; a 
small increase of IL-6 will lead to a higher production than degradation of IL-6 (pos-
itive dIL-6/dt). The system will not be able to return to its former (lower IL-6) state. 
There are regions for which the net-rate decreases with IL-6 (d/dIL-6•dIL-6/dt<0). A 
steady state situated in such a region is stable; a small increase of IL-6 will lead to a 
negative dIL6/dt. The system will return to its former (lower IL-6) state.
A steady state of a system is reached when the production rate equals the degrada-
tion rate. In this case they are obtained by solving:
The solutions of the system is plotted against the activity of US28 in Figure 4, with 
the assumption IL6I and IL6E are in steady state. The solid lines indicate stable steady 
state solutions and the dashed line represents unstable ones. When US28 activity 
increases the steady state is low until a critical value (US28
critical
) is reached. After 
this point the steady state of the system jumps to a higher value. A decrease in 
US28 activity will not yield the low steady state value again. Therefore this system 
is called an irreversible bistable switch. This behavior is called hysteresis; a system 
is in a certain state depending on its history. Depending on the chosen parameters, 
this model can also act as a reversible switch and a monostable model (Figure 7).
Apart from the dependence of the system on US28 activity, Figure 4 shows that 
when US28 activity is lower than US28
critical
 (subcritical), the level of IL6E at t=0 con-
trols whether the system will settle at the high or low steady state. Values of IL6E(0) 
higher than the unstable solution direct the system to the high steady state. The 
critical IL6E level (IL6E,critical) depends on the US28 activity, for a cell with high US28 
activity (but still subcritical) the IL6
E,critical
 decreases.
Figure 5 shows this characteristic in an intuitive manner. Figure 5A shows analyses 
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Figure 5. (A) Change in IL6 over time with 
no US28 activity present. The steady state 
reached by the cell depends on the IL6 present 
at t=0. The dashed line indicates the critical 
value of IL6, which determines which steady 
state is reached. (B) When US28 activity is 
temporal (between the red lines, 0.5 < t < 10), 
the strength of the signal determines the IL6 
produced by the cell. When the activity is high 
enough to produce more IL6 than the critical 
IL6 level, the IL6 induced IL6 production is ac-
tivated to a sufficient level to maintain the IL6 
producing phenotype of the cell. Parameters: 
Parameters: k1=1, k2=1.2, k3=0.9, k4=10, k5=1, 
k6=0.9, E1=5, K1=3, n1=1, E2=5, K2=3, n2=5.
of IL6E in the time domain with a subcritical US28 activity (in this case US28activity=0). 
The steady state reached by the system depends on the initial value of IL6E. In the 
case of a temporal signal the same behavior is observed. When the US28 activity 
directs the IL6E above IL6E,critical the system will continue to occupy the high steady 
state even when the US28 activity is decreased (Figure 5B).
4.3.3 Development of a multicellular model.
As discussed before, STAT3 phosphorylation in NIH-3T3 cells can be induced by treat-
ing cells with conditioned medium from US28-expressing cells. This prompted us to 
study the single cell model in a multicellular context. In this case, a cell expressing 
US28 can affect the cells around it by secreting IL-6. Subsequently, the surrounding 
cells will also display STAT3 phosphorylation, resulting in further production of IL-6. 
This scenario is further explored below.
The single cell model (a US28-expressing cell, Figure 1) is first expanded with an-
other cell that does not express US28, and therefore unable to initiate its own IL6 
synthesis by US28. A schematic representation of such a system is given in Figure 6.
The additional cell has all the same properties as the US28-expressing cell, except 
for of course the US28-induced IL-6 production. Therefore, production and degra-
dation of such a cell is already visualized in the lowest sigmoidal line of Figure 3A, 
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Table 1. Overview of parameter settings.
Name Function Irr. bistable Re. bistable monostable unit
k1 Production of IL6 I by signal 1 1 1 s-1
k2 Production of IL6 I by IL6 E 2 2 2 s-1
k3 Degradation of IL6 I 0.01 0.01 0.01 s-1
k4 Secretion of IL6I 10 10 10 s-1
k5 Uptake of IL6E 1 1 1 s-1
k6 Degradation of IL6E 0.01 0.01 0.01 s-1
E1 Total NfkB 3 3 3 *
K1 Concentration where NFkBactive = 0.5 NFkBtotal 6 6 6 *
n1 Steepness, Hill coefficient 1 1 1 -
E2 Total STAT3 1 1 1 *
K2
Concentration where STAT3
active 
= 0.5 
STAT3total
10 115 200 *
n2 Steepness, Hill coefficient 5 5 1 -
where US28
activity
=0. This figure indicates that there are multiple steady states for 
this cell, two stable ones and one unstable solution. The switch between the stable 
steady states is triggered by the IL-6 outside the cell as can be seen in the bifurca-
tion diagram (Figure 4, by US28
activity
=0). The critical external IL-6 level for non-vi-
rus-infected cells is visualized in Figure 3 where the steady state concentration of 
IL-6E is plotted against the IL-6E concentration at t=0.
This model still treats IL-6E in a similar manner as in the single cell model, using it di-
rectly as input for the cells. However, a multicellular environment is more complex 
than this. The secreted IL-6 is hindered to reach another cell in the medium due to 
diffusion and is subject to extracellular degradation. To study the behavior of cells 
in a multicellular context we developed a model for spreading of IL-6E (or any other 
substance) over distance and time with a discrete approximation of two dimension-
al diffusion. This model is expanded with single cell models covering a whole area 
of interest. Where available we used parameter values from literature for the single 
cell module and for the diffusion model. We implemented these in our model and 
we assigned values to the unknown parameters. Parameters for the Hill-equation of 
the relation between IL-6E and STAT3P were selected to obtain three different kinds 
of behavior of the single cell model. The first set was chosen to make the system act 
as an irreversible bistable switch. The second set of parameters makes the switch 
reversible and the third set results in a monostable cell (Table 1 and Figure 7).
In human blood mononuclear cells most IL-6 was found in the extracellular fluid, 
whereas between 5% and 15% remained in the intracellular compartment (14). Al-
though we are aware that this pattern of secretion of IL-6 might be different in 
other cell types, we use these findings to choose a secretion rate of 10 s-1 and an 
uptake rate of 1 s-1.
Diffusion of IL-6 in the medium depends on the diffusion coefficient of IL-6. By our 
knowledge, the exact diffusion coefficient of IL-6 is not documented. There are 
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Figure 7. Overview of the behavior of the model for three different parameter settings for the relation between 
phosphorylated STAT3 and IL6. The parameter values of the three different situations are described in Table 1. The 
first column of pictures displays the behavior as result of a sigmoidal relation between STAT3P and IL6. This leads 
to an irreversible bistable system that is also described in the analyses of the single cell model. The second column 
shows the behavior of the system as a result of a sigmoidal relation between STAT3P and IL6, only here the result 
is a reversible bistable system. The last column shows the results of the model when STAT3P increases hyperbola 
as a function of IL6 present in the system. (A-C) The IL6 induced STAT3 phosphorylation patterns for the three 
different parameter settings. A and B show sigmoidal dependence whereas C shows a hyperbola relation. (D-F) 
The change in IL6 over time for the single cell model. The US28 activity is set to 1, which initiates IL6 production 
in the model. Depending on the parameters for the positive feedback mechanism of IL6 via STAT3 signaling there 
will be additional IL6 production. These figures show an increase in IL6 that implies an increase in STAT3P. Legend 
continues on the next page
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Figure 7. Continued from previous page. (G-I) Production rates (blue solid lines) and degradation rate (red dashed 
line) as a function of IL6. The production rate depends on the activity of US28 and is visualized for three different 
activities (US28
activity
=0, US28
activity
=1 US28
activity
=2). Stable steady state points are indicated in green and unstable 
steady state points in red. Note that with changing the US28 activity the number of steady state solutions varies in 
G and H. When there is no US28 activity only the irreversible bistable system has two stable steady state solutions. 
(J-L) The net rate of IL6 production as a function of IL6. When the net rate of IL6 production is zero (production 
equals degradation) the system is at steady state. As described in the text, a stable steady state is situated in a re-
gion where the net rate increases. (M-O) The steady state IL6 as a function of the US28 activity. The solid lines rep-
resent stable steady states whereas the dotted line represents the unstable ones. For certain values of US28 activity 
the cell has two possible stable steady states (bistability), which one it occupies depends on the history of the cell. 
The black dots indicate the critical values of US28 activity. At such point a small change in the US28 activity gives a 
large transition in the steady state value of IL6. M shows irreversible bistable behaviour, once occupying the high 
steady state solution branch, no critical US28 activity point is present to return to the low stable solution branch. N 
shows reversible bistability because such point of return is present. L shows that this system is monostable for all 
US28 activities. (P-R) The behavior of the models as a function of the initial IL6 concentration. Only the model with 
irreversible bistable behavior is sensitive to the initial present IL6. The critical IL6(0) value is the unstable steady 
state solution of the system.
methods, which estimate the diffusion coefficient of cytokines based on their mo-
lecular weight and the radius of gyration (15). This reference gives the diffusion co-
efficient in an aqueous solution of IL-5 (9.39 10-7 cm2s-1), a cytokine with a molecular 
weight of 26 kDa. The weight of IL-6 is, depending on the glycosylation and phos-
phorylation, between 21,5 and 28 kDa. We assume the diffusion coefficient of IL=6 
to be in the same order, DIL-6 = 1*10
-6 cm2s-1. An overview of the different parameter 
settings is described in Table 1. In Figure 7 the analyses using these parameters are 
shown.
As shown by the single cell analyses the STAT3P increases with ascending IL-6 in 
our model (Figure 7A-C). As a result of this induced STAT3P, the production rate of 
IL-6 will increase. We subjected the multicellular lattice model to a high amount of 
IL-6 (IL-6(0)=220) and followed its behavior over time. On the single cell level we 
used the three different parameter settings as given in Table 1 and no US28 activity. 
Given the high IL-6 levels the single cell models on the lattice start producing IL-6. 
Only the lattice with the irreversible bistable behavior of the single cell model keeps 
a stable IL-6 concentration on the lattice over time, implying a constant production 
of IL-6 since there is IL-6 turnover.
Autocrine signaling of IL6 enhances STAT3P and proliferative signaling. Furthermore, 
paracrine signaling can lead to induced STAT3 phosphorylation in other cells. In this 
manner, US28 may facilitate tumor progression. The next analysis shows that a sin-
gle US28-expressing cells can enhance IL-6 production (as a function of enhanced 
STAT3P) in cells that are not expressing US28.  This may enhance proliferative sig-
naling in those cells too.
This experiment has also been done for an irreversible bistable, reversible bistable 
and mono stable model at the single cell level. The centre cell on the lattice is given 
a transient US28 activity. In response this cell starts IL6 production and secretion. 
The external IL6 will diffuse in space and stimulate IL6 production in its surround-
ing cells. When the single cell behavior is reversible bistable or monostable and 
no US28 activity is present, the IL6 feedback is too weak to maintain the high IL6 
levels in the extracellular space. In fact this is already visualized in the bifurcation 
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diagrams (Figure 7N-O). When no US28 activity exists the only steady state for the 
single cell model is reached when IL6 is zero.
4.3.4 Experimental validation of the model
To confirm the models described previously experimentally, several conditions must 
be met. First of all, the model assumes a sigmoidal relationship between IL-6 levels 
and the amount STAT3 phosphorylation. Secondly, cells with US28 activity should 
be able to continue to display STAT3 phosphorylation after US28 activity has been 
ceased. Finally, medium of US28-expressing cells should be able to induce STAT3 
phosphorylation in cells that are not expressing US28. The last condition has al-
ready shown to be true in Chapter 3, but the first two conditions have not been 
satisfied yet.
While ideally one would like to switch off US28 at will, this has proven to be difficult. 
Using inverse agonists on US28 would be preferable. However, while such inverse 
agonists have been generated (16-18), their potency is not high enough to inhibit 
proliferation (data not shown). An alternative would be to use an inducible system 
for controlling US28-expression, however that would entail the generation of sev-
eral new cell line which would take a significant amount of time. Instead we have 
opted to reduce the role US28 in the specific case of STAT3 signaling to IL-6 produc-
tion. In this scenario, US28 activity can be replaced with recombinant IL-6. Using 
recombinant IL-6, pulse-chase experiments were performed where the cells were 
pulsed with IL-6 and then followed in time. In Figure 8A, the cells were treated with 
10 ng/ml IL-6 for 10 minutes (t=0). Then at t=3, t=8, t=24, and t=32, samples were 
taken and the phospho-STAT3 content was analyzed by Western-blot analysis. Fol-
lowing quantification and correction for loading using β-actin as loading control, the 
amount of STAT3 phosphorylation was plotted in a graph against time. This shows 
that cells treated with IL-6 indeed show sustained STAT3 phosphorylation, while 
the vehicle treated cells do not show STAT3 phosphorylation. In Figure 8B a similar 
experiment is shown, but in this case two additional conditions were taken along. 
In one case, following IL-6 treatment and washing the cells were treated with 1 μg/
ml anti-IL-6 neutralizing antibodies. In the other case, the cells were treated with 
30 μg/ml cycloheximide which is an inhibitor of protein synthesis. The treatment 
with anti-IL-6 failed to inhibit STAT3 phosphorylation, indicating that other factors 
that can activate STAT3 may also be present or that anti-IL-6 may not be able to 
bind all the IL-6 being secreted. Treatment with cycloheximide completely inhibits 
STAT3 phosphorylation; this indicates that the cells need to be able to produce new 
factors in order to display sustained STAT3 phosphorylation.
Utilizing a STAT3 reporter gene, we assessed the amount STAT3 transcriptional ac-
tivation after treatment with different concentrations of recombinant IL-6 (Figure 
8C). The reporter gene data indicates the dose-response of IL-6 treated HEK293T 
cells. 
Thus far indirect methods have been used to assess IL-6 production following an 
IL-6 pulse. As an extra confirmation, a more direct approach in the form of quan-
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Figure 8. (A) A 10 minute pulse with 10 ng/ml recombinant IL-6 results in increased STAT3 phosphorylation in 
NIH-3T3 up until 32 hours post-pulse. Vehicle treated cells do not show this behaviour (B) IL-6-induced STAT3 phos-
phorylation after the initial treatment can be prevented using 30 ug/ml cycloheximide (protein synthesis inhibitor). 
However, anti-IL-6 neutralizing antibodies cannot prevent IL-6-induced STAT3 phosphorylation indicating either 
incomplete neutralization or other factors (eg. IL-5 or IL-10). (C) Treatment of NIH-3T3 with different concentrations 
of recombinant IL-6 shows a sigmoidal relationship between IL-6 concentration and STAT3 phosphorylation. (D) As-
sessment of IL-6 mRNA production shows a 1.2 fold increase of IL-6 mRNA 24 hours post-pulse, while vehicle treat-
ed cells show a 0.35 fold decrease of IL-6 mRNA production in the same time-span (**p<0.01). As a positive control 
US28-expressing cells were used, which show a 3.2 fold increase of IL-6 mRNA versus mock transfected cells.
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titative RT-PCR was used to assess IL-6 mRNA production (Figure 8D). This analysis 
confirmed the result from Figure 8A, showing significantly higher IL-6 mRNA levels 
in IL-6 treated cells 24 hours after administering the IL-6 pulse (p<0.01). As a con-
trol US28 expressing cells were used, since these cells are known to produce IL-6 
constitutively (11). These data together with those from Chapter 3 indicate that the 
model may be a good approximation of what happens in the NIH-3T3 cells.
4.4 Discussion
In this study we investigate US28 activated STAT3 phosphorylation mediated by an 
IL-6 positive feedback loop. When a human cell is infected with HCMV, the viral 
gene that encodes the GPCR homologue US28 is transcribed. In proliferating cells, 
US28 constitutively activates IL-6 transcription mediated by NF-κB signaling.  Subse-
quently, an IL-6 positive feedback loop is activated that includes phosphorylation of 
the transcription factor STAT3. STAT3P is known to regulate VEGF, an important fac-
tor in tumorigenesis (19). Furthermore, STAT3 activation has also been documented 
in brain tumors (20) and is known to hinder immune surveillance (21). Analyses of 
human glioblastoma tissue showed US28 expression and activated STAT3 in cells 
lining blood vessels (11), suggesting that US28 and its activation of STAT3 may play 
a role in tumor vascularization.
In order to investigate the IL-6 positive feedback mechanism we use a mathematical 
model based on the experimental data from Chapter 3. We model a single cell that 
includes simplified NF-κB and STAT3 signaling. We apply this to a multicellular set 
up where spreading of the STAT3-positive phenotype (due to STAT3P) occurs via IL-6 
present in the extracellular matrix. 
Figure 7J-L shows IL-6 production as a response to US28 activity in our model, 
for all three different parameter settings. STAT3P levels are known to increase in 
mock-transfected cells if they are grown in medium originating from US28 trans-
fected cells due to the presence of IL-6 in the medium. Corresponding, the model 
gives increasing STAT3P levels in response to extracellular IL-6 in all three different 
parameter settings (Figures 7A-C).
When US28 is active, the model gives a constant production of IL-6 due to NF-kB ac-
tivation (Figures 7D-F). The parameters of the positive feedback module determine 
the additional amount of IL-6 production via the positive feedback mechanism. Be-
cause US28 activity is constant, so is the US28 induced IL6 production rate. Figures 
7G-M show the production rate of IL-6 as a function of the IL6 concentration. The 
influence of US28 activity is the same at any IL6 concentration. This shows that the 
parameters of the US28 induced IL6 production do not influence the qualitative 
behavior of the model. It does influence the US28critcal and the steady state IL6 
production in US28 active cells.
In a multicellular context the behavior of the model differs as a function of different 
parameter settings for the STAT3 phosphorylation level as a function of IL6 (Figure 
8). Figure 8 shows a lattice of cells subjected to a high initial IL6. All cells present on 
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the plate are uninfected meaning that there will be no US28 induced IL6 produc-
tion. When followed in time, the only multicellular model that is able to maintain 
the high IL6 levels is the lattice with irreversible bistable cells. 
Analyses of the single cell model show the underlying reason for the behavior ob-
served in the multicellular context. When the STAT3P level increases in a hyperbole 
manner as a function of increasing IL6, there is activation of STAT3 and additional 
production of IL6 present in a virus infected cell (Figure 7F,I,L,O). When there is no 
US28 activity in such a cell, there is also no steady state IL-6 production and, accord-
ingly, no STAT3P (Figure 7C). Only when constantly activated by external IL-6 (orig-
inating from neighboring cells) such a cell can produce IL6 at a constant rate, but 
even then the degradation dominates (Figure 7I). In other words, the STAT3-positive 
phenotype is only present when US28 is present. 
The same conclusions can be drawn for sigmoidal dependence between STAT3P 
and IL-6 that gives reversible bistable IL-6 production for US28 activity (Figure 7N). 
By increasing US28 activity the system switches to a high steady state of IL-6 level 
when a level of activity is passed. A second threshold exists that is crossed when the 
amount of US28 activity diminishes. This results in a rapid decrease in steady state 
IL6 that eventually returns to zero when no activity is left. Figure 7H and Figure 7K 
also show the tendency of the model to return to zero (net) IL6 production in US28 
negative cells.
Sigmoidal dependence between STAT3P and IL6E can also give rise to an irreversible 
bistable IL6 production (Figure 7M). This means that the positive feedback loop is 
self-sustaining after a transient stimulus. This is an interesting property for such a 
system. In this case the virus is able to spread its proliferative phenotype to sur-
rounding cell without infecting them (Figure 7P). This can be achieved by the secret-
ed IL6 of infected cells, which is sufficient to activate the positive feedback loop for 
IL6 production in uninfected cells. In contrast to previous cases, the US28 induced 
IL6 production via NF-kB is not necessary to maintain IL6 production in the single 
cells (Figure 7G-I).
In the multicellular context, the behavior of the model is strikingly different for the 
chosen parameter settings. The irreversible bistable single cell model shows an ir-
reversible activation of the proliferating phenotype once initiated by US28 or IL-6. 
This model implies a spreading of virus-induced phenotype in tissues without in-
fecting individual cells. The following experimental setup may be useful to deter-
mine whether the positive feedback mechanism is indeed irreversible. 
A first attempt at experimentally validating the model was made. Although only a 
limit amount of experiment was performed, we can conclude that several charac-
teristics of the model can at least be partially validated. For example, the increased 
IL-6 expression 24 hours after a pulse with IL-6 indicates that NIH-3T3 cells can be 
triggered to produce new IL-6 after being subjected to a pulse with IL-6. Normal 
NIH-3T3 cells temporally exposed to IL-6 show induced STAT3 phosphorylation (Fig-
ures 10A,B, and D). Subsequently, activated STAT3 induces IL-6 production. Based 
on this experiment we propose an experimental setup as follows: Mock transfected 
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NIH-3T3 cells are to be exposed to medium originating from US28-expressing cells. 
The cells are subsequently washed, put in fresh medium and induced STAT3P levels 
are assessed. Because induced STAT3P will lead to IL-6 production, the medium will 
contain IL-6. If this medium is able to again induce STAT3P in normal NIH-3T3 cells 
to the same extend as before, the feedback loop may be considered to be self-sus-
taining/irreversible bistable. 
If the feedback mechanism is indeed irreversible bistable, our model indicates that 
a single infected cell can enhance IL6 production in uninfected cells. High IL-6 means 
high levels of STAT3P and VEGF, which is of advantage for a tumor and its progres-
sion. When the system is not self sustainable, infected cells can induce STAT3 acti-
vation and IL6 production in uninfected cells but only locally and only for as long as 
the infection is present. This actually seems to fit quite well with the observations 
thus far made of US28 localization in tumors. Only a small subpopulation of the 
tumor is actually US28 positive, but besides their small number they would be able 
to influence the entire tumor by secreting factors like IL-6. This behavior may not be 
unique to HCMV either. The Kaposi Sarcoma associated Herpes Virus (KSHV) encod-
ed GPCR, ORF74, has been shown to induce tumorigenesis in mice (22). Moreover, 
ORF74, like US28, induces STAT3 activation (23). Interestingly, immuno staining for 
ORF74 in Kaposi Sarcoma lesions show that only a small subset of the tumor cell 
population is ORF74 positive (24), which implies that a similar mechanism may be 
at play.
In conclusion, we present here a mathematical model describing US28-induced 
STAT3 activation. This model shows that STAT3-signaling in general has the poten-
tial to grow out of control. Considering its important role in the immune system, it 
seems logical that IL-6 signaling through STAT3 is very potent. However, there must 
be negative regulation at the same time to prevent the formation of positive feed-
back loops. One of these mechanisms is negative regulation by the Suppresors of 
Cytokine Signaling (SOCS), these proteins silence STAT3 signaling after activation by 
ligands (such as IL-6) (25). There are two general scenarios that allow for a positive 
feedback loop to form. The first scenario entails inactivating mutations in the SOCS 
genes. Such mutations have been described, and are associated with cancer devel-
opment and progression (26, 27). The second scenario would involve US28 itself, in 
this case US28-induced IL-6 production overcomes silencing of STAT3 signaling by 
SOCS. In this case US28 renders a cell more susceptible to engage into a IL-6 drive 
positive feedback loop.
The model presented here is a first step in further understanding US28-induced 
STAT3 activation, and perhaps STAT3 activation in general. With this understanding 
it may be possible to formulate strategies of interfering in this feedback loop which 
may result in new therapeutic strategies against STAT3 associated diseases.
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4.5 Materials and methods
Materials and reagents
Antibodies directed against phospho-STAT3 (Tyr705) and STAT3 were purchased from Cell 
Signaling Technology (Boston, MA, USA). Neutralizing antibody against murine IL-6 was from 
BD Biosciences (Franklin Lakes, NJ, USA). Tris base and cycloheximide were obtained from 
Sigma-Aldrich (St. Louis, MO); other chemicals were obtained from Applichem (Darmstadt, 
Germany). Murine IL-6 was obtained from Peprotech (Rocky Hill, NJ, USA). Dulbecco’s Mod-
ified Eagle Medium (DMEM) was purchased from PAA Laboratories (Pasching, Austria). Bo-
vine serum was purchased from Invitrogen.
Cell culture
Murine NIH-3T3 cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) sup-
plemented with 50 IU/ml penicillin, 50 μg/ml streptomycin, and 10% bovine serum. Stable 
clones of NIH-3T3 expressing US28 or US28 R129A mutant  (12) were kept under a selective 
pressure of 400 µg/ml neomycin in the culture medium to ensure homogenous receptor ex-
pression in the cells. Expression of US28 in the NIH-3T3 cells was confirmed using [125I]-CCL5 
binding (specific binding was determined using CX3CL1 10-7 M), as previously described (28).
Western-blot analysis
A Biorad (Hercules, CA) minigel system was used to perform SDS/PAGE, and a Biorad elec-
troblot system was used to transfer protein samples to a 0.45 μm polyvinylidene fluoride 
membrane. Cells were lysed in RIPA-buffer supplemented with α-complete protease inhib-
itor cocktail from Hoffmann-La Roche (Basel, Switzerland), 1 mM PMSF, 1 mM NaVO4, and 
1 mM NaF added. Samples were normalized using the BCA total protein determination kit 
obtained from Thermo Fisher Scientific (Rockford, IL, USA). Blots were quantified using Im-
ageJ (Rasband, W.S., U. S. National Institutes of Health, Bethesda, MD, USA).
Quantitative RT-PCR
For assessing the amount of IL-6 mRNA cells were first scraped in ice-cold phosphate buff-
ered saline (PBS). The cells were subsequently pelleted by centrifugation and stored as a 
pellet at -80°C until analysis. The RNA was isolated from the samples using the RNeasy kit 
from Qiagen (Hilden, Germany). Following RNA isolation, the amount of RNA obtained was 
determined by use of a NanoDrop from Thermo Fisher Scientific. For cDNA synthesis 200 ng 
RNA was used as template, and for the synthesis itself iScript cDNA synthesis kit from Biorad 
was utilized. PCR reactions were performed using SYBR Green mix with MyiQ Real-Time 
PCR detection system (Bio-Rad). The validated primers targeting murine IL-6 mRNA were 
obtained from Origene (Rockville, MD, USA).
Development of the mathematical models
For development of the models Mathematica  7.0 from Wolfram Research was used (Cham-
paign, IL, USA).
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Statistical analysis
All experiments were performed at least two times in duplicate. When comparisons be-
tween treated and vehicle-treated cell were made a Student T-test was performed using the 
GraphPad Prism software (San Diego, CA, USA). Bars and error bars represent the mean and 
SEM, respectively.
85
Development of a mathemathical model describing STAT3 signaling
4
References
1. H. J. Snippert et al., Prominin-1/CD133 marks stem cells and early progenitors in mouse small intestine. 
Gastroenterology 136, 2187 (Jun, 2009).
2. M. K. Gandhi, R. Khanna, Human cytomegalovirus: clinical aspects, immune regulation, and emerging 
treatments. Lancet Infect Dis 4, 725 (Dec, 2004).
3. D. A. Mitchell et al., Sensitive detection of human cytomegalovirus in tumors and peripheral blood of 
patients diagnosed with glioblastoma. Neuro Oncol 10, 10 (Feb, 2008).
4. L. Harkins et al., Specific localisation of human cytomegalovirus nucleic acids and proteins in human 
colorectal cancer. Lancet 360, 1557 (Nov 16, 2002).
5. M. S. Chee, S. C. Satchwell, E. Preddie, K. M. Weston, B. G. Barrell, Human cytomegalovirus encodes 
three G protein-coupled receptor homologues. Nature 344, 774 (Apr 19, 1990).
6. U. A. Gompels, H. A. Macaulay, Characterization of human telomeric repeat sequences from human 
herpesvirus 6 and relationship to replication. J Gen Virol 76 ( Pt 2), 451 (Feb, 1995).
7. M. Thelen, J. V. Stein, How chemokines invite leukocytes to dance. Nat Immunol 9, 953 (Sep, 2008).
8. F. Balkwill, Cancer and the chemokine network. Nat Rev Cancer 4, 540 (Jul, 2004).
9. J. R. Randolph-Habecker et al., The expression of the cytomegalovirus chemokine receptor homolog 
US28 sequesters biologically active CC chemokines and alters IL-8 production. Cytokine 19, 37 (Jul 7, 
2002).
10. D. Maussang et al., The human cytomegalovirus-encoded chemokine receptor US28 promotes angio-
genesis and tumor formation via cyclooxygenase-2. Cancer Res 69, 2861 (Apr 1, 2009).
11. E. Slinger et al., HCMV-encoded chemokine receptor US28 mediates proliferative signaling through the 
IL-6-STAT3 axis. Sci Signal 3, ra58 (Aug 3, 2010).
12. D. Maussang et al., Human cytomegalovirus-encoded chemokine receptor US28 promotes tumorigene-
sis. Proc Natl Acad Sci U S A 103, 13068 (Aug 29, 2006).
13. H. Sumimoto, F. Imabayashi, T. Iwata, Y. Kawakami, The BRAF-MAPK signaling pathway is essential for 
cancer-immune evasion in human melanoma cells. J Exp Med 203, 1651 (Jul 10, 2006).
14. N. Barker et al., Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 449, 
1003 (Oct 25, 2007).
15. N. Barker et al., Lgr5(+ve) stem cells drive self-renewal in the stomach and build long-lived gastric units 
in vitro. Cell Stem Cell 6, 25 (Jan 8, 2010).
16. U. Fischer et al., A different view on DNA amplifications indicates frequent, highly complex, and stable 
amplicons on 12q13-21 in glioma. Mol Cancer Res 6, 576 (Apr, 2008).
17. K. Kemper, C. Grandela, J. P. Medema, Molecular identification and targeting of colorectal cancer stem 
cells. Oncotarget 1, 387 (Oct, 2010).
18. X. Liu et al., beta-Catenin overexpression in malignant glioma and its role in proliferation and apoptosis 
in glioblastma cells. Med Oncol,  (Mar 19, 2010).
19. G. Niu et al., Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Onco-
gene 21, 2000 (Mar 27, 2002).
20. H. Wang et al., Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. 
Stem Cells 27, 2393 (Oct, 2009).
21. H. Yu, M. Kortylewski, D. Pardoll, Crosstalk between cancer and immune cells: role of STAT3 in the tu-
mour microenvironment. Nat Rev Immunol 7, 41 (Jan, 2007).
22. C. Bais et al., G-protein-coupled receptor of Kaposi’s sarcoma-associated herpesvirus is a viral oncogene 
and angiogenesis activator. Nature 391, 86 (Jan 1, 1998).
23. M. Burger, T. Hartmann, J. A. Burger, I. Schraufstatter, KSHV-GPCR and CXCR2 transforming capacity 
and angiogenic responses are mediated through a JAK2-STAT3-dependent pathway. Oncogene 24, 2067 
(Mar 17, 2005).
24. C. J. Chiou et al., Patterns of gene expression and a transactivation function exhibited by the vGCR 
(ORF74) chemokine receptor protein of Kaposi’s sarcoma-associated herpesvirus. J Virol 76, 3421 (Apr, 
2002).
25. D. J. Hilton, Negative regulators of cytokine signal transduction. Cell Mol Life Sci 55, 1568 (Sep, 1999).
26. F. Pierconti et al., Epigenetic silencing of SOCS3 identifies a subset of prostate cancer with an aggressive 
behavior. The Prostate, n/a (2010).
27. Y. C. Lin et al., Adenovirus-mediated SOCS3 gene transfer inhibits the growth and enhances the radio-
sensitivity of human non-small cell lung cancer cells. Oncol Rep 24, 1605 (Dec, 2010).
28. P. Casarosa et al., Constitutive signaling of the human cytomegalovirus-encoded chemokine receptor 
US28. J Biol Chem 276, 1133 (Jan 12, 2001).

5
Constitutive β-catenin signaling by the viral chemokine receptor US28
Adapted from:
Ellen V. Langemeijer*, Erik Slinger*, Sabrina de Munnik, Andreas Schreiber, David 
Maussang, Henry Vischer, Folkert Verkaar, Rob Leurs, Marco Siderius and Martine 
J. Smit
PLoS One (In press)
* authors contributed equally to this manuscript
88
Constitutive β-catenin signaling by the viral chemokine receptor US28
5.1 Abstract
Chronic activation of Wnt/β-catenin signaling is found in a variety of human ma-
lignancies including melanoma, colorectal and hepatocellular carcinomas. Inter-
estingly, expression of the HCMV-encoded chemokine receptor US28 in intestinal 
epithelial cells promotes intestinal neoplasia in transgenic mice, which is associated 
with increased nuclear accumulation of β-catenin. In this study we show that this 
viral receptor constitutively activates β-catenin and enhances β-catenin-dependent 
transcription. Our data illustrate that this viral receptor does not activate β-catenin 
via the classical Wnt/Frizzled signaling pathway. Analysis of US28 mediated signal-
ing indicates the involvement of the Rho-Rho kinase (ROCK) pathway in the activa-
tion of β-catenin. Moreover, cells infected with HCMV show significant increases in 
β-catenin stabilization and signaling, which is mediated to a large extent by expres-
sion of US28. The modulation of the β-catenin signal transduction pathway by a vi-
ral chemokine receptor provides alternative regulation of this pathway, with poten-
tial relevance for the development of colon cancer and virus-associated diseases.
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5.2 Introduction
The Wnt/β-catenin signaling pathway plays critical roles in embryonic develop-
ment, stem cell self-renewal and regeneration (1, 2). Perturbations in this signal-
ing cascade have been implicated in the pathogenesis of cancer. Notably, chronic 
activation of Wnt/β-catenin signaling is found in a variety of human malignancies 
including melanoma, colorectal and hepatocellular carcinomas (3, 4). Accordingly, 
components of the Wnt/β-catenin pathway are important targets for cancer thera-
peutics (3). In the absence of an extracellular Wnt ligand, cytoplasmic β-catenin is 
phosphorylated through the action of the “destruction complex”, a large protein as-
sembly that contains the Ser/Thr kinases casein kinase 1α (CK1), glycogen synthase 
kinase 3 (GSK-3) and the tumor suppressors Axin and Adenomatous polyposis coli 
(APC) (1). Phosphorylation of β-catenin targets it for ubiquitin-mediated proteaso-
mal degradation. However, upon stimulation of the seven-transmembrane receptor 
Frizzled and the single-pass low-density lipoprotein receptor-related protein LRP5/6 
by a Wnt ligand, the destruction complex function is compromised through a not 
fully understood mechanism. As a result, β-catenin will not be phosphorylated and 
will no longer be subject to degradation, and will subsequently translocate to the 
nucleus (5). Nuclear β-catenin functions as a transcriptional co-activator of target 
genes such as c-myc and cyclin D1, which are involved in proliferation, survival and 
oncogenic transformation (6-8).  
The importance of GPCR-mediated signaling in onset and development of various 
types cancer (9) is underscored by the observation that β-catenin activation is trig-
gered by a 7TM spanning receptor, Frizzled which is activated by its cognate ligand 
Wnt (1). Besides Frizzled receptors, a few other G protein-coupled receptors (GP-
CRs) mediate β-catenin induced transcriptional activation (10, 11). The lysophos-
phatidic acid LPA2 receptor and LPA3 both trigger β-catenin stabilization and cell 
proliferation via protein kinase C activation (12). Additionally, the pro-inflammatory 
metabolite prostaglandin E2 activates β-catenin through activation of its cognate 
receptor (13). The human protease-activated receptor-1 (PAR-1) stabilizes β-catenin 
through phosphorylation of GSK-3b at Ser9 . Altogether, these pathways converge 
on the Wnt signaling route to induce cytoplasmic β-catenin accumulation, nuclear 
localization, and enhanced transcriptional activation (14).
In this study we show that the human cytomegalovirus (HCMV)-encoded GPCR 
US28 positively modulates β-catenin signaling, resulting in enhanced β-catenin-
dependent transcription. US28 is one of four GPCRs encoded by the HCMV (15). In-
terestingly, this widely spread b-herpesvirus (16) has been associated with vascular 
diseases (17) and is suggested to act as an oncomodulator (18). All four HCMV-en-
coded GPCRs (vGPCRs) show high homology to human chemokine receptors, which 
play a fundamental role in the control and regulation of the immune system and in 
the progression of cancer and metastasis (19, 20). US28 is able to signal in a consti-
tutive, ligand-independent, manner via Gαq and Gβγ but also in a ligand-dependent 
manner via Gα12 to proliferative and pro-angiogenic signaling pathways (15, 21, 22). 
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US28 has oncogenic properties as US28-expressing NIH-3T3 cells promote tumor-
igenesis when injected into nude mice (23). Moreover, US28 expression was de-
tected in human glioblastomas and medulloblastomas, which was associated with 
increased STAT3/IL-6 and COX-2 activity (24-26) Moreover, transgenic mice express-
ing US28 in intestinal epithelial cells, including LGR5-positive stem cells, develop 
adenomas and adenocarcinomas, associated with increases in β-catenin protein 
stabilization and nuclear localization (27). Additionally, transcriptional profiling of 
US28-expressing fibroblasts indicated also an overrepresentation of genes involved 
in the Wnt/β-catenin signaling pathway (28). These observations suggest that US28 
may facilitate transformation and development of intestinal neoplasia via activation 
of β-catenin (27).
In this study we show that the viral chemokine receptor US28 positively modulates 
the β-catenin pathway via a non-conventional novel pathway, involving Rho kinase. 
5.3 Results
5.3.1 Viral chemokine receptor US28 activates the β-catenin pathway.
Transgenic mice expressing US28 in intestinal epithelial cells develop adenomas and 
adenocarcinomas that express high levels of nuclear β-catenin protein (27). Addi-
tionally, US28-mediated up-regulation of genes associated with β-catenin signaling 
was described (28). These findings and the role of β-catenin in oncogenesis (1, 2), 
prompted us to investigate the mechanism by which this viral GPCR activates β-cat-
enin signaling. Since this receptor displays constitutive active properties (29) we 
used the wild type (WT) as well as a G protein-uncoupled mutant receptor (US28-
R129A) in these studies. US28-WT expressing NIH-3T3 cells displayed [125I]-CCL5 bind-
ing and increased inositol phosphate production compared to mock-transfected 
cells (Fig. 1A,B), indicative of proper plasma membrane targeting and functionality 
of the receptor. Cells expressing the G protein-uncoupled mutant US28 (US28-R129A) 
receptor displayed [125I]-CCL5 binding but no constitutive signaling (Figure 1A, B). 
Using Western blot analysis, non-phospho (active) β-catenin levels were shown to 
be elevated in US28-expressing NIH-3T3 cells compared to mock-transfected and 
US28-R129A expressing cells (Figure 1C). Further indication for US28-mediated acti-
vation of β-catenin signaling was generated using a β-catenin-specific reporter gene 
construct containing TCF/Lef binding sites (TOPflash) (30). Analysis of activation of 
TOPflash in the NIH-3T3 cells stably expressing US28 confirmed US28-mediated ac-
tivation of β-catenin signaling (Figure 1D). As expected stable expression of the G 
protein-uncoupled mutant (US28-R129A) did not display β-catenin activation.  Also in 
HEK293T cells, increasing expression of US28 resulted in dose-dependent activation 
of the β-catenin signaling pathway as demonstrated using the TOPflash reporter 
gene (Figure 1E). A reporter gene containing mutant TCF/Lef-binding sites (FOP-
flash), used as a negative control, was not induced in US28 expressing cells (data 
not shown). In accordance with the Western blot data, cells expressing the G pro-
tein-uncoupled mutant US28-R129A did not display TOPflash reporter gene activity, 
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indicating the importance of G-protein signaling in US28-induced activation of the 
β-catenin signaling pathway (Figure 1E). Treatment of US28 transfected cells with 
the US28 small molecule inverse agonist VUF6064 (31) at a 10µM concentration, 
prevented activation of the Tcf-Lef reporter gene construct (Figure 1E).
To investigate whether US28-mediated β-catenin signaling can be modulated by 
chemokine ligands, we stimulated US28-expressing cells with CCL5, which enhanc-
es US28-dependent signaling through Gαq and Gα12 pathways (32). Stimulation of 
US28 with 100 nM CCL5 yielded a small but significant increase in TOPflash reporter 
gene activity (Figure 1F). Expression of CCR1, a human chemokine receptor dis-
playing close homology to US28, did not induce activation of TOPflash, neither in 
a constitutive manner, nor upon stimulation with 100 nM of its endogenous ligand 
CCL5 (Figure 1F). 
 
5.3.2 US28 activates β-catenin/TOPflash via a non-classical signal transduction 
pathway. 
We next compared the mechanism by which the classical activator of the Wnt/Friz-
zled pathway Wnt3a and US28 activate β-catenin signaling. As depicted in Figure 
2A, both Wnt3a [200 ng/ml] and US28 expression induced stabilization of β-catenin 
in NIH3T3 cells. Activation of β-catenin through the classical Wnt/Frizzled pathway 
involves the CK1g/GSK3b-mediated phosphorylation of LRP 5/6, which leads to 
recruitment of Axin and Dishevelled to the plasma membrane, culminating in the 
disruption of the destruction complex (33, 34). Analysis of LRP6 phosphorylation 
in US28-expressing cells indicated that in contrast to Wnt3a-stimulated β-caten-
in activation of either mock or US28  transfected cells, LRP6 phosphorylation was 
absent at serine residue 1490, suggesting an alternative mechanism of β-catenin 
activation for US28 (Figure 2B and Figure S1). In line with this notion, activation of 
TOPflash activity through Wnt3a and US28 were additive (Figure 2C), suggesting 
parallel modes of pathway activation. These data illustrate that US28 does not ac-
tivate β-catenin via the classical Wnt/Frizzled signaling pathway. To investigate this 
alternative mechanism of US28-mediated β-catenin signaling, various inhibitors of 
potential effectors of the GSK-3b/APC destruction complex, such as PLC (U73122), 
PKC (203291), Akt (124005), PI3K (Wortmannin and LY294002), Src (PP-2) and STAT-
3 (Stattic) were analysed as potential modulators of US28-mediated β-catenin ac-
tivation. Neither of these showed any effect on US28-induced TOPflash reporter 
gene activation (data not shown).
Earlier studies attributed a role for COX-2 in US28-mediated cellular responses (24, 
28). Since COX-2 activation has been linked to activation of the β-catenin pathway 
(13) we analysed the effect of celecoxib (COX-2 inhibitor) on US28-mediated β-cat-
enin-dependent reporter gene activity. Celecoxib treatment inhibited the TOPflash 
reporter gene activity only partially at relatively high celecoxib concentrations, indi-
cating only a minor contribution of COX-2 (Figure 2D). 
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- CCL5
+ CCL5
Figure 1. US28 induces constitutively activates β-catenin signaling. US28 is expressed and functional in NIH-3T3 
cells. (A) Whole cell binding of 125[I]-CCL5 on NIH-3T3 cells expressing wild-type (WT), mutant R129A or HA-tagged 
US28 is displaced by fractalkine (CX3CL1). (B) US28-WT constitutively stimulates inositol phosphate (IPx) accumu-
lation in NIH-3T3, while the non-G protein-coupling mutant US28-R129A shows no activation. (C) Total cell extracts 
of NIH-3T3 cells stably expressing US28, the non G-protein-coupling mutant and empty plasmid control (mock) 
were analysed on Western blot with antibodies recognizing the non-phospho (active) β-catenin, total β-catenin 
and actin. (D) NIH-3T3 cells stably expressing US28 and the non G-protein coupling US28 mutant R129A were trans-
fected with the Tcf-Lef reportergene construct. Luciferase activity was measured 24hr after transfection. (E) US28 
dose-dependently induces Tcf-Lef transcriptional activation in HEK293T cells. The non-G protein coupling mutant 
US28 R129A does not display activation of the reportergene at 25ng DNA transfected (dark grey bar). Treatment of 
HEK293T cells transfected with 25ng US28 DNA with inverse agonist VUF 6064 (10 µM) prevents activation of Tcf-
Lef reortergene (light grey bar). (F) HEK293T cells transfected with the human chemokine receptor CCR1 and the 
Tcf-Lef reportergene construct do not show Tcf-Lef activation nor after exposure to 100 nM CCL5 (RANTES). US28 
expressing HEK293T cells display constitutive signaling to the Tcf-Lef reportergene, which is significantly enhanced 
by exposure to 100 nM CCL5 (RANTES).
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Figure 2. Classical Wnt/Frizzled/β-catenin signaling is not involved in US28-mediated Tcf-Lef activation. (A) West-
ern blot analysis of total cell extracts of NIH-3T3 cells, stably expressing US28 or an empty plasmid (mock) which 
were treated with Wnt3a-(overnight, 200ng/ml) and vehicle  treated mock cells. The blot was probed with anti-
bodies recognizing the non-phosphorylated (active) β-catenin, total β-catenin and actin. A representative blot is 
shown and normalized quantifications of (active) β-catenin of independent experiments are shown below the blot. 
(B) Western blot analysis of total cell extracts of NIH-3T3 cells stably expressing US28, the non G-protein coupling 
US28 mutant R129A or an empty plasmid (mock) and Wnt3a-treated mock cells. The blot was probed with antibod-
ies recognizing Lrp6-phospho-ser1490 and β-actin. A representative blot is shown and normalized quantifications of 
Lrp6-phospho-ser1490 of independent experiments are shown below the blot. (C) HEK293T cells co-transfected with 
the Tcf-Lef reporter gene construct and either US28-expressing or an empty control plasmid (mock) exposed to 
Wnt3a (overnight, 200 ng/ml). Luciferase activity was measured 24hr after transfection and is displayed here as the 
percentage of the non-treated mock control that is set at 100%. (D) HEK293T cells co- transfected with the Tcf-Lef 
reportergene and an US28-expressing construct or empty plasmid control (mock) were exposed to various concen-
trations (ON, 10-25 µM) of the COX2 inhibitor celecoxib (Cxb). Tcf-Lef reporter gene activation was measured 24hr 
after transfection and is displayed here as the percentage of the mock control that is set at 100%.
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5.3.3 G protein involvement in US28 enhanced TOPflash reporter gene activation. 
The complete lack of activity of the G protein-uncoupled receptor US28-R129A mu-
tant towards β-catenin signaling suggested that G protein coupling is essential for 
activation of β-catenin by US28. The involvement of G-proteins in US28-mediated 
TOPflash reporter gene activation was further examined by co-expressing different 
G protein subunits or by co-expressing constructs known to negatively regulate G 
protein function. Co-transfection of the Ga-proteins Gαs, Gαi2, Gαi3, Gα11, Gα13 with 
US28 did not influence TOPflash reporter gene activation nor did overnight treat-
ment with the Gαi–specific inhibitor pertussis toxin (PTX) (data not shown). Co-ex-
pression of Gαq enhanced US28-mediated TOPflash reporter gene activation, while 
knocking down Gαq with shGαq resulted in over 50% inhibition of US28-mediated 
TOPflash activation (Figure 3A). Downregulation of Gαq protein levels was confirmed 
by Western blot analysis (Figure 3B). Expression of the regulator of G protein signal-
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Figure 3. G protein involvement in US28-mediated Tcf-Lef activation. (A) HEK293T cells were co-transfected with 
the Tcf-Lef reporter gene construct, a US28-expressing construct or empty plasmid control (mock) and various 
constructs expressing Gα-proteins as indicated, Gαq-11 shRNA construct or a construct expressing regulator of G 
protein signaling 2 (RGS2), known to specifically interfere with Gαq signaling. Tcf/Lef reporter gene activation was 
measured 24hr after transfection and is displayed here as the percentage of the mock control that is set at 100%. 
(B) HEK293T cells were co-transfected with the Tcf-Lef reporter gene construct, US28-expressing construct or emp-
ty plasmid control (mock) and an shRNA construct to decrease protein levels of Gαq. Total cell extracts were anal-
ysed on Western blot using antibodies recognizing Gαq or β-actin (insert). Bars represent level of Gαq protein level 
compared to the actin levels, with the ratio in non-treated mock cells set at 100%. (C) HEK293T cells were co-trans-
fected with the Tcf/Lef reporter gene construct, a US28-expressing construct or empty plasmid control (mock) and 
various constructs expressing Gα13, a constitutive active (CA) Gα13 or Lsc-RGS, encoding the RGS domain of the Rho 
GTPase guanine nucleotide exchange factor (Rho-GEF) Lsc, known to specifically interfere with transmembrane 
signaling mediated by activated Gα12/13. Tcf/Lef reporter gene activation was measured 24hr after transfection and 
is displayed here as the percentage of the mock control that is set at 100%. (D) HEK293T cells co-transfected with 
the Tcf/Lef reporter gene construct, a US28-expressing construct or empty plasmid control (mock) were treated 
(overnight) with various concentrations of the ROCK inhibitor Y27632 as indicated.
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ing 2 (RGS2), which is known to specifically interfere with Gαq-mediated signaling 
(35) strongly reduced US28-induced TOPflash activation (Figure 3A). Interestingly, 
co-transfection of a constitutively active mutant of Gα13 (Gα13-CA), but not wild type 
Gα13, resulted in enhanced TOPflash activation in mock cells (Figure 3C). This ef-
fect was enhanced when US28 was co-transfected. Finally, we co-transfected cells 
with US28 and the Lsc-RGS scavenger, encoding the RGS domain of the Rho GTPase 
guanine nucleotide exchange factor (Rho-GEF) Lsc. Lsc-RGS is known to specifically 
interfere with transmembrane signaling mediated by activated Gα12/13 signaling (35, 
36). Expression of Lsc-RGS in US28-expressing cells resulted in a strong inhibition of 
US28-mediated TOPflash reporter gene activation (Figure 3C), indicating an import-
ant role for Gα12/13 proteins.
As Gαq and Gα12/13 proteins mediate activation of Rho via the Rho-GEFs p63 and p115 
(36, 37), respectively and Rho in turn is known to activate ROCK kinase (Rho ROCK 
REF), we investigated the role of the Rho-Rho kinase (ROCK) pathway in US28-me-
diated signaling to β-catenin. Exposure of US28-expressing cells to increasing con-
centrations of the ROCK inhibitor Y27632 resulted in a dose-dependent attenuation 
of the US28 mediated TOPflash activation (Figure 3D), indicating involvement of 
Rho-ROCK signaling in the US28-induced β-catenin activation pathway. 
5.3.4 Role for US28 in HCMV induced activation of β-catenin signaling
The HCMV Titan 2B strain (referred to as WT) (28) and a strain deficient for the US28 
gene (HCMV-DUS28) were used to examine the ability of HCMV, and the possible 
contribution of US28, in activating β-catenin signaling after infection. Infection of 
human foreskin fibroblasts (HFFs) with HCMV-WT resulted in increased presence 
of active β-catenin in cytoplasm and nuclei of infected cells, as evidenced by the 
expression of the immediate early antigen (IEA) (Figure 4A). Cells infected with the 
deletion mutant HCMV-DUS28 showed only marginal active β-catenin in these cells 
and no active β-catenin was apparent in non-infected cells (Figure 4A). Since HFFs 
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Figure 4. HCMV-infected cells stimulate activation of β-catenin in a US28 dependent manner. (A) HFF cells were 
infected with HCMV-WT or HCMV-ΔUS28 with a M.O.I of 1 on IBIDI slides. Cells were fixed 24 hours post-infection 
(hpi) and stained with antibodies recognizing the HCMV immediate early antigen (IEA) and activated β-catenin 
respectively. (B) U373-MG cells transfected with Tcf-Lef reporter gene were either infected with HCMV-WT or 
HCMV-ΔUS28 with a M.O.I. of 2, or left uninfected (mock). Luciferase activity was measured 48h post-infection.
96
Constitutive β-catenin signaling by the viral chemokine receptor US28
show low transfection efficiencies we used U373-MG glioma cells to transfect the 
TOPflash reporter gene construct to monitor β-catenin-dependent transcriptional 
activation after HCMV infection. U373-MG glioma cells were transfected with the 
TOPflash reporter gene construct, followed by infection with either HCMV-WT or 
HCMV-DUS28. Cells infected with HCMV-WT showed strong β-catenin-dependent 
transcriptional activation (Figure 4B), while cells infected with the deletion mutant 
HCMV-DUS28 displayed a significantly lower level of TOPflash reporter gene activity 
(Figure 4B). The levels of infection between HCMV-WT and HCMV-DUS28 were simi-
lar, as determined by back titration (Figure S2). These data clearly indicate a role for 
US28 in regulation of β-catenin signaling during HMCV-infection.
5.5 Discussion
 We have demonstrated that HCMV partly through expression of the constitutively 
active chemokine receptor US28 induces β-catenin signaling upon infection. Indeed, 
mounting evidence links viral infection to β-catenin hyperactivation. For instance, 
the Epstein-Barr virus (EBV) activates β-catenin in latently infected B lymphocytes 
(38).  The human papillomavirus (HPV) E6 and E7 oncogenes appear to contribute 
to activation of β-catenin signaling in HPV16-positive oropharyngeal squamous car-
cinoma cells (39) and the hepatitis C virus (HCV) encoded core protein potentiates 
Wnt/β-catenin signaling in hepatocellular carcinoma cells (40). For the human im-
munodeficiency virus (HIV), however, active Wnt/β-catenin signaling plays a signifi-
cant role in repression of HIV-1 replication in multiple cell targets (41, 42). 
Interestingly, expression of the HCMV-encoded chemokine receptor US28 in intes-
tinal epithelial cells promotes intestinal neoplasia in transgenic mice (27), which is 
associated with increased accumulation of β-catenin in the nucleus. In this study we 
show that this viral receptor leads to activation of β-catenin and enhanced β-caten-
in-dependent transcription in a manner distinct from conventional Wnt-mediated 
signaling when expressed in NIH3T3 cells or HEK293T cells. Classical Wnt-mediated 
β-catenin signaling entails the phosphorylation of LRP 5/6, ultimately leading to the 
nuclear accumulation of β-catenin (1, 43). The absence of LRP6 phosphorylation in 
US28-expressing cells supports the notion that US28 activates the β-catenin path-
way through alternative routes. Unlike some of the lysophosphatidic acid, prosta-
glandin and protease activated receptors shown to stabilize β-catenin at the level 
of the destruction complex (12), US28-induced TOPflash activation is not PI3K- nor 
PKC-dependent. COX-2, via concomitant production of prostaglandins and activa-
tion of their cognate receptors in US28 expressing cells (Maussang, Langemeijer et 
al. 2009) is partially involved and does not account for the large increase in β-caten-
in activity observed in US28 expressing cells.
In this study it is shown for the fist time that a GPCR, the viral chemokine receptor 
US28, activates β-catenin signaling through the Rho-ROCK pathway. Our data show 
that coupling of US28 to both Gαq and Gα12/13 proteins is essential for the observed 
activation of β-catenin signaling. Overexpression, scavenging and/or downmod-
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ulation of either G protein greatly affect US28 mediated β-catenin signaling. The 
reported ligand-independent, constitutive, activity displayed by US28 is primarily 
exerted through activation of Gαq proteins (29, 44). Earlier, US28 was shown to also 
constitutively activate the serum response factor via Gαq proteins and RhoA, the 
small G protein that is activated by Gαq proteins through RhoGEF (35, 37). The li-
gand-dependent activity of US28 directs smooth muscle migration via Gα12/13 and 
RhoA (45). Interestingly, several regulators of the Wnt/β-catenin signaling pathway 
were found to be associated with pro-migratory signaling of US28 via activation of 
the Pyk2 kinase (46). In view of the importance of Gαq and Gα12/13 in US28 medi-
ated β-catenin signaling and reported coupling of US28 to RhoA we postulated a 
role for its downstream target Rho kinase (ROCK) in US28 mediated activation of 
β-catenin. Inhibition of ROCK, with the specific inhibitor Y27632, substantiates a 
role for Rho-ROCK axis in the US28 induced activation of the β-catenin pathway. 
Exposure of US28 expressing cells to the chemokine CCL5 result in further increases 
in β-catenin signaling, infering involvement of Gα12/13 proteins which is in line with 
previous studies indicating the involvement of these G proteins in US28-mediated 
responses (47). Altogether, our studies demonstrate that US28 activates β-catenin 
signaling in a ligand dependent and independent manner, involving Gα12/13 and Gαq 
proteins converging at RhoA/ROCK (Figure 5). Additional experiments are currently 
ongoing to elucidate the molecular mechanism by which ROCK stabilizes β-catenin 
and induces TOPflash activation. 
Of importance is that significant increases of β-catenin stabilization and signaling 
are observed in HCMV-infected HFFs and glioblastoma cells. This increase in β-cat-
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Figure 5. Schematic representa-
tion of the classic Wnt signaling 
pathway and model of US28-me-
diated activation of β-catenin sig-
naling pathway. 
The left side of the model indi-
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Wnt/Frizzled mediated activation 
of β-catenin. In this pathway the 
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that enables GSK3β− and Caseine 
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enin signaling upon HCMV infection is mediated to a large extent by expression 
of US28, as shown using the deletion mutant HCMV-DUS28. Besides US28, other 
CMV encoded proteins, including another viral GPCR UL33, also contribute to the 
observed increase in β-catenin signaling upon HCMV infection (Figure S3). Increas-
es in β-catenin nuclear localization were also reported upon infection of murine 
CMV (48), reinforcing a role of HCMV-encoded proteins, like US28, in regulating 
β-catenin signaling. Sustained activation of the Wnt/β-catenin pathway induced by 
gain-of-function mutations of activators of the Wnt pathway, for e.g. mutations in 
the β-catenin gene that enhance its stability, or mutations in genes that control 
β-catenin stability like APC, the Axins, or E-cadherin, is found in various cancers (3, 
4). Hence, the ability of US28 to constitutively activate β-catenin signaling, as well 
as other oncogenic signaling pathways (22, 24, 25, 28, 49) illustrates that this viral 
receptor may contribute to a malignant phenotype in HCMV positive cells. The fact 
that expression of US28 promotes development of intestinal dysplasia and cancer 
in transgenic mice (27) suggest that CMV infection may facilitate development of 
intestinal neoplasia in humans. Moreover, β-catenin and components of the Wnt 
canonical pathway are commonly overexpressed in glioblastoma multiforme (50). 
The high incidence of HCMV infection and detection of expression of US28 in hu-
man glioblastomas (24, 25) further underscores the relevance of this receptor in 
cancer development. 
Taken together, in this study we have shown an alternative regulation of the β-cat-
enin pathway. The viral chemokine receptor US28, induces activation of β-catenin, 
via the Rho-ROCK pathway. By expression of viral receptor proteins viruses might be 
able to rewire β-catenin signaling, contributing to malignant phenotypes. 
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5.5 Materials and methods
Cell culture and transfections 
Human HEK293T, human glioblastoma U373-MG, human foreskin fibroblasts (HFF) and NIH-
3T3 mouse fibroblast cells were all obtained from ATCC, and cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM) (PAA Laboratories), supplemented with penicillin (50 IU/ml), strep-
tomycin (50 mg/ml) (PAA Laboratories) and 10% fetal bovine serum (FBS) (PAA Laboratories), 
heat-inactivated FBS and bovine serum (Gibco) respectively. NIH-3T3-stable cell lines (Mock, 
US28, HA-US28 and US28-R129A mutant) were kept under the selective pressure of neomycin 
(400 mg/ml) (Sigma) to ensure homogenous receptor expression. Transient transfections of 
HEK293T cells were performed with the polyelthyleneimine (PEI) method (51, 52) followed 
by luciferase activity measurement the next day. Transient transfections of NIH-3T3 and 
U373-MG cells were performed with the Lipofectamine2000 method (Invitrogen).  
Reporter gene analysis
106 HEK293T cells were transfected with plasmids encoding a TOP-flash reporter construct 
(TOPflash or the negative control Fopflash, kindly provided by Prof. H. Clevers and Dr. M. vd 
Wetering) and 25 ng of US28 receptor DNA (wild type or G-protein-uncoupled mutant R129A) 
unless indicated differently and 25 ng of DNA encoding G-proteins (RGS2 and Lsc-RGS G pro-
tein scavengers were kindly provided by Dr. B. Moepps). Comparable TOPflash reportergene 
transfection protocols were used for U373-MG and NIH-3T3 cells, respectively. Total DNA 
amounts were kept constant by addition of empty vector. Inhibitors Y27632 (Rock, Sigma) 
were incubated overnight and added directly after transfection. 200ng/ml human recombi-
nant Wnt3a (R&D systems, 5036-WN-010) was incubated overnight to activate the canon-
ical Wnt signaling pathway. Luciferase activity was measured 24 h post transfection (RLU, 
relative light units) with a Victor2 multilabel plate reader from (PerkinElmer Life Sciences). 
Statistical analyses, * or ** indicating p<0.05 or p<0.001, using Anova and Bonferroni post 
test 95% confidence interval.
Virus infection
Human Foreskin Fibroblasts (HFF) infected at a multiplicity of infection (MOI) of 1 on IBIDI 
slides with the TB40wt and TB40-DUS28 strains, respectively. Anti-IEA (Milipore) and an-
ti-non-phospho-β-catenin antibodies (Cell Signaling Technology) were used to visualize IEA 
and activated β-catenin. After transfection of the TOPflash reporter gene in U373-MG cells 
(24 h), different HCMV Titan strains (WT or -DUS28) were used to infect U373-MG at an MOI 
of 2. Multiple viral stocks (3 for HCMV-WT, 4 for -DUS28) were assayed in triplicate. The rate 
of infectivity was controlled by back titration and IEA staining on parallel clear plates (data 
not shown). 48h post-infection luciferase activity was measured. 
Chemokine binding and inositol phosphate accumulation experiments
Stably transfected NIH-3T3 cells (Mock, HA-US28 and US28) were analyzed for radiolabelled 
chemokine binding and inositol phosphate accumulation as previously described (15).
Western Blot Analysis
Biorad minigel and electroblot systems (Biorad) were used to perform SDS-PAGE and subse-
quent protein transfer onto 0.45 mm nitrocellulose or PVDF membranes. After an overnight 
serum starvation in medium containing 0.5% bovine serum, NIH-3T3 stable cell lines (Mock, 
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US28 and US28-R129A) were lysed in radioimmunoprecipitation assay buffer supplemented 
with a-Complete Protease Inhibitor Cocktail (Hoffmann-la Roche), 1 mM PMSF, 1 mM NaVO4 
and 1 mM NaF. Samples were normalized using the BCA total protein determination kit 
(Thermo Fisher Scientific, Rockford lL, USA). Antibodies were used for detection of active 
β-catenin (Millipore and Cell Signaling Technology), total β-catenin (BD Transduction Labora-
tories), mouse monoclonal b-actin expression (Sigma), Gαq (Santa-Cruz) and P-LRP6 (Ser
1490) 
(Cell Signaling Technology).
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Figure S1. Wnt3a induces LRP6 phosphorylation at serine 
1490 in US28-transfected NIH3T3 cells. Mock cells and 
US28 expressing cells were treated with 500 ng/ml recombi-
nant Wnt3a. Subsequently, LRP6 Ser1490 phosphorylation 
was analysed by Western blot analysis.
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Figure S2. Back titration of wild-type HCMV and HCMV 
ΔUS28. The levels of infection were assessed by staining 
for Immediate Early (IEA). The amount of IEA+ cells is not 
significantly different between the different viral strains. 
This backtitration was performed on the samples that were 
used for the analysis shown in Figure 4B.
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Figure S3. Activation of Tcf/Lef by UL33. UL33 and TOPflash 
were co-transfected, and luciferase activity was analysed 
24 hours post-transfection. UL33 induces Tcf/Lef activation 
strongly.
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6.1 Abstract
The human cytomegalovirus genome contains several genes encoding chemokine 
receptor homologs. One of these homologs is US28, a constitutive active receptor 
that activates several signaling pathways and which is capable of inducing prolifer-
ation. In order to understand how US28 can elicit such behavior, several signaling 
pathways have already been analyzed to date. However, there are still significant ca-
veats in our understanding of US28 signaling. To address this, the US28 signalosome 
was characterized using a methodology designed for isolating receptor complexes. 
The obtained complexes were analyzed using liquid chromatography coupled on-
line to a tandem mass-spectrometer. Analysis of the signalosome using Ingenuity 
Pathway Analysis software and STRING has revealed several pathways to be over-
represented. The data from these analyses was used to further investigate the na-
ture of US28-induced Tcf/Lef signaling. These data represent a first view of a viral 
G-protein coupled receptor’s signalosome.
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6.2 Introduction
The virally encoded G-protein coupled receptor (GPCR) US28 has been shown to 
possess oncogenic properties in an earlier study (1). Since the first description of 
this receptor’s oncogenic potential, the molecular mechanisms by which US28 in-
duces a proliferative phenotype have been investigated. These investigations have 
shown that US28 activates multiple pathways that are required for the US28-in-
duced proliferation. The first factor that was shown to be critical for proliferation 
instigated by US28 is cyclooxygenase-2 (COX2). Using the non-steroidal inflamma-
tory inhibitor (NSAID) Celecoxib, COX2 activity was shown to be required for both 
the increased cellular growth rate and tumorigenic potential displayed by US28 ex-
pressing cells (2). Another cellular factor shown to be of import to US28-induced 
proliferation is STAT3 (see Chapter 3 of this thesis). This transcription factor was 
shown, like COX2, to be a key factor for inducing the US28-related proliferative and 
oncogenic phenotype (3). Treating cells with the STAT3 inhibitor JSI-124 resulted in 
decreased proliferation as well as reduced focus formation. Finally, β-catenin signal-
ing, a transcription factor that is associated with many cancers, in particular colon 
cancer, is also influenced by US28 (see Chapter 5 of this thesis). A study using trans-
genic mice expressing US28 targeted to the intestine showed that these mice devel-
oped tumors in the small intestine and these tumors display constitutive β-catenin 
activation (4).
These examples clearly show that US28 activates multiple cellular pathways. An 
analysis of the US28 signalosome was performed to gain more understanding of 
US28 signaling. The signalosome can be defined as the proteins that form a complex 
with a receptor to facilitate (receptor-) signaling, in the case of GPCRs the signalo-
some contains, among others, proteins such as the G-proteins (5). In this study we 
have employed an immunoprecipitation technique using N-terminally HA-tagged 
US28 which, following immunoprecipitation and sample preparation was subjected 
to liquid chromatography tandem mass-spectrometry (LC-MS/MS). The resulting 
list of proteins was then analyzed for gene ontology and potential interactions, us-
ing Ingenuity Pathway Analysis software.
 A STRING analysis was used on the same dataset in combination with other experi-
mental data to build an interaction map. Based on the result of these analyses, and 
the data shown in Chapter 5, the link between US28 induced Rho/ROCK signaling 
and Tcf/Lef activation was further investigated. 
In this study a general technique for performing immunoprecipitations on GPCRs 
leaving protein-protein interactions intact is described, as well as a workflow for 
preparing the eluates from the immunoprecipitations for LC-MS/MS analysis. The 
obtained knowledge about the signalosome will aid in identifying novel signaling 
pathways through which US28 signals.
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Figure 1. Characterization of HA-tagged US28. (A) 
Radioligand binding using [125I]-CCL5 which was 
displaced by 10-7 M CX3CL1 shows expressing of 
wild-type US28 and HA-US28. (B) Functionality of the 
receptors was determined with a NFAT-reportergene 
assay which shows increased NFAT transcriptional 
activity in both the wild-type and the HA-tagged re-
ceptor. (C) Thymidine incorporation shows that HA-
US28 also induces cellular proliferation, determined 
by [3H]-thymidine incorporation.
6.3 Results
6.3.1 Characterization of N-terminally HA-tagged US28 expressing cells
Although it is possible to perform immunoprecipitation using antibodies raised 
against US28 in conjuction with protein-A conjugated agarose, such an approach 
is not as efficient as using a more direct approach using antibodies that are con-
jugated to agarose. Therefore, we chose to use anti-HA conjugated agarose. For 
our purposes we used a HA-tag fused N-terminally to US28. In Figure 1A shows 
US28 binding to [125I]-CCL5 in transiently transfected HEK293T. With expression be-
ing confirmed by the aforementioned binding assay, functionality was confirmed 
using a reportergene assay measuring transcriptional activity of NFAT (Figure 1B). 
Furthermore, NIH-3T3 cells stably expressing HA-US28 display a similar proliferative 
phenotype as the wild-type US28 expressing NIH-3T3 (Figure 1C).
6.3.2 Immuno-precipitation of HA-US28
Following confirmation of expression and functionality, HA-US28 was immuno-pre-
cipitated from transiently transfected cells. For this purpose a lysis buffer preserv-
ing as many protein-protein interactions as possible, while still efficiently lysing the 
cells was required. Subsequently, the obtained eluates were first separated by SDS/
PAGE. Presence of US28 was confirmed by Western-blot analysis, using anti-HA an-
tibodies (Figure 2A). Coomassie brilliant blue (CBB) staining was used to assess the 
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amount of proteins that were co-precipitated (Figure 2B). This gel was then further 
processed and the co-precipitating proteins were identified by LC-MS/MS. The LC-
MS/MS analysis yielded 491 proteins that were specifically co-precipitating with 
US28, and these proteins are listed in Table S1 (Supplemental data). The spectral 
counts indicate the abundance of the proteins in the immuno-precipitation, with a 
higher number indicating a greater abundance of protein.
6.3.3 Further analysis of the US28 signalosome
In order to gain further insight in the roles of the proteins listed in Table 1, the data-
set for US28 was analyzed using Ingenuity Pathway Analysis (IPA) software. Proteins 
that were more or less expected to be present in the dataset, such as Gai were 
found to be present in the dataset. The functional annotation is shown in Figure 
3. This analysis shows that 28% of the identified proteins are enzymes and 13% 
of the proteins are transporters. IPA was also used to perform a core analysis on 
the different datasets. These datasets were subsequently cross-analyzed in order to 
Figure 3. Distribution of cellular 
functions among proteins pres-
ent in the US28 signalosome. The 
different protein functions are de-
noted in colors and the size of each 
portion of the pie-chart is represen-
tative of the percentage of proteins 
that were identified within the sig-
nalosome.
Mock HA-US28 Mock
A B
Lysate IP
~40kD
~40kD
Mock US28HA-US28
Figure 2. Immuno-precipitation of the US28 signalosome. (A) Western-blot using antibodies raised against the 
HA-tag. Both US28 wild-type and US28 R129A mutant are present in either the lysate and the immuno-precipitated 
proteins (IP). The predicted mass of US28 is marked at the side. (B) Coomassie Brilliant Blue staining of a SDS/PAGE 
on which IP proteins was loaded. Again the approximate size of US28 is marked at the side. The difference between 
the mock pull-down and the wild-type pulldown is visible as a lower amount of bands.
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Figure 4. Canonical pathways that are overrepresented in the list of proteins of the US28 signalosome. On the 
X-axis significance is shown in –log(p) where p is the result of a Fisher’s Exact Test. The threshold is indicated as the 
white dotted line and is set at p<0.05 (-log(p)=1.3).
identify overrepresented pathways. As expected, several pathways associated with 
the regulation of cell survival and proliferation, were found to be overrepresented 
(threshold was set at p<0.05, using Fisher’s Exact Test). Among the proteins present 
in the pathways associated with proliferation and survival were several mitochon-
drial proteins. This may reflect changes in cellular metabolism that are induced by 
US28. Another set of proteins that stands out are the 14-3-3 proteins, which are 
important mediators of cellular signaling (6). All the canonical pathways of which 
proteins were found to be significantly overrepresented are listed in Figure 4 in de-
scending order of significance. In total 42 pathways were found to contain proteins 
that were found in the co-immunoprecipitation.
6.3.4 14-3-3 proteins interact with Cby and potentially influence 
 β-catenin signaling
As mentioned above, analysis of the signalosome revealed that several pathways 
were overrepresented. Among these pathways is RhoA signaling. In Chapter 5, ex-
periments with the ROCK inhibitor Y-27632 show that US28-induced Tcf/Lef acti-
vation is dependent on ROCK. G-protein signaling can activate Rho (7, 8), which in 
turn can activate ROCK (9). We decided to further investigate the proteins that were 
found to play a role in these pathways. When we were first exploring US28-induced 
Tcf/Lef activation, one of the mechanisms that was considered was US28-induced 
activation of Akt, which then phosphorylates Gsk3b resulting in disruption of the 
destruction complex. However, further investigation showed that this was not the 
case, as US28 does not induce Akt phosphorylation. In fact, US28 appears to inhibit 
Akt phosphorylation (Figure 6A). Therefore, a protein-protein interaction analysis 
with the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) was 
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performed on proteins found in the signalosome as well as proteins that are known 
to associate with factors found in our dataset based on experimental data. Proteins 
that were included from the mass-spectrometry dataset and reported to play a role 
in Tcf/Lef activation are ROCK1, RHOA, ARHGEF11, the 14-3-3 proteins (YWHAx), 
PPP2R1A (PP2A subunit). CTNNB1 (β-catenin) was included because of the data 
shown in Chapter 5, and Akt was included based on the data described above. Since 
PTEN is regulated by ROCK and controls Akt activity and CBY1 is phosphorylated by 
Akt and reported to play a role in b-catenin signaling (10, 11) these proteins were 
also included in the STRING analysis. Immunoprecipitation experiments revealed 
that US28 is co-immunoprecipitating with PTEN and CBY1 (data not shown). Figure 
5 shows that a protein-protein interaction map of these proteins can be built that 
links to b-catenin. 
Cby is a protein that controls the intracellular distribution and function of β-catenin. 
Another protein that plays a pivotal role in this interaction map is Akt. As mentioned 
above, US28-expressing cells show lower phosphorylation of Akt S473 (Figure 6A), 
which is consistent with lower Akt activity (12). When Cby and β-catenin are both 
phosphorylated by Akt, they are recognized by 14-3-3 proteins (Note that the pro-
tein symbol for 14-3-3 proteins is YWHAx). Subsequently the complex is then ex-
ported out of the nucleus and b-catenin is degraded (10). Indeed, when Cby func-
tion is impaired in SW480 colon carcinoma cells, their growth is suppressed (13). 
In this light, the presence of known inhibitory factors (such as the PP2A subunit 
PPP2R1A) of Akt in the US28 signalosome is intriguing since this suggests a novel 
way for US28 to influence β-catenin signaling.
To test whether inhibitory factors like PTEN or PP2A are controlling US28-induced 
b-catenin signaling, we treated cells with inhibitors against PTEN (bpV) and PP2A 
(okadaic acid). Figure 6B shows that both bpV and okadaic acid can inhibit US28-in-
duced activation of Tcf-Lef. To investigate the role of 14-3-3 in US28-induced Tcf-
ROCK1
PTEN
RHOA
ARHGEF11
CTNNB1
YWHAH
AKT1
YWHAZ
YWHAQ
CBY1
YWHAE YWHAG
PPP2R1A
Figure 5. Protein-protein interac-
tion map connecting the 14-3-3 
pathway with the RhoA signaling 
pathway. The STRING program was 
used to build this interaction map. 
Proteins involved in either pathway, 
which were found in either the sig-
nalosome or that were known to be 
involved from earlier studies where 
used as input. The lines indicate dif-
ferent sources of evidence for the 
interactions. Neighborhood (green), 
gene fusion (red), co-occurrence 
(blue), co-expression (black), exper-
iments (purple), databases (cyan), 
text mining (yellow).
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Figure 6. Cby is phosphorylated by Akt and 
14-3-3-mediated binding to β-catenin inhib-
its US28-induced signaling. (A) Cells expressing 
US28 have lower levels of phospo-Akt (S437). (B) 
Furthermore, treating cells that were transfected 
with US28 with inhibitors against PTEN (bpV) or 
PP2A (okadaic acid, OA) results in an inhibition of 
US28-induced Tcf/Lef activation. (C) Dose-depen-
dent inhibition of Tcf/Lef activation by fusicoccin, 
due to its stabilizing effect on 14-3-3-interactions. 
(D) BRET experiments performed with 14-3-3ε and 
Cby fused to Renilla luciferase and YFP respective-
ly shows interaction between these two proteins, 
while in (E) no interaction can be shown between 
14-3-3ε and β-arrestin. (F) Similarly, the mutant 
S20A form of Cby does not show any interaction 
with 14-3-3ε.
Lef activation, we made use of the phytotoxin fusicoccin. Fusicoccin has been de-
scribed as a stabilizer of 14-3-3 interactions in both plants as well as in human cells 
(14-16). Because of its ability to promote 14-3-3 interactions with client proteins, 
and the data we obtained with bpV and okadaic acid, we expected fusicoccin to 
inhibit US28-induced Tcf-Lef activation. Figure 6C shows that treatment with fu-
sicoccin showed a dose-dependent reduction in Tcf-Lef activation, confirming our 
hypothesis. To investigate the interaction between Cby and b-catenin we used a bio-
luminescence resonance energy transfer (BRET) assay. Therefore 14-3-3e and Cby 
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were tagged with Rluc and YFP, respectively. In this assay the light emitted by the 
donor 14-3-3e-Rluc is used to excite the Cby-YFP in case of close proximity of the 
proteins (energy transfer). In BRET analysis, the donor DNA concentration is kept 
constant, while the acceptor is varied in a wide range in transfection. Saturation 
of the energy transfer indicates close proximity of the two assessed proteins. BRET 
with 14-3-3e-Rluc and Cby-YFP shows a saturable BRET signal (Figure 6D), indicating 
an affinity of both proteins for each other. In contrast, the energy transfer from 
14-3-3e-Rluc to b-Arrestin-YFP protein was found not to be saturable, which indi-
cates that there is no or very low affinity between these two partners (Figure 6E). 
Studies with Cby-S20A-YFP, which lacks the phosphorylation site that is required for 
interacting with 14-3-3, and the 14-3-3e-Rluc also showed a complete loss of affin-
ity (Figure 6F). These data show that phosphorylation of Cby is required to be able 
to interact with 14-3-3 proteins. Furthermore, the experiments performed with the 
different inhibitors suggest that Cby may be a factor in  US28-induced b-catenin 
signaling.
6.4 Discussion
In recent years proteomic analysis has become an important tool to gain further 
understanding of the proteome. Powerful analysis techniques like LC-MS/MS have 
been instrumental in this effort. In this study the US28 signalosome was analyzed 
in an effort to further clarify the manner by which US28 signals. To this end we 
endeavored to isolate US28 and its associated proteins by way of immunoprecipi-
tation. The results shown in this study show that we are able to efficiently isolate 
US28 and their associated proteins. Analysis of these pull-downs identified 491 pro-
teins to specifically co-precipitate with either US28 
The US28 signalosome was analyzed using the IPA software. This resulted in a num-
ber of pathways that were overrepresented in the signalosome. Some of these 
pathways were expected to be present, such as clathrin-mediated endocytosis (in-
volved in GPCR internalization), calcium signaling, and phospholipase C (PLC) sig-
naling (both are associated with Gαq signaling). The pathways related to internaliza-
tion are expected to be there since US28 displays constitutive internalization, while 
calcium signaling and PLC signaling are both function of Gαq activation. Analysis of 
the US28 signalosome shows over-representation of proteins involved in prolifer-
ation and survival. Examples of affected pathways are: breast cancer regulation, 
RhoA signaling, mTOR signaling, Cdc42 signaling, and PI3K/Akt signaling. A set of 
proteins that was identified in the US28 signalosome were the 14-3-3 proteins. This 
protein family is composed of 7 members (14-3-3β, γ, ε, σ, ζ, τ, and η), which are 
important mediators of signaling, that act by facilitating protein-protein interac-
tions (e.g. kinase-substrate) (6). These proteins are present in all eukaryotes and 
well conserved, indicating their vital role in cellular function. While, removal of one 
of the 14-3-3 members generally does not result in a phenotype in the presence of 
the other members, removal of all 14-3-3s results in (cell-) death. Several studies 
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phosphorylation. Phosphorylation of 
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have indicated that 14-3-3 proteins may have a role in mediating GPCR signaling. 
For example, 14-3-3ζ was shown to occupy a Raf-binding site on the α2-Adrenergic 
receptor (α2AR) and could be displaced with phosphorylated Raf-1 (24). In this case 
14-3-3ζ is proposed to anchor receptors to the cell-surface, and when the receptors 
are activated the 14-3-3 anchors are released. Subsequently, α2AR will undergo 
the cycle of activation, inactivation, and internalization. Membrane expression of 
the HIV co-receptor GPR15 is stabilized in a similar manner by 14-3-3 proteins (25), 
which suggests the existence of a general mechanism where 14-3-3 proteins reg-
ulate the subcellular localization of GPCRs. The presence of 14-3-3 proteins in the 
vicinity of US28 could be evidence of such a role for 14-3-3 in US28 localization. Ad-
ditionally, US28 may bind so much 14-3-3 that it impairs the functionality of the 14-
3-3 proteins by sequestering a large fraction of the 14-3-3 proteins. Further analysis 
using STRING suggests that the presence of 14-3-3 proteins and proteins involved 
in RhoA signaling may be a consequence of US28 influencing b-catenin signaling by 
inhibiting a regulatory component, Cby. Experiments with inhibitors of PP2A and 
PTEN seem to confirm this. Furthermore, when US28-expressing cells are treated 
with fusicoccin, a compound that promotes 14-3-3 interactions, US28-induced Tcf-
Lef signaling is inhibited. In Figure 7, this proposed model is shown, where signaling 
by US28 increases PP2A and PTEN activity. This results in dephosphorylation of Akt, 
which inactivates Akt. Subsequently, Cby phosphorylation is diminished. This pro-
cess ‘unlocks’ b-catenin which is now far more likely to be retained in the nucleus, 
thus potentiating any signaling through b-catenin, as is shown in Figure 7.
Pathways like mitochondrial dysfunction may be a result of apoptotic factors that 
were found in the pull-downs (eg. annexins like ANXA6 and ANXA5). Alternatively, 
these proteins may reflect US28-induced changes in cell metabolism considering 
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that HCMV is known to change the cellular metabolism (26). Such virus-induced 
changes in metabolism are of interest, since transformed cells often display an al-
tered metabolism. This is known as the Warburg effect and is characterized by the 
switch from pyruvate oxidation to lactic acid fermentation (27). The Warburg effect 
is a common effect in more than 90% of cancers (28). Indeed, KSHV has been shown 
to induce the Warburg effect in infected cells. Moreover, inhibiting glycolysis result-
ed in apoptosis of latently infected cells, which suggests that the metabolic changes 
effected by the Warburg effect circumvents apoptosis that would otherwise by in-
duced by virally encoded factors (29). Whether the Warburg effect only facilitates 
proliferation or actively promotes transformation in the setting of US28-induced 
proliferation remains to be seen.
A list of proteins that were co-immunoprecipitated with US28 can be found in Table 
S1. An analysis of the function of the protein in Table 1 shows that most of them are 
enzymes, which fits with a role of these proteins in signaling. Interestingly, one cy-
tokine, Macrophage migration Inhibitory Factor (MIF), was found to co-precipitate 
with US28. MIF is a pro-inflammatory cytokine, which also possesses characteristics 
reminiscent of chemokines. While CD74 is considered the cognate receptor for MIF 
(17), binding to the chemokine receptors CXCR4 and CXCR2 has also been described 
to bind to MIF (18). Furthermore, MIF has also been shown to be capable of pro-
moting tumorigenesis and has been associated with several types of cancers (19, 
20). The link of MIF with brain tumors, and glioblastomas in particular (21), is in-
triguing considering the data in Chapter 3, where US28 was shown to be present in 
glioblastoma tumors, mediating STAT3 responses (3). In glioblastomas MIF appears 
to be mainly involved in the neovascularization of the tumors (21). The presence 
of this cytokine in the pull-downs may be an indication of direct binding of MIF to 
US28, but could also be evidence of interaction of US28 with another receptor. In 
the latter case this could either be a chemokine receptor like CXCR2 or CXCR4, but 
it could also be CD74. Support for an interaction of CD74 with US28 exists, as CD74 
has been shown to functionally interact with CXCR4 (22). However, arguing against 
such a dimerization model, the US28 pull-downs contain neither chemokine recep-
tors nor CD74. Further experiments using labeled MIF should be able to address 
this question. 
While US28 can be expected to be present on the plasma membrane and in par-
ticular in the cytoplasm based on current knowledge of US28 localization (23), the 
presence of nuclear proteins is somewhat puzzling. However, a similar analysis per-
formed on the Histamine H1-receptor (H1R) has also yielded similar nuclear pro-
teins (data not shown). A possible explanation could be that these proteins are 
involved in GPCR protein synthesis and maturation, although this does not explain 
the presence of DNA-repair enzymes.
The data presented in this study are an important first step in understanding the 
US28 signalosome. Furthermore, a methodology for isolating GPCRs and their asso-
ciated proteins has been established. However, several challenges still remain to be 
met. First of all, more information about the US28 signalosome could be obtained if 
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the immunoprecipitation is performed on the different cellular compartments sepa-
rately. This could be accomplished by sucrose-gradient separation, which allows for 
separation of all the different cellular compartments. However, alternative methods 
are available if one is mainly interested in the plasma membrane. First sulfo-NHS-
SS-biotin can be used to biotinylate proteins that have extra-cellular domains and 
are thus considered to be present on the plasma membrane. Using streptavidin 
conjugated agarose these biotinylated proteins can be separated from the rest of 
the proteins (30). Another technique for isolating plasma membrane proteins en-
tails the use of the lectin concanavalin A immobilized on magnetic beads (31). 
Further development of the techniques discussed above will result in a better char-
acterization of the US28 signalosome. Together with pathway analysis of the ob-
tained data, this should lead to increased understanding of US28 mediated signal-
ing.
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6.5 Materials and methods
Materials and reagents
Anti-HA conjugated agarose was obtained from Sigma-Aldrich (St. Louis, MO, USA). The an-
ti-HA monoclonal antibodies were purchased from Hoffman-La Roche (Basel, Switzerland). 
Rabbit anti-rat conjugated to horseradish peroxidase was purchased from Thermo Fisher 
Scientific (Rockford, IL, USA). All other chemicals were purchased from Applichem (Darm-
stadt, Germany).
Cell culture
Human HEK293T cells were cultured were cultured in Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 50 IU/ml penicillin, 50 μg/ml streptomycin, and 10% fetal bo-
vine, heat inactivated fetal bovine serum. Transient transfections of HEK293T cells were 
performed using the polyethylenimine method (32). Expression of US28 in HEK293T cells 
was confirmed using [125I]-CCL5 binding (specific binding was determined using CX3CL1 10-7 
M), as previously described (33).
Western-blot analysis
A Biorad (Hercules, CA) minigel system was used to perform SDS/PAGE, and a Biorad elec-
troblot system was used to transfer protein samples to a 0.45 μm polyvinylidene fluoride 
membrane from PerkinElmer (Waltham, MA, USA). Primary antibodies were incubated 
overnight in Tris-buffered saline with 0.1% Tween20 (TBST) added. Secondary antibodies 
were incubated for 90 minutes in TBST, and subsequently ECL from PerkinElmer was used to 
visualize the bound antibodies.
Co-immunoprecipitation and Mass-spectrometry
Analysis of the US28 signalosome was done by immuno-precipitating HA-tagged US28. To 
this end, the cells were lysed in 1% NP-40, 1 mM EDTA, 150 mM NaCl, 10% glycerol, and 1 
mM CaCl2. After 30 minutes incubation on ice, the lysates were clarified by centrifugation. 
Subsequently, anti-HA conjugated agarose (Sigma) was added to the lysate and left to incu-
bate for 90 minutes at 4°C. The conjugated agarose was then washed 3 times with a wash 
buffer containing 0.1% Triton X-100, 50 mM Tris, 300 mM NaCl, and 5 mM EDTA, the pH was 
set at 7.5 with HCl. The proteins were eluted from the conjugated agarose with Laemmli 
buffer. The eluted proteins were separated on a 12% poly-acryl-amide gel, which was sub-
sequently stained with Coomassie blue. Protein lanes from Coomassie stained SDS-PAGE 
gels were excised and prepared for LC-MS/MS analysis as previously described (34, 35). 
Peptides were separated by an Ultimate 3000 nanoLC-MS/MS system (Dionex LC-Packings, 
Amsterdam, The Netherlands) equipped with a 20 cm × 75 μm ID fused silica column custom 
packed with 3 μm 120 Å ReproSil Pur C18 aqua (Dr Maisch GMBH, Ammerbuch-Entringen, 
Germany). After injection, peptides were trapped at 30 μl/min on a 5 mm × 300 μm ID 
Pepmap C18 cartridge (Dionex LC-Packings, Amsterdam, The Netherlands) at 2% buffer B 
(buffer A: 0.05% formic acid in MQ; buffer B: 80% ACN + 0.05% formic acid in MQ) and sep-
arated at 300 nl/min in a 10–40% buffer B gradient in 60 min. Eluting peptides were ionized 
at 1.7 kV in a Nanomate Triversa Chip-based nanospray source using a Triversa LC coupler 
(Advion, Ithaca, NJ). Intact peptide mass spectra and fragmentation spectra were acquired 
on a LTQ-FT hybrid mass spectrometer (Thermo Fisher, Bremen, Germany). Intact masses 
were measured at resolution 50.000 in the ICR cell using a target value of 1 Χ 106 charges. 
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In parallel, following an FT pre-scan, the top 5 peptide signals (charge-states 2+ and higher) 
were submitted to MS/MS in the linear ion trap (3 amu isolation width, 30 ms activation, 
35% normalized activation energy, Q value of 0.25 and a threshold of 5000 counts). Dynamic 
exclusion was applied with a repeat count of 1 and an exclusion time of 30s.
The obtained MS/MS spectra were searched against the Human IPI database (v3.59; 80128 
entries) using Sequest (version 27, rev 12), which is part of the BioWorks 3.3 data analysis 
package (Thermo Fisher, San Jose, CA). MS/MS spectra were searched with a maximum 
allowed deviation of 10 ppm for the precursor mass and 1 amu for fragment masses. Me-
thionine oxidation and cysteine carboxamidomethylation were allowed as variable modifi-
cations, two missed cleavages were allowed. Scaffold (version Scaffold 2.01.02, Proteome 
Software Inc., Portland, OR) was used to validate MS/MS based peptide and protein iden-
tifications. Peptide identifications were accepted when established at greater than 95,0% 
probability as specified by the Peptide Prophet algorithm (36). Protein identifications were 
accepted when established at greater than 99,0% probability and contained at least 2 iden-
tified peptides. Protein probabilities were assigned by the Protein Prophet algorithm (37). 
Proteins that contained similar peptides and could not be differentiated based on MS/MS 
analysis alone were grouped to satisfy the principles of parsimony. Proteins were quanti-
fied by spectral counting (i.e. the sum of all MS/MS spectra per identified protein) (Liu H, 
Sadygov RG, Yates JR, III. A model for random sampling and estimation of relative protein 
abundance in shotgun proteomics. Anal.Chem. 76(14), 4193-4201 (15-7-2004). Old WM, 
Meyer-Arendt K, Aveline-Wolf L et al. Comparison of label-free methods for quantifying hu-
man proteins by shotgun proteomics. Mol.Cell Proteomics. 4(10), 1487-1502 (2005).)). The 
beta-binominal statistical test (Pham TV, Piersma SR, Warmoes M, Jimenez CR. On the be-
ta-binomial model for analysis of spectral count data in label-free tandem mass spectrome-
try-based proteomics. Bioinformatics. 26(3), 363-369 (1-2-2010).) was used to calculate fold 
changes and p-values between U28HA and mock.
Bioluminescence Energy Transfer (BRET)
For BRET measurements, 14-3-3ε was C-terminally fused to Renilla reniformus luciferase to 
function as the donor. As acceptor, Cby C-terminally fused to enhanced yellow fluorescent 
protein (eYFP) was used. In BRET analysis, the donor DNA concentration is kept constant, 
while the acceptor is varied in a wide range in transfection. Both constructs were co-trans-
fected into HEK293T and seeded into a 96-well white bottom plate. Measurements were 
taken 24 hours post-transfection, using a Victor3 multi label plate reader (PerkinElmer Life 
Sciences). The donor signal was detected as luminescence at 460 nm, while acceptor fluo-
rescence was measured at 535 nm, after 10 minute incubation with 5 μM coelenterazine-H 
(Promega). The BRET ratio was calculated by dividing the fluorescence by the luminescence 
which was then plotted against the different cDNA ratios. Saturation of the energy transfer 
indicates close proximity of the two assessed proteins.
Reporter Gene Analysis
106 HEK293T cells were transfected with plasmids encoding a Tcf-Lef reporter construct 
(TOP-flash or the negative control Fop-flash) and 25 ng of US28 receptor DNA (wild type or 
G-protein-uncoupled mutant R129A) unless indicated differently and 25 ng of DNA encoding 
G-proteins in cotransfection. Total DNA amounts were kept constant by addition of empty 
vector. Inhibitors bpV (PTEN, Alexis Biochemicals) and Okadaic acid (PP2A, Calbiochem), 
Fucicoccin (FC, Calbiochem) were incubated overnight and added directly after transfection. 
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Luciferase activity was measured 24 h post transfection (RLU, relative light units) with a Vic-
tor2 multilabel plate reader from (PerkinElmer Life Sciences). The TOP-flash and FOP-flash 
reporter gene plasmids to study Tcf-Lef activation were kindly provided by Prof. H. Clevers 
and Dr. M. vd Wetering.
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Supplemental table S1. Proteins identified by LC-MS/MS, sorted by subcellular location. Abundance is indicated as normal-
ized spectral counts in the rightmost columns.
Function/Description Symbol Localization Function
Spectral 
counts
macrophage migration inhibitory factor (glycosyla-
tion-inhibiting factor) MIF
Extracellular 
Space cytokine 5
acyl-CoA dehydrogenase family, member 9 ACAD9 Cytoplasm enzyme 5
acetyl-CoA acetyltransferase 1 ACAT1 Cytoplasm enzyme 10
ATP citrate lyase ACLY Cytoplasm enzyme 8
adenosylhomocysteinase AHCY Cytoplasm enzyme 10
aldo-keto reductase family 1, member B1 (aldose 
reductase) AKR1B1 Cytoplasm enzyme 2
aldehyde dehydrogenase 3 family, member A2 ALDH3A2 Cytoplasm enzyme 2
adenine phosphoribosyltransferase APRT Cytoplasm enzyme 0
ADP-ribosylation factor 1 ARF1 Cytoplasm enzyme 7
ADP-ribosylation factor 4 ARF4 Cytoplasm enzyme 8
asparagine synthetase (glutamine-hydrolyzing) ASNS unknown enzyme 6
5-aminoimidazole-4-carboxamide ribonucleotide form-
yltransferase/IMP cyclohydrolase ATIC unknown enzyme 9
HLA-B associated transcript 1 BAT1 Nucleus enzyme 5
carbonic anhydrase II CA2 Cytoplasm enzyme 12
cell division cycle 42 (GTP binding protein, 25kDa) CDC42 Cytoplasm enzyme 2
CDP-diacylglycerol--inositol 3-phosphatidyltransferase CDIPT Cytoplasm enzyme 0
CDP-diacylglycerol synthase (phosphatidate cytidylyl-
transferase) 2 CDS2 Cytoplasm enzyme 5
cytochrome c oxidase subunit Va COX5A Cytoplasm enzyme 5
citrate synthase CS Cytoplasm enzyme 5
cytochrome b-245, alpha polypeptide CYBA Cytoplasm enzyme 0
cytochrome c-1 CYC1 Cytoplasm enzyme 1
aspartyl-tRNA synthetase DARS Cytoplasm enzyme 9
DEAD (Asp-Glu-Ala-Asp) box polypeptide 1 DDX1 Nucleus enzyme 4
DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, X-linked DDX3X Nucleus enzyme 3
DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 DDX5 Nucleus enzyme 9
DEAD (Asp-Glu-Ala-Asp) box polypeptide 6 DDX6 Nucleus enzyme 4
7-dehydrocholesterol reductase DHCR7 Cytoplasm enzyme 3
DEAH (Asp-Glu-Ala-His) box polypeptide 15 DHX15 Nucleus enzyme 2
DEAH (Asp-Glu-Ala-His) box polypeptide 30 DHX30 Nucleus enzyme 2
DEAH (Asp-Glu-Ala-His) box polypeptide 9 DHX9 Nucleus enzyme 11
dihydrolipoamide dehydrogenase DLD Cytoplasm enzyme 4
DnaJ (Hsp40) homolog, subfamily A, member 2 DNAJA2 Nucleus enzyme 11
deoxyuridine triphosphatase
DUT (includes 
EG:1854) Nucleus enzyme 1
eukaryotic translation initiation factor 4A3
EIF4A3 (includes 
EG:9775) Nucleus enzyme 3
fatty acyl CoA reductase 1 FAR1 Cytoplasm enzyme 5
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phenylalanyl-tRNA synthetase, alpha subunit FARSA Cytoplasm enzyme 3
phenylalanyl-tRNA synthetase, beta subunit FARSB Cytoplasm enzyme 3
fatty acid synthase FASN Cytoplasm enzyme 25
flap structure-specific endonuclease 1 FEN1 Nucleus enzyme 2
fumarate hydratase FH Cytoplasm enzyme 2
FK506 binding protein 4, 59kDa FKBP4 Nucleus enzyme 10
GTPase activating protein (SH3 domain) binding protein 
1 G3BP1 Nucleus enzyme 7
glucosidase, alpha; neutral AB GANAB Cytoplasm enzyme 5
galactosidase, alpha GLA Cytoplasm enzyme 1
glutaredoxin 3 GLRX3 Cytoplasm enzyme 3
glutamate dehydrogenase 1 GLUD1 Cytoplasm enzyme 4
guanine nucleotide binding protein (G protein), alpha 
inhibiting activity polypeptide 3 GNAI3 Cytoplasm enzyme 3
guanine nucleotide binding protein (G protein), beta 
polypeptide 2-like 1 GNB2L1 Cytoplasm enzyme 9
glutamic-oxaloacetic transaminase 2, mitochondrial 
(aspartate aminotransferase 2) GOT2 Cytoplasm enzyme 5
glucose-6-phosphate isomerase GPI
Extracellular 
Space enzyme 16
glutathione reductase GSR Cytoplasm enzyme 2
glutathione S-transferase omega 1 GSTO1 Cytoplasm enzyme 4
glutathione S-transferase pi 1 GSTP1 Cytoplasm enzyme 3
hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA 
thiolase/enoyl-CoA hydratase (trifunctional protein), 
alpha subunit HADHA Cytoplasm enzyme 5
hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA 
thiolase/enoyl-CoA hydratase (trifunctional protein), 
beta subunit HADHB Cytoplasm enzyme 3
heme oxygenase (decycling) 1 HMOX1 Cytoplasm enzyme 0
hypoxanthine phosphoribosyltransferase 1 HPRT1 Cytoplasm enzyme 4
hydroxysteroid (17-beta) dehydrogenase 10 HSD17B10 Cytoplasm enzyme 1
hydroxysteroid (17-beta) dehydrogenase 12 HSD17B12 Cytoplasm enzyme 1
isoleucyl-tRNA synthetase IARS Cytoplasm enzyme 3
isocitrate dehydrogenase 2 (NADP+), mitochondrial IDH2 Cytoplasm enzyme 2
inositol-3-phosphate synthase 1 ISYNA1 unknown enzyme 6
KH-type splicing regulatory protein KHSRP Nucleus enzyme 2
leucyl-tRNA synthetase LARS Cytoplasm enzyme 3
lysophosphatidylcholine acyltransferase 1 LPCAT1 Cytoplasm enzyme 5
leukotriene A4 hydrolase LTA4H Cytoplasm enzyme 5
magnesium transporter 1 MAGT1
Plasma Mem-
brane enzyme 1
malate dehydrogenase 2, NAD (mitochondrial) MDH2 Cytoplasm enzyme 36
NADH dehydrogenase, subunit 5 (complex I) MT-ND5 Cytoplasm enzyme 6
methylenetetrahydrofolate dehydrogenase (NADP+ 
dependent) 1, methenyltetrahydrofolate cyclohydrolase, 
formyltetrahydrofolate synthetase MTHFD1 Cytoplasm enzyme 2
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NADH dehydrogenase (ubiquinone) 1 alpha subcom-
plex, 13 NDUFA13 Cytoplasm enzyme 0
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 
10, 22kDa NDUFB10 Cytoplasm enzyme 5
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 
9, 22kDa NDUFB9 Cytoplasm enzyme 0
NADH dehydrogenase (ubiquinone) Fe-S protein 2, 
49kDa (NADH-coenzyme Q reductase) NDUFS2 Cytoplasm enzyme 6
NADH dehydrogenase (ubiquinone) Fe-S protein 3, 
30kDa (NADH-coenzyme Q reductase) NDUFS3 Cytoplasm enzyme 4
NADH dehydrogenase (ubiquinone) Fe-S protein 8, 
23kDa (NADH-coenzyme Q reductase) NDUFS8 Cytoplasm enzyme 1
NADH dehydrogenase (ubiquinone) flavoprotein 1, 
51kDa NDUFV1 Cytoplasm enzyme 4
NADH dehydrogenase (ubiquinone) flavoprotein 2, 
24kDa NDUFV2 Cytoplasm enzyme 3
ornithine aminotransferase OAT Cytoplasm enzyme 6
oxidase (cytochrome c) assembly 1-like OXA1L Cytoplasm enzyme 3
prolyl 4-hydroxylase, beta polypeptide P4HB Cytoplasm enzyme 9
phosphoribosylaminoimidazole carboxylase, phosphori-
bosylaminoimidazole succinocarboxamide synthetase PAICS unknown enzyme 5
protein-L-isoaspartate (D-aspartate) O-methyltrans-
ferase PCMT1 Cytoplasm enzyme 0
pyruvate dehydrogenase (lipoamide) beta PDHB Cytoplasm enzyme 5
protein disulfide isomerase family A, member 6 PDIA6 Cytoplasm enzyme 12
phosphoribosylformylglycinamidine synthase PFAS Cytoplasm enzyme 2
phosphogluconate dehydrogenase PGD Cytoplasm enzyme 3
phosphatidylinositol glycan anchor biosynthesis, class S PIGS Cytoplasm enzyme 4
purine nucleoside phosphorylase PNP Nucleus enzyme 1
peptidylprolyl isomerase B (cyclophilin B) PPIB Cytoplasm enzyme 2
peroxiredoxin 1 PRDX1 Cytoplasm enzyme 14
peroxiredoxin 3 PRDX3 Cytoplasm enzyme 8
peroxiredoxin 4 PRDX4 Cytoplasm enzyme 2
peroxiredoxin 5 PRDX5 Cytoplasm enzyme 1
peroxiredoxin 6 PRDX6 Cytoplasm enzyme 10
protein kinase C substrate 80K-H PRKCSH Cytoplasm enzyme 2
protein arginine methyltransferase 5 PRMT5 Cytoplasm enzyme 3
phosphoserine aminotransferase 1 PSAT1 Cytoplasm enzyme 4
proteasome (prosome, macropain) 26S subunit, 
non-ATPase, 6 PSMD6 Cytoplasm enzyme 3
polypyrimidine tract binding protein 1 PTBP1 Nucleus enzyme 5
prostaglandin E synthase 3 (cytosolic)
PTGES3 
(includes 
EG:10728) Cytoplasm enzyme 2
glutaminyl-tRNA synthetase QARS Cytoplasm enzyme 2
RAB11B, member RAS oncogene family RAB11B Cytoplasm enzyme 2
RAB1A, member RAS oncogene family RAB1A Cytoplasm enzyme 3
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RAB2A, member RAS oncogene family RAB2A Cytoplasm enzyme 0
RAB5B, member RAS oncogene family RAB5B Cytoplasm enzyme 2
RAB5C, member RAS oncogene family RAB5C Cytoplasm enzyme 4
RAB6A, member RAS oncogene family RAB6A Cytoplasm enzyme 3
RAB7A, member RAS oncogene family RAB7A Cytoplasm enzyme 3
RAP1B, member of RAS oncogene family RAP1B Cytoplasm enzyme 0
arginyl-tRNA synthetase RARS Cytoplasm enzyme 6
ras homolog gene family, member A RHOA Cytoplasm enzyme 0
SAR1 homolog A (S. cerevisiae) SAR1A Cytoplasm enzyme 0
succinate dehydrogenase complex, subunit A, flavopro-
tein (Fp) SDHA Cytoplasm enzyme 2
septin 2 SEPT2 Cytoplasm enzyme 4
serine hydroxymethyltransferase 2 (mitochondrial) SHMT2 Cytoplasm enzyme 4
superoxide dismutase 1, soluble SOD1 Cytoplasm enzyme 0
serine palmitoyltransferase, long chain base subunit 1 SPTLC1 Cytoplasm enzyme 2
STT3, subunit of the oligosaccharyltransferase complex, 
homolog B (S. cerevisiae)
STT3B (includes 
EG:201595) unknown enzyme 3
transaldolase 1 TALDO1 Cytoplasm enzyme 2
threonyl-tRNA synthetase TARS Nucleus enzyme 2
thioredoxin-related transmembrane protein 1 TMX1 Cytoplasm enzyme 0
TNF receptor-associated protein 1 TRAP1 Cytoplasm enzyme 9
thioredoxin TXN Cytoplasm enzyme 5
ubiquitin-like modifier activating enzyme 1 UBA1 Cytoplasm enzyme 9
ubiquinol-cytochrome c reductase binding protein UQCRB Cytoplasm enzyme 0
ubiquinol-cytochrome c reductase core protein II UQCRC2 Cytoplasm enzyme 8
vinculin VCL
Plasma Mem-
brane enzyme 3
valosin-containing protein VCP Cytoplasm enzyme 16
X-ray repair complementing defective repair in Chinese 
hamster cells 5 (double-strand-break rejoining) XRCC5 Nucleus enzyme 5
X-ray repair complementing defective repair in Chinese 
hamster cells 6 XRCC6 Nucleus enzyme 17
tyrosyl-tRNA synthetase YARS Cytoplasm enzyme 2
tyrosine 3-monooxygenase/tryptophan 5-monooxygen-
ase activation protein, zeta polypeptide YWHAZ Cytoplasm enzyme 13
sigma non-opioid intracellular receptor 1 SIGMAR1
Plasma Mem-
brane
G-protein cou-
pled receptor 3
chloride intracellular channel 1 CLIC1 Nucleus ion channel 1
translocase of outer mitochondrial membrane 40 
homolog (yeast) TOMM40 Cytoplasm ion channel 4
adenylate kinase 1 AK1 Cytoplasm kinase 1
adenylate kinase 2 AK2 Cytoplasm kinase 2
aldehyde dehydrogenase 18 family, member A1 ALDH18A1 Cytoplasm kinase 5
hexokinase 1 HK1 Cytoplasm kinase 3
non-metastatic cells 3, protein expressed in NME3 Cytoplasm kinase 0
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phosphoglycerate kinase 1 PGK1 Cytoplasm kinase 12
phosphatidylinositol 4-kinase, catalytic, alpha PI4KA Cytoplasm kinase 3
protein kinase, cAMP-dependent, regulatory, type II, 
alpha PRKAR2A Cytoplasm kinase 6
actin, beta-like 2 ACTBL2 unknown other 3
actinin, alpha 1 ACTN1 Cytoplasm other 25
ARP2 actin-related protein 2 homolog (yeast) ACTR2
Plasma Mem-
brane other 4
ARP3 actin-related protein 3 homolog (yeast) ACTR3
Plasma Mem-
brane other 4
AHA1, activator of heat shock 90kDa protein ATPase 
homolog 1 (yeast) AHSA1 Cytoplasm other 2
allograft inflammatory factor 1-like AIF1L unknown other 15
acidic (leucine-rich) nuclear phosphoprotein 32 family, 
member B ANP32B Nucleus other 1
annexin A5 ANXA5
Plasma Mem-
brane other 7
annexin A6 ANXA6
Plasma Mem-
brane other 17
archain 1 ARCN1 Cytoplasm other 4
Rho guanine nucleotide exchange factor (GEF) 11 ARHGEF11 Cytoplasm other 2
actin related protein 2/3 complex, subunit 3, 21kDa ARPC3 Cytoplasm other 2
actin related protein 2/3 complex, subunit 4, 20kDa ARPC4 unknown other 7
ATPase family, AAA domain containing 3A ATAD3A Nucleus other 12
ataxin 10 ATXN10 Cytoplasm other 5
ancient ubiquitous protein 1 AUP1 Cytoplasm other 6
BRI3 binding protein BRI3BP unknown other 8
basigin (Ok blood group) BSG
Plasma Mem-
brane other 6
chromosome 14 open reading frame 166 C14ORF166 Nucleus other 0
complement component 1, q subcomponent binding 
protein C1QBP Cytoplasm other 5
chromosome 22 open reading frame 28 C22ORF28 unknown other 4
chromosome 8 open reading frame 41 C8ORF41 unknown other 3
chromosome 8 open reading frame 55 C8ORF55 unknown other 2
caldesmon 1 CALD1 Cytoplasm other 16
calnexin CANX Cytoplasm other 13
CAP, adenylate cyclase-associated protein 1 (yeast) CAP1
Plasma Mem-
brane other 8
coiled-coil domain containing 47 CCDC47
Extracellular 
Space other 6
chaperonin containing TCP1, subunit 3 (gamma) CCT3 Cytoplasm other 15
chaperonin containing TCP1, subunit 4 (delta) CCT4 Cytoplasm other 20
cell division cycle 37 homolog (S. cerevisiae) CDC37 Cytoplasm other 3
centrosomal protein 55kDa CEP55 unknown other 2
cofilin 1 (non-muscle) CFL1 Nucleus other 18
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cofilin 2 (muscle) CFL2 Nucleus other 1
chromatin modifying protein 4B CHMP4B Cytoplasm other 3
cytoskeleton-associated protein 4 CKAP4 Cytoplasm other 8
CLPTM1-like CLPTM1L unknown other 3
coronin, actin binding protein, 1B CORO1B Cytoplasm other 9
cysteine and glycine-rich protein 2 CSRP2 Nucleus other 6
cortactin CTTN
Plasma Mem-
brane other 3
cytospin A CYTSA unknown other 2
drebrin-like DBNL Cytoplasm other 2
dynactin 2 (p50) DCTN2 Cytoplasm other 2
density-regulated protein
DENR (includes 
EG:8562) unknown other 2
dehydrogenase/reductase (SDR family) member 7B DHRS7B unknown other 1
diablo homolog (Drosophila) DIABLO Cytoplasm other 0
dermokine DMKN unknown other 1
DnaJ (Hsp40) homolog, subfamily A, member 1 DNAJA1 Nucleus other 14
DnaJ (Hsp40) homolog, subfamily B, member 11 DNAJB11 Cytoplasm other 2
DnaJ (Hsp40) homolog, subfamily B, member 12 DNAJB12 Cytoplasm other 2
DnaJ (Hsp40) homolog, subfamily C, member 7 DNAJC7 Cytoplasm other 4
dedicator of cytokinesis 7
DOCK7 (includes 
EG:85440) unknown other 5
dymeclin DYM unknown other 2
EF-hand domain family, member D2 EFHD2 unknown other 4
eukaryotic translation initiation factor 3, subunit L EIF3L Cytoplasm other 2
eukaryotic translation initiation factor 3, subunit M EIF3M unknown other 2
erythrocyte membrane protein band 4.1-like 2 EPB41L2
Plasma Mem-
brane other 4
Fas associated factor family member 2 FAF2 unknown other 4
family with sequence similarity 101, member B FAM101B unknown other 3
Fanconi anemia, complementation group D2 FANCD2 Nucleus other 7
Fanconi anemia, complementation group I FANCI unknown other 5
FK506 binding protein 8, 38kDa FKBP8 Cytoplasm other 2
filamin C, gamma FLNC Cytoplasm other 3
GDP dissociation inhibitor 2 GDI2 Cytoplasm other 8
gem (nuclear organelle) associated protein 4 GEMIN4 Nucleus other 2
growth factor receptor-bound protein 2 GRB2 Cytoplasm other 1
GrpE-like 1, mitochondrial (E. coli) GRPEL1 Cytoplasm other 1
gelsolin GSN
Extracellular 
Space other 3
HCLS1 associated protein X-1 HAX1 Nucleus other 5
histone cluster 1, H2bl HIST1H2BL Nucleus other 2
heterogeneous nuclear ribonucleoprotein A1 HNRNPA1 Nucleus other 9
heterogeneous nuclear ribonucleoprotein A2/B1 HNRNPA2B1 Nucleus other 5
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heterogeneous nuclear ribonucleoprotein H1 (H) HNRNPH1 Nucleus other 4
heterogeneous nuclear ribonucleoprotein K HNRNPK Nucleus other 12
heat shock protein 90kDa alpha (cytosolic), class B 
member 1 HSP90AB1 Cytoplasm other 16
heat shock protein 90kDa beta (Grp94), member 1 HSP90B1 Cytoplasm other 8
heat shock 70kDa protein 4 HSPA4 Cytoplasm other 7
heat shock 70kDa protein 5 (glucose-regulated protein, 
78kDa) HSPA5 Cytoplasm other 18
heat shock 70kDa protein 9 (mortalin) HSPA9 Cytoplasm other 34
heat shock 27kDa protein 1 HSPB1 Cytoplasm other 0
KIAA0368 KIAA0368 Cytoplasm other 5
KIAA1211 KIAA1211 unknown other 5
KIAA1524 KIAA1524 Cytoplasm other 4
high-mobility group box 1-like 10 LOC100130561 Nucleus other 4
RAN binding protein 1 pseudogene LOC389842 Cytoplasm other 4
leucine-rich PPR-motif containing LRPPRC Cytoplasm other 5
leucine rich repeat containing 59 LRRC59 Cytoplasm other 2
leucine zipper protein 1 LUZP1 Nucleus other 11
myristoylated alanine-rich protein kinase C substrate MARCKS
Plasma Mem-
brane other 2
membrane bound O-acyltransferase domain containing 
7 MBOAT7
Plasma Mem-
brane other 2
malectin MLEC
Plasma Mem-
brane other 1
mitochondrial ribosomal protein L47 MRPL47 Cytoplasm other 1
mitochondrial ribosomal protein S26 MRPS26 Cytoplasm other 0
mitochondrial carrier homolog 2 (C. elegans) MTCH2 Cytoplasm other 2
myosin, light chain 6, alkali, smooth muscle and 
non-muscle MYL6 Cytoplasm other 0
myosin XVIIIA MYO18A Cytoplasm other 4
myosin IB MYO1B Cytoplasm other 4
myosin IC MYO1C Cytoplasm other 17
myosin ID MYO1D
Plasma Mem-
brane other 9
myosin VI MYO6 Cytoplasm other 15
nucleosome assembly protein 1-like 1 NAP1L1 Nucleus other 9
nucleosome assembly protein 1-like 4 NAP1L4 Nucleus other 2
nuclear autoantigenic sperm protein (histone-binding) NASP Nucleus other 3
nebulette NEBL Cytoplasm other 2
non-POU domain containing, octamer-binding NONO Nucleus other 7
5’-nucleotidase domain containing 2 NT5DC2 unknown other 1
nuclear distribution gene C homolog (A. nidulans) NUDC Cytoplasm other 5
Obg-like ATPase 1 OLA1 Cytoplasm other 2
Parkinson disease (autosomal recessive, early onset) 7 PARK7 Nucleus other 0
poly(rC) binding protein 2 PCBP2 Nucleus other 5
129
6
Characterization of the US28 signalosome
proliferating cell nuclear antigen PCNA Nucleus other 3
phosphatidylethanolamine binding protein 1 PEBP1 Cytoplasm other 3
profilin 1 PFN1 Cytoplasm other 11
progesterone receptor membrane component 1 PGRMC1
Plasma Mem-
brane other 0
plakophilin 1 (ectodermal dysplasia/skin fragility 
syndrome) PKP1
Plasma Mem-
brane other 0
plastin 3 PLS3 Cytoplasm other 24
proteasome (prosome, macropain) 26S subunit, non-AT-
Pase, 11 PSMD11 Cytoplasm other 5
proteasome (prosome, macropain) 26S subunit, non-AT-
Pase, 12 PSMD12 Cytoplasm other 3
proteasome (prosome, macropain) 26S subunit, 
non-ATPase, 3 PSMD3 Cytoplasm other 6
proteasome (prosome, macropain) 26S subunit, 
non-ATPase, 7 PSMD7 Cytoplasm other 3
paraspeckle component 1 PSPC1 Nucleus other 2
protein tyrosine phosphatase-like A domain containing 1 PTPLAD1 Cytoplasm other 40
glutaminyl-peptide cyclotransferase-like QPCTL unknown other 2
RAD23 homolog B (S. cerevisiae) RAD23B Nucleus other 2
Ran GTPase activating protein 1 RANGAP1 Cytoplasm other 5
RNA binding motif protein, X-linked RBMX Nucleus other 2
regulator of chromosome condensation 2 RCC2 Nucleus other 4
reticulocalbin 2, EF-hand calcium binding domain RCN2 Cytoplasm other 7
RFT1 homolog (S. cerevisiae) RFT1 unknown other 4
ribonuclease/angiogenin inhibitor 1 RNH1 Cytoplasm other 2
replication protein A1, 70kDa RPA1 Nucleus other 3
ribosomal protein L10a
RPL10A (in-
cludes EG:4736) Cytoplasm other 4
ribosomal protein L11 RPL11 Cytoplasm other 6
ribosomal protein L13a RPL13A Cytoplasm other 3
ribosomal protein L14 RPL14 Cytoplasm other 6
ribosomal protein L17 RPL17 Cytoplasm other 0
ribosomal protein L18 RPL18 Cytoplasm other 3
ribosomal protein L22 RPL22 Nucleus other 2
ribosomal protein L23 RPL23 Cytoplasm other 7
ribosomal protein L26 RPL26 Cytoplasm other 7
ribosomal protein L35a RPL35A Cytoplasm other 0
ribosomal protein L36
RPL36 (includes 
EG:25873) Cytoplasm other 1
ribosomal protein L7a
RPL7A (includes 
EG:6130) Cytoplasm other 5
ribosomal protein L9
RPL9 (includes 
EG:6133) Cytoplasm other 3
ribosomal protein S10 RPS10 Cytoplasm other 3
ribosomal protein S13 RPS13 Cytoplasm other 11
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ribosomal protein S16 RPS16 Cytoplasm other 2
ribosomal protein S2
RPS2 (includes 
EG:6187) Cytoplasm other 14
ribosomal protein S27 RPS27 Cytoplasm other 2
ribosomal protein S3A RPS3A Cytoplasm other 4
ribosomal protein S5 RPS5 Cytoplasm other 3
ribosomal protein S7 RPS7 Cytoplasm other 2
ribosomal protein S9 RPS9 Cytoplasm other 9
serum amyloid A-like 1 SAAL1 unknown other 6
sorting and assembly machinery component 50 homo-
log (S. cerevisiae) SAMM50 Cytoplasm other 8
suprabasin SBSN unknown other 0
SCO cytochrome oxidase deficient homolog 2 (yeast)
SCO2 (includes 
EG:9997) Cytoplasm other 2
stromal cell derived factor 4 SDF4 Cytoplasm other 2
SEC22 vesicle trafficking protein homolog B (S. cerevisi-
ae) (gene/pseudogene) SEC22B Cytoplasm other 5
septin 7 SEPT7 Cytoplasm other 5
SERPINE1 mRNA binding protein 1 SERBP1 Nucleus other 4
splicing factor 3b, subunit 3, 130kDa SF3B3 Nucleus other 2
splicing factor proline/glutamine-rich SFPQ Nucleus other 6
solute carrier family 25 (mitochondrial oxodicarboxylate 
carrier), member 21 SLC25A21 Cytoplasm other 0
small nuclear ribonucleoprotein polypeptide A SNRPA Nucleus other 2
SLIT-ROBO Rho GTPase activating protein 2 SRGAP2 unknown other 3
signal recognition particle 68kDa SRP68 Nucleus other 2
serine/arginine-rich splicing factor 3 SRSF3 Nucleus other 2
signal sequence receptor, gamma (translocon-associat-
ed protein gamma) SSR3 Cytoplasm other 7
signal sequence receptor, delta (translocon-associated 
protein delta) SSR4 Cytoplasm other 2
suppression of tumorigenicity 13 (colon carcinoma) 
(Hsp70 interacting protein) ST13 Cytoplasm other 3
stress-induced-phosphoprotein 1 STIP1 Cytoplasm other 10
stathmin 1 STMN1 Cytoplasm other 3
stomatin STOM
Plasma Mem-
brane other 2
synaptotagmin binding, cytoplasmic RNA interacting 
protein SYNCRIP Nucleus other 3
transgelin 2 TAGLN2 Cytoplasm other 13
tubulin folding cofactor A TBCA Cytoplasm other 0
t-complex 1 TCP1 Cytoplasm other 15
trans-2,3-enoyl-CoA reductase TECR
Plasma Mem-
brane other 5
TEL2, telomere maintenance 2, homolog (S. cerevisiae) TELO2 unknown other 2
transmembrane protein 109 TMEM109 Cytoplasm other 3
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transmembrane protein 126B TMEM126B unknown other 1
transmembrane protein 161A TMEM161A unknown other 6
transmembrane protein 165 TMEM165
Plasma Mem-
brane other 2
transmembrane protein 41B TMEM41B unknown other 2
thymopoietin TMPO Nucleus other 8
tropomyosin 1 (alpha) TPM1 Cytoplasm other 31
tropomyosin 4 TPM4 Cytoplasm other 41
translocation associated membrane protein 1 TRAM1 Cytoplasm other 2
tubulin, beta 2A TUBB2A Cytoplasm other 4
tubulin, beta 2C TUBB2C Cytoplasm other 12
tubulin, beta 3 TUBB3 Cytoplasm other 2
tubulin, beta 4 TUBB4 Cytoplasm other 3
tubulin, gamma 1 TUBG1 Cytoplasm other 2
U2 small nuclear RNA auxiliary factor 2
U2AF2 (includes 
EG:11338) Nucleus other 2
VAMP (vesicle-associated membrane protein)-associat-
ed protein A, 33kDa VAPA
Plasma Mem-
brane other 1
WD repeat domain 6
WDR6 (includes 
EG:11180) unknown other 2
exportin, tRNA (nuclear export receptor for tRNAs) XPOT Nucleus other 14
YTH domain family, member 2 YTHDF2 unknown other 2
tyrosine 3-monooxygenase/tryptophan 5-monooxygen-
ase activation protein, epsilon polypeptide YWHAE Cytoplasm other 40
tyrosine 3-monooxygenase/tryptophan 5-monooxygen-
ase activation protein, gamma polypeptide YWHAG Cytoplasm other 5
tyrosine 3-monooxygenase/tryptophan 5-monooxygen-
ase activation protein, theta polypeptide
YWHAQ 
(includes 
EG:10971) Cytoplasm other 2
AFG3 ATPase family gene 3-like 2 (S. cerevisiae) AFG3L2 Cytoplasm peptidase 4
dynein, cytoplasmic 1, heavy chain 1 DYNC1H1 Cytoplasm peptidase 4
leucine aminopeptidase 3 LAP3 Cytoplasm peptidase 3
nicalin NCLN Cytoplasm peptidase 2
protein disulfide isomerase family A, member 3 PDIA3 Cytoplasm peptidase 14
presenilin 1 PSEN1
Plasma Mem-
brane peptidase 2
proteasome (prosome, macropain) subunit, alpha type, 
1 PSMA1 Cytoplasm peptidase 2
proteasome (prosome, macropain) subunit, alpha type, 
3 PSMA3 Cytoplasm peptidase 1
proteasome (prosome, macropain) subunit, alpha type, 
4 PSMA4 Cytoplasm peptidase 6
proteasome (prosome, macropain) subunit, alpha type, 
7 PSMA7 Cytoplasm peptidase 0
proteasome (prosome, macropain) subunit, beta type, 1 PSMB1 Cytoplasm peptidase 1
proteasome (prosome, macropain) subunit, beta type, 2 PSMB2 Cytoplasm peptidase 2
proteasome (prosome, macropain) subunit, beta type, 5 PSMB5 Cytoplasm peptidase 2
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proteasome (prosome, macropain) subunit, beta type, 6 PSMB6 Cytoplasm peptidase 2
proteasome (prosome, macropain) subunit, beta type, 7 PSMB7 Cytoplasm peptidase 4
proteasome (prosome, macropain) 26S subunit, ATPase, 
1 PSMC1 Nucleus peptidase 4
proteasome (prosome, macropain) 26S subunit, ATPase, 
2 PSMC2 Nucleus peptidase 1
SEC11 homolog A (S. cerevisiae) SEC11A Cytoplasm peptidase 2
tubulin, gamma complex associated protein 2 TUBGCP2 Cytoplasm peptidase 2
ubiquitin carboxyl-terminal esterase L1 (ubiquitin 
thiolesterase) UCHL1 Cytoplasm peptidase 4
YME1-like 1 (S. cerevisiae) YME1L1 Cytoplasm peptidase 10
protein phosphatase 1, catalytic subunit, alpha isozyme PPP1CA Cytoplasm phosphatase 3
protein phosphatase 2, regulatory subunit A, alpha PPP2R1A Cytoplasm phosphatase 10
protein tyrosine phosphatase, mitochondrial 1 PTPMT1 Cytoplasm phosphatase 2
SAC1 suppressor of actin mutations 1-like (yeast) SACM1L Cytoplasm phosphatase 3
SET nuclear oncogene SET Nucleus phosphatase 4
calreticulin CALR Cytoplasm
transcription 
regulator 7
cullin-associated and neddylation-dissociated 1 CAND1 Cytoplasm
transcription 
regulator 3
ClpB caseinolytic peptidase B homolog (E. coli) CLPB Nucleus
transcription 
regulator 5
far upstream element (FUSE) binding protein 1 FUBP1 Nucleus
transcription 
regulator 2
histone deacetylase 1 HDAC1 Nucleus
transcription 
regulator 2
heterogeneous nuclear ribonucleoprotein D (AU-rich 
element RNA binding protein 1, 37kDa) HNRNPD Nucleus
transcription 
regulator 3
huntingtin HTT Cytoplasm
transcription 
regulator 0
interleukin enhancer binding factor 2, 45kDa
ILF2 (includes 
EG:3608) Nucleus
transcription 
regulator 8
LAG1 homolog, ceramide synthase 2 LASS2 Nucleus
transcription 
regulator 8
MYB binding protein (P160) 1a MYBBP1A Nucleus
transcription 
regulator 2
nascent polypeptide-associated complex alpha subunit NACA Nucleus
transcription 
regulator 5
proliferation-associated 2G4, 38kDa PA2G4 Nucleus
transcription 
regulator 5
PDZ and LIM domain 1 PDLIM1 Cytoplasm
transcription 
regulator 2
prohibitin
PHB (includes 
EG:5245) Nucleus
transcription 
regulator 11
prolactin regulatory element binding PREB Nucleus
transcription 
regulator 2
proteasome (prosome, macropain) 26S subunit, ATPase, 
3 PSMC3 Nucleus
transcription 
regulator 7
proteasome (prosome, macropain) 26S subunit, ATPase, 
5 PSMC5 Nucleus
transcription 
regulator 2
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retinoblastoma binding protein 7 RBBP7 Nucleus
transcription 
regulator 5
RuvB-like 1 (E. coli) RUVBL1 Nucleus
transcription 
regulator 11
RuvB-like 2 (E. coli) RUVBL2 Nucleus
transcription 
regulator 9
tripartite motif-containing 28 TRIM28 Nucleus
transcription 
regulator 3
thyroid hormone receptor interactor 13 TRIP13 Cytoplasm
transcription 
regulator 2
Y box binding protein 1 YBX1 Nucleus
transcription 
regulator 10
tyrosine 3-monooxygenase/tryptophan 5-monooxygen-
ase activation protein, eta polypeptide YWHAH Cytoplasm
transcription 
regulator 1
basic leucine zipper and W2 domains 1 BZW1 Cytoplasm
translation 
regulator 4
eukaryotic translation elongation factor 1 alpha 2 EEF1A2 Cytoplasm
translation 
regulator 2
eukaryotic translation elongation factor 1 delta (guanine 
nucleotide exchange protein) EEF1D Cytoplasm
translation 
regulator 5
eukaryotic translation elongation factor 2 EEF2 Cytoplasm
translation 
regulator 42
eukaryotic translation initiation factor 2B, subunit 4 
delta, 67kDa EIF2B4 Cytoplasm
translation 
regulator 2
eukaryotic translation initiation factor 2, subunit 1 
alpha, 35kDa EIF2S1 Cytoplasm
translation 
regulator 3
eukaryotic translation initiation factor 3, subunit A EIF3A Cytoplasm
translation 
regulator 4
eukaryotic translation initiation factor 3, subunit B EIF3B Cytoplasm
translation 
regulator 2
eukaryotic translation initiation factor 3, subunit D EIF3D Cytoplasm
translation 
regulator 2
eukaryotic translation initiation factor 3, subunit E EIF3E Cytoplasm
translation 
regulator 4
eukaryotic translation initiation factor 3, subunit F EIF3F Cytoplasm
translation 
regulator 4
eukaryotic translation initiation factor 3, subunit H EIF3H Cytoplasm
translation 
regulator 3
eukaryotic translation initiation factor 4A1 EIF4A1 Cytoplasm
translation 
regulator 19
eukaryotic translation initiation factor 4 gamma, 1 EIF4G1 Cytoplasm
translation 
regulator 3
eukaryotic translation initiation factor 5A EIF5A Cytoplasm
translation 
regulator 3
GCN1 general control of amino-acid synthesis 1-like 1 
(yeast) GCN1L1 Cytoplasm
translation 
regulator 30
insulin-like growth factor 2 mRNA binding protein 1 IGF2BP1 Cytoplasm
translation 
regulator 8
methylthioribose-1-phosphate isomerase homolog (S. 
cerevisiae) MRI1 Cytoplasm
translation 
regulator 2
poly(rC) binding protein 1
PCBP1 (includes 
EG:5093) Nucleus
translation 
regulator 9
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ribosomal protein S23 RPS23 Cytoplasm
translation 
regulator 2
Tu translation elongation factor, mitochondrial TUFM Cytoplasm
translation 
regulator 14
ATP-binding cassette, sub-family D (ALD), member 3 ABCD3 Cytoplasm transporter 5
ATP-binding cassette, sub-family E (OABP), member 1 ABCE1 Cytoplasm transporter 4
apolipoprotein D APOD
Extracellular 
Space transporter 2
ATP synthase, H+ transporting, mitochondrial Fo com-
plex, subunit B1 ATP5F1 Cytoplasm transporter 5
ATP synthase, H+ transporting, mitochondrial Fo com-
plex, subunit d
ATP5H (includes 
EG:10476) Cytoplasm transporter 0
ATP synthase, H+ transporting, mitochondrial F1 com-
plex, O subunit ATP5O Cytoplasm transporter 4
ATPase, H+ transporting, lysosomal V0 subunit a1 ATP6V0A1 Cytoplasm transporter 1
ATPase, H+ transporting, lysosomal 70kDa, V1 subunit A ATP6V1A Cytoplasm transporter 10
ATPase, H+ transporting, lysosomal 31kDa, V1 subunit 
E1 ATP6V1E1 Cytoplasm transporter 2
ATPase, H+ transporting, lysosomal 50/57kDa, V1 
subunit H ATP6V1H Cytoplasm transporter 5
calcium binding protein P22 CHP Cytoplasm transporter 3
coatomer protein complex, subunit alpha COPA Cytoplasm transporter 9
coatomer protein complex, subunit beta 1 COPB1 Cytoplasm transporter 4
coatomer protein complex, subunit beta 2 (beta prime) COPB2 Cytoplasm transporter 4
coatomer protein complex, subunit gamma COPG Cytoplasm transporter 3
CSE1 chromosome segregation 1-like (yeast) CSE1L Nucleus transporter 15
endoplasmic reticulum protein 29 ERP29 Cytoplasm transporter 4
electron-transfer-flavoprotein, alpha polypeptide ETFA Cytoplasm transporter 3
electron-transfer-flavoprotein, beta polypeptide ETFB Cytoplasm transporter 2
hemoglobin, beta
HBB (includes 
EG:3043) Cytoplasm transporter 8
heterogeneous nuclear ribonucleoprotein U (scaffold 
attachment factor A) HNRNPU Nucleus transporter 6
importin 4 IPO4 Nucleus transporter 6
importin 5 IPO5 Nucleus transporter 2
importin 7 IPO7 Nucleus transporter 6
importin 8 IPO8 Nucleus transporter 2
importin 9 IPO9 Nucleus transporter 6
karyopherin alpha 2 (RAG cohort 1, importin alpha 1) KPNA2 Nucleus transporter 5
karyopherin (importin) beta 1 KPNB1 Nucleus transporter 23
protein kinase C and casein kinase substrate in neurons 
2 PACSIN2 Cytoplasm transporter 4
sec1 family domain containing 1 SCFD1 Cytoplasm transporter 5
Sec61 alpha 1 subunit (S. cerevisiae) SEC61A1 Cytoplasm transporter 7
SEC62 homolog (S. cerevisiae) SEC62 Cytoplasm transporter 4
sideroflexin 1 SFXN1 Cytoplasm transporter 3
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sideroflexin 4 SFXN4 Cytoplasm transporter 2
solute carrier family 16, member 1 (monocarboxylic acid 
transporter 1) SLC16A1
Plasma Mem-
brane transporter 14
solute carrier family 16, member 1 (monocarboxylic acid 
transporter 1) SLC16A1
Plasma Mem-
brane transporter 2
solute carrier family 1 (neutral amino acid transporter), 
member 5 SLC1A5
Plasma Mem-
brane transporter 10
solute carrier family 25 (mitochondrial carrier; citrate 
transporter), member 1 SLC25A1
Plasma Mem-
brane transporter 4
solute carrier family 25 (mitochondrial carrier; oxogluta-
rate carrier), member 11 SLC25A11 Cytoplasm transporter 14
solute carrier family 25, member 13 (citrin) SLC25A13 Cytoplasm transporter 10
solute carrier family 25 (mitochondrial thiamine pyro-
phosphate carrier), member 19 SLC25A19 Cytoplasm transporter 3
solute carrier family 25 (mitochondrial carrier: gluta-
mate), member 22 SLC25A22 Cytoplasm transporter 4
solute carrier family 25 (mitochondrial carrier; phos-
phate carrier), member 3 SLC25A3 Cytoplasm transporter 42
solute carrier family 35, member B2 SLC35B2 Cytoplasm transporter 2
solute carrier family 39 (zinc transporter), member 14 SLC39A14
Plasma Mem-
brane transporter 6
solute carrier family 6 (neutral amino acid transporter), 
member 15 SLC6A15
Plasma Mem-
brane transporter 1
solute carrier family 7 (cationic amino acid transporter, 
y+ system), member 1 SLC7A1
Plasma Mem-
brane transporter 4
solute carrier family 7 (cationic amino acid transporter, 
y+ system), member 5 SLC7A5
Plasma Mem-
brane transporter 2
structural maintenance of chromosomes 2 SMC2 Nucleus transporter 5
spinster homolog 1 (Drosophila) SPNS1 Cytoplasm transporter 2
synaptogyrin 1 SYNGR1
Plasma Mem-
brane transporter 1
transferrin receptor (p90, CD71) TFRC
Plasma Mem-
brane transporter 5
transmembrane 9 superfamily member 1 TM9SF1
Plasma Mem-
brane transporter 2
transmembrane 9 superfamily member 3 TM9SF3 Cytoplasm transporter 4
transmembrane emp24-like trafficking protein 10 (yeast) TMED10 Cytoplasm transporter 3
transportin 1 TNPO1 Nucleus transporter 3
translocase of outer mitochondrial membrane 22 
homolog (yeast) TOMM22 Cytoplasm transporter 7
translocase of outer mitochondrial membrane 70 homo-
log A (S. cerevisiae) TOMM70A Cytoplasm transporter 3
exportin 4 XPO4 Nucleus transporter 4
exportin 5 XPO5 Nucleus transporter 4
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7.1 Abstract
The human cytomegalovirus (HCMV), associated with the development of malig-
nancies, encodes the constitutively active G protein coupled receptors (GPCRs) 
UL33 and US28. As US28 possesses oncogenic properties and is expressed in CMV 
positive human glioblastomas, we set out to investigate the signaling properties of 
UL33. US28 expression is detected early after infection, whereas UL33 is expressed 
at later stages. In transient, as well as stable transfection systems, UL33, like US28, 
constitutively activates various proliferative, pro-angiogenic signal transduction 
pathways. In xenograft models, UL33 was shown to induce tumor growth. As shown 
previously for US28, UL33 expression was also detected in human glioblastoma. In-
terestingly, the distribution of UL33 in the primary glioblastoma samples was more 
dispersed, while expression of US28 was confined to the vascular niche.  Taken 
together, our data indicate that the viral GPCR UL33 has oncogenic potential and 
could play a role in HCMV-associated malignancies. The differential kinetics of UL33 
and US28 expression and pronounced expression of UL33 in human glioblastoma, 
indicate that HCMV has devised distinct means to engage or prolong proliferative 
signaling pathways upon infection through expression of these viral receptors.
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7.2 Introduction
The mammalian line of defence against invasion of pathogens or injury depends on 
timely activation and proper targeting of leukocytes (1, 2). Chemokine-chemokine 
receptor interactions are crucial to control both onset and localization of leuko-
cyte-mediated responses. Several b-herpesviruses have corrupted this system by hi-
jacking and subverting components, both ligands and receptors, of the chemokine 
system (3-5). Human cytomegalovirus (HCMV, HHV-5), a member of the b-herpesvi-
rus subfamily has successfully utilized this strategy resulting in high prevalence with 
up to 90% of the population harbouring a latent infection (5). While HCMV infec-
tion is asymptomatic in immune-competent individuals, it can cause severe pathol-
ogies in immune-compromised patients (6, 7). Moreover, HCMV infection during 
pregnancy is the leading infectious agent causing mental retardation and deafness 
of the unborn child (8). Furthermore, HCMV infection is associated with several 
pathologies, such as atherosclerosis (9), autoimmune diseases and cancers (6, 7, 
10, 11). HCMV infection has been proposed to aggravate the malignant phenotype 
of e.g. colon cancer (12) malignant glioma (6, 13) and medulloblastoma (14). The 
HCMV-encoded chemokine receptor US28 is one of the HCMV-encoded proteins 
believed to contribute to the malignant phenotype (14-16).
US28 has been shown to scavenge and internalize different members of the CC 
family chemokines including CCL5 and CCL2, and also CX3CL1 (17). Furthermore, 
US28 has been shown to constitutively stimulate proliferative signaling (16, 18-20). 
Moreover, this GPCR have been implicated in oncomulation in vivo, as heterolo-
gous expression of US28 in mice, stimulates intestinal neoplasia (21). Furthermore, 
expression of US28 was correlated to proliferative signaling and poor prognosis in 
human glioblastoma (16).  
Besides US28, HCMV encodes three other viral G protein coupled receptors (vG-
PCRs) with homology to human chemokine receptors; US27, UL33, and UL78 (3). 
These receptors and two chemokine homologues (vCXCL1 and 2) (22) may be uti-
lized by the virus to deceive the host’s immune system and could be instrumental 
in viral pathology. Homologues of UL33 and UL78 are conserved throughout the 
β-herpesvirus family (23). In contrast, US28 and US27 have been identified only in 
CMVs, closely related to HCMV, targeting primate hosts (24). 
Like US28, UL33 has been shown to signal in a constitutive manner via Gaq, Gai, and 
Gas (25). The constitutive activation of both receptors could be instrumental in HC-
MV-mediated pathology. Therefore, it is crucial to determine the kinetics and cellu-
lar consequences of signaling mediated by these vGPCRs. The UL33 homologue in 
the murine cytomegalovirus (M33) was shown to be functional in viral dissemina-
tion (26). Interestingly, loss of M33 can be partially complemented with functional 
UL33, suggesting conservation of functionality. Both UL33 and US28 were found to 
co-localize with the viral envelop glycoproteins gB and gH (Margulies, Browne et al. 
1996, Fraile-Ramos, Pelchen-Matthews et al. 2002). Although UL33 (27) and US28 
(28) are dispensable for viral replication in respectively MCR5 and human forskin 
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fibroblasts, functional consequence of expressing vGPCRs on the viral particle may 
enhance binding of the virus particles to target cells. Alternatively, these receptors 
could exert their effect by rewiring cellular signaling of the host cells. 
In this study we describe the UL33-mediated constitutive activation of proliferative 
signal transduction pathways, and consequences for cellular transformation. More-
over, we detected the expression of this vGPCR in human glioblastoma. As UL33 and 
US28 expression patterns after HCMV infection revealed different kinetics, our data 
suggest HCMV may use both UL33 and US28 to successfully engage proliferative 
signaling pathways in the host cell. 
7.3 Results
7.3.1 UL33 is expressed with different kinetics compared to US28 in HCMV infec- 
 tion cycle 
As both US28 and UL33 were previously shown to constitutively signal via multi-
ple Ga-dependent signaling pathways, we examined the possibility of these events 
to occur in concert by monitoring expression of both receptors during the HCMV 
infection cycle. We evaluated the kinetics of US28 and UL33 expression after in-
fection of human foreskin fibroblasts (HFF) using the HCMV TB40-BAC4 strain. We 
analyzed the kinetics of UL33 expression taking advantage of the N-terminally Flag 
tagged UL33 (TB40-BAC4-UL33ex1-FLAG). US28 was visualized using the antibody 
described (16). Intracellular distribution of both US28 and UL33 was similar as de-
scribed earlier (35, 36) with UL33 mostly present in intracellular vesicles and US28 
concentrated in the perinuclear area (data not shown). The kinetics of expression 
of both UL33 and US28 were investigated in situ and by Western analysis (Figure 
1A and B). As can be seen in Figure 1A, expression of UL33ex1-FLAG was observed 
at 96, 120 and 144 hours post infection (h.p.i.), whereas US28 is already detectable 
24 h.p.i., at low levels as indicated by Western blotting (Figure  1B). This may in-
dicate an exclusive role of US28 early after infection and collective effects of both 
receptors, later in the infection cycle. Confirmation of US28 expression early in the 
HCMV infection cycle was obtained by means of radioligand binding assays, using 
[125I]-CCL5, a chemokine known to bind US28. In these analyses, increased binding 
of [125I]-CCL5 was observed 48 hrs after infection with the wild type HCMV strain 
(Wt) but not with the DUS28 (US28 deletion strain) - or UV-inactivated virus (Figure 
1C). As no ligands for UL33 have been identified to date, these assays could not 
be performed for this vGPCR. To examine the functional consequence of differen-
tial expression of both viral GPCRs, PLC activation was measured in HCMV infected 
cells. For this purpose, TB40 wild type and mutant viral strains, deleted for UL33, 
US28 or both were used (33). All HCMV mutants used in this study displayed similar 
infection properties as confirmed by back titration (data not shown). Activation of 
PLC in HFF was significantly reduced for DUS28 and the double deletion mutant 
DUS28-DUL33 viral strains 48 h.p.i. (Figure 1D). Deletion of UL33 alone did not re-
sult in a significant reduction of PLC activation 48 h.p.i.
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Figure 1. Kinetics of expression UL33 and US28 after HCMV infection. (A) UL33 receptor expression after infec-
tion with  TB40 UL33ex1-FLAG (green) increases 96, 120, and 144 hours post infection in HFF cells. US28 (red) is 
expressed expression 24 hours post infection, with strongest expression from 48 hours post infection and onwards. 
All micrographs have been taken at 40x magnification. Nuclei of the cells were stained with DAPI (blue). (B) West-
ern-blot analysis of both UL33ex1-FLAG and US28 expression in infected cells. The US28 typically antibody stains 
two bands of approximately 45 kD and 40 kD as shown in the panel. Expression of Flag-tagged UL33 (35 kDa) is 
observed at 96, 120 and 144 hours post infection (h.p.i.), whereas US28 is already detectable at low levels 24 
h.p.i. Presence of US28 increases at later time-points.  (C) [125I]-CCL5 binding shows early kinetics of US28 protein 
expression in AD169-WT–infected cells with a peak at 48 h.p.i. No [125I]-CCL5 binding is detected in cells infected 
with AD169-ΔUS28 mutant or in UV-inactivated WT virus infected cells. (D) PLC activation is significantly reduced 
in the absence of US28 in TB40-BAC4 deletion mutant virus infected cells 48 h.p.i. Inositol phosphate accumulation 
performed on HFF cells, infected with m.o.i. of 2 of  different deletion HCMV TB40-BAC4 strains shows significant 
reduction in inositol phosphate accumulation by US28 and a double deletion mutant viral strain compared to wild-
type infected cells (*p < 0.05, **p < 0.01, ***p <0.001 respectively). Virus m.o.i. used in infections was confirmed 
to be comparable by back titration (data not shown).
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Figure 2. Viral chemokine receptor UL33 constitutively activates various signal transduction pathways. (A) ELISA 
of expression of UL33 after transfection with various amounts of the pcDEF3-UL33 to HEK293 cells. Bars represent 
the expression in permeabilized cells.  Anti-UL33, kindly provided by Prof. W. Gibson, was used to detect UL33. (B) 
UL33 dose-dependently activates VEGF promotor activity. UL33 also induces NFAT transcriptional activation (C), 
COX-2 promoter activation (D), and STAT3 transcriptional activation (E). For all reporter gene assays HEK293T cells 
(1x106) are transiently transfected with 25 ng UL33 DNA in combination with the respective reporter constructs. 
Luciferase expression was determined 24 hrs post transfection. Results are presented in relative light units (RLU) 
and are all normalized (Mock is 100).
7.3.2 HCMV-encoded UL33 constitutively activates multiple signaling pathways
As US28 was described to promiscuously trigger activation of various prolifera-
tive-, angiogenic- and inflammatory signaling pathways resulting in oncomodula-
tory effects (16, 32, 37), we evaluated UL33-mediated activation of these signaling 
pathways. As can be seen in Figure 2A, transfection of increasing amounts of pc-
DEF3-UL33 increased levels of UL33 protein as detected in an ELISA using anti-UL33 
antibody (27). UL33 constitutively induced VEGF promotor activity in a dose-depen-
dent manner, as was measured with a specific reportergene (Figure  2B). Likewise, 
UL33 expression induced activation of the NFAT pathway, COX2 promotor activity 
and STAT3 transcriptional activity as measured with specific reportergenes when 
expressed in HEK293T cells (Figure  2C-E). 
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Figure 3. UL33 induces a proliferative phenotype in NIH-3T3. (A) UL33 shows constitutive inositol phosphate ac-
cumulation in NIH-3T3 cells stably expressing UL33 wt and UL33-eGFP. Constitutive accumulation of inositol phos-
phate in NIH-3T3 cells expressing US28 was used as positive control. (B) UL33 expressing NIH-3T3 cells display 
increased proliferation as measured by [3H]-thymidine incorporation. Data are normalized over 3T3-Mock values. 
[3H]-thymidine incorporation by NIH-3T3 cells stably expressing US28 was used as positive control. (C) NIH-3T3 cells 
expressing UL33-eGFP show loss of contact inhibition as evidenced by the appearance of foci, albeit to a lesser de-
gree compared to NIH-3T3 cells expressing US28. (D) Inhibition of foci formation by NIH-3T3 cells stably expressing 
UL33-eGFP and US28, respectively, in the presence of 1 µM Stattic (specific  inhibitor of STAT3 dimerization). 
7.3.3 UL33 induces a transformed phenotype in NIH-3T3 cells 
To investigate whether UL33 expression was associated with onset of transfor-
mation, as shown earlier for US28 (19), stable NIH-3T3 cell lines expressing UL33 
were generated. To this end, wildtype UL33 and C-terminally eGFP-tagged UL33 
constructs were used. Constitutive PLC activation indicated proper receptor func-
tionality and expected signaling properties of both wt UL33 and eGFP-tagged UL33 
receptors (Figure  3A). The observed increase in PLC activation in cell lines express-
ing UL33 was lower compared to those in US28-expressing NIH-3T3 cells
To examine the proliferative potential of UL33, a thymidine incorporation assay 
was done. Clearly, cell lines expressing UL33 displayed increased [3H]-thymidine 
incorporation. DNA synthesis upon serum starvation was two-to four-fold higher 
in UL33-expressing cells compared to mock transfected cells. To confirm the onco-
genic potential of UL33 a foci formation assay was performed. As depicted in Figure 
3C UL33-eGFP expressing cells lost contact inhibition and formed foci as seen for 
US28-expressing cells, albeit with a lower efficiency compared to US28. In view of 
convergence of UL33 signaling into the STAT3 pathway, observed earlier for US28 
(16), cells were treated with stattic, a small inhibitor molecule inhibitor targeting 
STAT3 (38). Stattic inhibited foci formation in UL33-expressing cells to a similar ex-
tent as seen in US28-expressing cells (Figure 3D).  
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Figure 4. UL33 promotes tumour formation in vivo. (A) 
Mice injected with 3T3-UL33-eGFP cells show tumour 
formation within 3 weeks, as indicated by the arrows. (B). 
Kaplan-Meier analysis showing tumours larger than 50 
mm3 formed by UL33-GFP (○) and US28 (●) (C). Analysis 
of US28 and UL33 mRNA levels by RT-PCR in the xeno-
grafts from nude mice injected with NIH-3T3 cells stably 
expressing US28 or UL33-eGFP, respectively.
7.3.4 UL33 stimulates proliferative signaling 
Since in vitro studies with UL33-expressing cells showed a transformed and prolif-
erative phenotype, we determined whether UL33-eGFP expressing cells could also 
induce tumor formation in vivo. To this end, UL33-eGFP or US28 expressing NIH-3T3 
cells were subcutaneously (s.c.) injected in the flanks of nude athymic mice (6 mice 
injected per cell line; 12 inoculations). First signs of tumor formation appeared as 
early as 1 week post injection for the mice injected with US28 expressing cells, and 
shortly after that for the mice injected with the UL33-eGFP cells, as shown in the Ka-
plan-Meier curve (Figure 4B). Tumours were clearly visible 2-3 weeks after inocula-
tion (Figure 4A), after which animals were sacrificed. Some mice injected with UL33 
expressing cells displayed smaller tumours at the exterior, however, large internal 
tumours were present in all cases. The mock group, as previously published (19), 
did not develop tumours up to 75 days after injection. Gene expression of US28 and 
UL33 was confirmed by RT-PCR in the tumours formed (Figure 4C). For US28 a much 
higher expression (>256x higher) was obtained than for UL33 mRNA. 
7.3.5 UL33 expression in primary glioblastoma 
Previous study from our laboratory has shown that US28 is expressed in primary 
glioblastoma tumors (16). To examine the potential presence of UL33 in primary 
glioblastoma, we examined tissue samples of 25 glioblastoma patients by immu-
nohistochemistry using antibodies raised against UL33. UL33 was expressed at dif-
ferent levels in GBM tumors, mainly in the tumor cells that appear as patches in 
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Figure 5 UL33 expression in primary glioblastoma specimens. Representative immunohistochemical stainings are 
shown. (A and E) Rabbit IgG isotype control staining (B, C, D and F) Samples stained with anti-UL33 antiserum 
(brown). Scale bars 100 µm. (G) Patient overall survival (OS), and (G) time to tumor progression (TTP) are not sig-
nificantly affected by UL33 expression.
the tissue (Figure 5 B –D and F). UL33 staining is primarily cytoplasmic (Figure 5D). 
Patients were categorized in two groups (based on approximately percentage num-
ber of UL33 positive cells in their tumors (negative or grade1; <10% and grade 2; 
>10%-50%). UL33 was expressed in <10% of the tumor cells in 15/25 (60%), in >10-
50% in 10/25 (40%). One of the samples tested in this study was negative for UL33. 
Median overall survival was 15.5 months in group 1 vs 13 months in group 2 of patients 
B
C
E F
D
A
G H
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(p= 0.09, Figure 5G). Time to first tumor progression was 5 months longer in group 
1 patients compared to group 2 patients (13 vs 8 months, p=0.67, Figure 5H). 5 pa-
tients were alive; 3 patients in group I and 2 patients in group 2.
Expression of UL33 around vessels, the main site for expression of US28 in primary 
glioblastoma, in these tissue samples (Figure 5F) was detected in 9 out of the 25 
(36%) of tumor samples. In these cases mostly endothelial cells and smooth muscle 
cells (SMC) appeared to be positive for UL33 staining. Interestingly, infiltrating neu-
trophils and granulocytes appear to be strongly positive for UL33 in 8/25 (32%) of 
these patients (Figure 5F). 
7.4 Discussion
Herpesviruses are known to alter cellular gene expression and cell function (39, 
40). While the oncogenic potential of some viruses like Kaposi sarcoma associat-
ed herpes virus and human papilloma virus is well established (41, 42), HCMV is 
believed to possess oncomodulatory properties. In view of the oncomodulatory 
potential of the HCMV-encoded chemokine receptor US28 (4, 15, 19, 43, 44), we 
subjected UL33, another constitutively active viral encoded chemokine receptor 
homolog (25) to signaling and cell proliferation studies. In this study we clearly 
demonstrate that UL33, like US28, has oncogenic potential in vitro as well as in vivo. 
UL33 constitutively activates several signaling pathways (Figure  2), which play key 
roles in enhanced cellular proliferation and oncogenesis  (45-47). UL33 stimulated 
transcriptional activation of NFAT and STAT3 (Figure 2C and 2E) and induced VEGF 
and COX-2 promoter activation (Figure 2B and 2D). NIH-3T3 cells stably expressing 
UL33 exhibit constitutive PLC activation, increases in DNA synthesis rate and loss 
of contact inhibition (Figure  3), properties indicative of transformation. UL33-eG-
FP expressing NIH-3T3 cells induce tumor growth within 3 weeks in a nude mice 
xenograft model (Figure  4). Tumor formation was apparent after 2 weeks, while 
did occur earlier for US28. The slower onset of tumor formation compared to mice 
injected with US28 expressing NIH-3T3 cells, can be explained by reduced increases 
in PLC activity and foci formation UL33 compared to US28 expressing NIH-3T3 cells. 
Moreover, the UL33 mRNA levels in the xenografts are significantly lower compared 
to US28 mRNA levels in US28-induced xenografts  (Figure  5 C), suggesting that the 
oncomodulatory effects of both US28 and UL33 may differ, despite the overlap in 
receptor-induced signaling we have observed. Noteworthy, unlike for US28 (16), 
increased IL6 levels could not be detected in medium from NIH-3T3 cells stably 
expressing UL33 (data not shown) nor could we measure increased PGE2 levels. Al-
though both vGPCRs can activate a comparable set of signaling pathways, a certain 
threshold of activation may be required to induce rapid onset of turmorigenesis. 
To study the expression kinetics of UL33 and US28 in HCMV infected cells, human 
foreskin fibroblasts (HFF) were infected with a mutant HCMV virus (BAC40-UL33ex1-
Flag). Intracellular localization of both US28 and UL33 was comparable as described 
earlier (Fraile-Ramos, Pelchen-Matthews et al. 2002). The kinetics of expression of 
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both vGPCRs differ, with US28 being detectable 24 h.p.i., whereas UL33 only ap-
peared after 72 h.p.i. Early expression kinetics of US28 was confirmed in a CCL5 
binding assay and by measuring PLC activation 48 h.p.i. using HCMV TB40 WT and 
mutant strains lacking either US28, UL33 or both vGPCRs (33). Our data show that 
UL33, unlike US28, is expressed at a late stage of the HCMV replication cycle. This 
confirmed earlier observations on US28 and UL33 expression profiles in HFF and 
U373-MG cells (28, 36, 48). In a viral setting, both receptors could have modulato-
ry functionalities important in HCMV pathology. As the UL33 expression kinetics is 
slower compared to that of US28, this may result in further activation of signaling 
pathways initially triggered by US28. For instance, the enhanced COX-2 promoter 
activity as previously described for US28 (32), could be prolonged by UL33 late ex-
pression. A comparable synergism could be postulated for the activation of STAT3 
signaling important in US28 mediated oncomodulation (16). Yet, co-expression of 
both receptors could also result in antagonizing effects. Recently, UL33 was report-
ed to co-localize and form heterodimers with US28 (49).  Interestingly, the constitu-
tive activation of the US28-mediated Gαq/phospholipase C pathway was not affect-
ed by receptor heteromerization, while UL33 was able to silence US28-mediated 
activation of the transcription factor NF-κB. These data imply that co-expression 
may result in inhibitory effects on downstream signaling. Further experiments are 
required to substantiate whether co-expression of both receptors does result in 
altered proliferative signaling. 
Besides temporal synergy or modulatory function between the vGPCRs also a spa-
tial complementarity between UL33 and US28 could affect HCMV-induced pathol-
ogy. In this study we have shown that UL33 is expressed at detectable levels in 
primary glioblastomas (Figure 5). Compared to our earlier observation regarding 
expression of US28 in glioblastoma the pattern of UL33 expressed in these tumors 
is more pronounced. Whereas US28 is primarily expressed around the blood vessels 
within the so-called vascular niche (Slinger, Maussang et al. 2010), UL33 expression 
is detected in the vessel area as well within the cells that make up the tumor tissue 
and in immune cells invading the tissue. However, UL33 expression levels do not 
significantly correlate with patient outcome and survival.
Taken together, our data indicate that the viral GPCR UL33 has oncogenic potential 
and could play a role in HCMV-associated malignancies. The differential kinetics of 
UL33 and US28 expression and pronounced expression of UL33 in human glioblas-
toma, indicate that HCMV has devised distinct means to engage or prolong prolifer-
ative signaling pathways upon infection through expression of these viral receptors.
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7.5 Materials and methods
Cell culture 
HEK293T cells, human glioblastoma U373 cells, and mouse fibroblast NIH-3T3 cells were 
cultured in DMEM supplemented with penicillin/streptomycin (50 IU/ml) and 10% of fetal 
bovine, heat inactivated fetal bovine or bovine serum, respectively. Transfections were per-
formed in HEK293T with the polyethylenimine (PEI) method (29). Transfections in U373 and 
NIH-3T3 cells were performed with the calcium phosphate method. Stably transfected NIH-
3T3 cells were selected and maintained in culture with neomycin (400 mg/ml) to ensure 
expression of UL33 and US28 receptors, respectively.
Receptor characterization by inositol phosphate formation and thymidine Incorporation 
UL33 or US28 expression and constitutive signaling were analyzed for inositol phosphate 
formation as previously described. As for thymidine incorporation measurement, the exper-
iment was carried out upon serum starvation by using medium containing 0.5% calf serum. 
[6-3H]-Thymidine was obtained from GE Healthcare Life Sciences (Buckinghamshire, UK) and 
used to label at a concentration of 1 μCi/ml [6-3H]-Thymidine. 
Reporter gene analysis 
For the promoter activation measurements, 106 HEK293T cells were transfected with 0.5-1.5 
mg of reporter-Luciferase plasmid and the indicated amounts (25 ng or 1 mg) of pcDEF3-UL33. 
To measure VEGF promoter activation, (500ng/1*106 cells) the pGL2-VEGF-Luciferaselucif-
erase construct, kindly provided by Dr. G. Pages (Institute of Signaling Development Biology 
and Cancer, Nice, France) was used. The Ly6E STAT3-–response element luciferase construct 
(500ng/1*106 cells) (30) was used for STAT3 activity measurements. The NFAT reporter 
gene (500ng/1*106 cells), pNFAT-luc was purchased from Stratagene. Total DNA amounts 
were kept constant using empty vector pcDEF3. In U373 infected cells, transfection of the 
VEGF-Luciferase plasmid (19) was performed 2 h post infection (multiplicity of infection 1). 
Luciferase activities were measured 24 h after transfection with a Victor2 multilabel plate 
reader from Perkin-Elmer.
Focus formation assay 
The focus formation assay was performed as described by (31) 400 stably transfected NIH-
3T3 cells were cultured with 2000 untransfected NIH-3T3 cells for 2 weeks in regular cul-
ture medium without G418 in 6 well plates. Treatment with Stattic was initiated 12 hours 
after seeding. Medium containing Stattic was replaced every 48 hours after seeding. After 
2 weeks, the cells were washed three times with phosphate buffered saline (PBS) and sub-
sequently fixed in cold methanol for 10 min. Subsequently, the cells were stained with 0.4% 
methylene blue in H2O and the foci were counted.
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Tumor formation in vivo 
All animal experiments were performed according to the National Institutes of Health prin-
ciples of laboratory animal care and Dutch national law and approved by the Dierexper-
imentencommissie from the VU Medical Center and performed in compliance with the 
protocol FaCh 05-02. Stably transfected NIH-3T3 cells (2*106) containing pcDEF3-US28, or 
pcDEF3-UL33-eGFP plasmids were injected s.c. into the flank of 8- to 10-week-old female 
nude mice (Hsd, athymic nu_nu, 25–32 g, Harlan Laboratories Cambridge Research Bio-
chemicals; Zeist, The Netherlands).
RT-PCR 
In the UL33-eGFP- and US28-expressing NIH-3T3 cells as well as the tumours formed, UL33 
and US28 gene expression was checked using standard reverse transcriptase PCR (RT-PCR) as 
previously described (32). For detection of US28 mRNA the primers used were US28 forward 
5-AGCGTGCCGTGTACGTTAC-3 and US28 reverse 5-ATAAAGACAAGCACGACC-3. For detection 
of UL33 mRNA the primers used were UL33 forward 5-GGAAAGTGCTGCTGACGCTAG-3 and 
UL33 reverse 5-GCTGTACGGTTGAGTAGAAGAAGG-3.
HCMV infections and Western blot analysis 
U373 MG cells were infected with TB40-BAC4-HCMV (33) strains containing the wild type 
genotype or a mutant version. Using a recombinant virus encoding a FLAG-tagged UL33 ex-
pression and sub cellular localization of UL33 was studied after HCMV-infection. 2*105 HFF 
cells were seeded in 6-well plates and infected the next day at m.o.i. of 2. After 2 hrs, virus 
was removed and cells were washed 3 times with PBS to enable a synchronized infection. 
After indicated time (1, 2, 3, 4, 5, 6, 7 or 8 dpi) cells were washed 3 times with cold PBS, 
scraped and stored as a dry cell pellet at -20. Cell lysates were prepared in Ripa buffer con-
taining protein inhibitors, lysates were sonicated for 10 sec. 12 µg of total protein was load-
ed on SDS-PAGE and after electrophoresis proteins were transferred to PVDF membranes by 
tank blotting (Biorad). Membranes were stained with anti-FLAG (Sigma polyclonal rabbit) to 
detect UL33ex1-FLAG expression. Loading on the gel was controlled by actin staining. West-
ern blots were detected using anti rabbit-HRP conjugated secondary antibodies (BioRad) 
and chemiluminescent ECL substrate.  
Patient Samples and Immunohistochemistry
Paraffin-embedded primary brain tumor specimens were available from 25 GBM patients 
who were admitted to the Karolinska University Hospital Sweden during 2009-2010. Tissue 
sections (6 um thick) were stained for UL33 using sensitive immunohistochemistry stain-
ing protocols as previously been described (Bellon and Nicot 2008). Briefly, the sections 
were deparaffinized in xylene (Sigma Aldrich), rehydrate in alcohol series, postfixed with 
4% neutral buffered formalin (Apoteketpharmaci, Stockholm, Sweden), treated with pepsin 
(Biogenex, San Ramon, CA), and then incubated in citrate buffer (Biogenex). The sections 
were treated with 3% H2O2 (Sigma-Aldrich) to inactivate endogenous peroxidase, avidin/
biotin blocking kit (DakoCytomation, Glostrup, Denmark), was used in order to block en-
dogenous biotin/avidin and FC receptor blocker (Innovex Biosciences) to block FC-R.  Finally, 
the tissue sections were treated with background buster (Innovex Biosciences). Incubation 
with primary polyclonal rabbit antibodies against human CMV-UL33 (Margulies, Browne et 
al. 1996) was done overnight at 4°C. Polyclonal rabbit IgG antibodies  (R&D Systems, Min-
neapolis, MN) was used as isotype control. After incubation with primary antibodies, the 
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sections were incubated with biotinylated anti-rabbit (DakoCytomation) antibodies. Finally, 
the antibodies were visualized using streptavidin-conjugated horseradish peroxidase and 
diaminobenzidine (Innovex Biosciences). This study was approved by the ethics committees 
at Karolinska Institutet, Stockholm, Sweden (Dnr (2008/628-31/2).
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In the previous chapters, US28 has been shown to activate a plethora of cellular 
pathways. In contrast to most chemokine receptors, which tend to couple to Gαi, 
US28 couples to multiple different Gα subunits. A second difference with the human 
chemokine receptors is the constitutive activation that is displayed by US28. Similar 
to the KSHV-encoded receptor ORF74, US28 constitutively signals through Gαq that, 
in turn, stimulates phospholipase C resulting in increased inositol-1,4,5-triphos-
phate  levels which bind to intracellular inositol receptors triggering Ca2+ release 
into the cytosol. This ultimately results in the activation of target genes like the 
nuclear factor of activated T-cells (NFAT) (1). Another factor activated by US28 via 
Gαq is NF-κB (1). This transcription factor is an important mediator of many cellular 
responses, including stress- and immune responses (2). The NF-κB signaling path-
way appears to play an important role in US28, and it is pivotal in the activation of 
the COX-2 and STAT3 pathways (3, 4). 
Multiple signaling pathways are activated by US28, and at least some of these path-
ways converge to induce a proliferative phenotype. The COX-2 and STAT3 pathways 
are both required for US28-induced VEGF production, and inhibition of either path-
way results in reduced proliferation. In order to gain more insight in the role of US28 
in tumor biology, two signaling routes activated by US28 have been characterized in 
this thesis, the IL-6/STAT3-axis (Chapter 3, 4) and Wnt/b-catenin (Chapter 5) signal-
ing. Furthermore, a first characterization of the US28 signalosome is shown Chapter 
6, which may lead to a more in-depth understanding of US28-induced signaling. 
Finally, the oncogenic properties of another HCMV-encoded GPCR, UL33 were in-
vestigated (Chapter 7).
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8.1 US28 and UL33 constitutively induce STAT3 activation
In Chapter 3, US28 is shown to constitutively induce STAT3 signaling. The first hints 
of the activation of this pathway were measurements of angiogenic factors in the 
medium of US28-expressing NIH-3T3 cells. These measurements showed that US28 
induces NIH-3T3 cells to secrete IL-6 and VEGF. In addition, CCL2 concentration in 
the growth medium is diminished which fits the proposed role of US28 as a chemo-
kine sink. Following IL-6 secretion, its cognate receptor is activated. Subsequently, 
STAT3 is phosphorylated by JAK1, resulting in dimerization and transcriptional acti-
vation (5). Additionally, UL33 is shown in Chapter 7 to also induce STAT3 activity, al-
though it is still unknown whether this is mediated via a mechanism similar to US28.
Chapter 3 represents the first observation of US28 protein expression in glioblas-
toma clinical samples. Moreover, we demonstrate that STAT3 is phosphorylated in 
the same niche of the tumor, which suggests that a similar mechanism that we ob-
served in our in vitro models is taking place within these tumors. Finally, the extent 
of STAT3 phosphorylation in the tumor correlates with patient survival and tumor 
progression, meaning that a high extent of STAT3 phosphorylation results in a poor 
prognosis.
The activation of STAT3 by US28 can be interfered with on multiple levels, on the 
transcriptional level by either the NF-κB inhibitor BAY11-7082 (6) or a STAT3 inhibi-
tor like JSI-124 (7) or Stattic (8). Inhibition at the level of IL-6 and the IL-6 receptor is 
accomplished via neutralizing antibodies against IL-6 or small molecules inhibiting 
IL-6 receptor function (9). The fact that conditioned medium derived from US28-ex-
pressing cells also results in STAT3 phosphorylation together with the knowledge 
that STAT3 can induce IL-6 production by itself (10) indicates the possibility of a 
positive feedback loop. In Chapter 4 this positive feedback loop is further investi-
gated, using a mathematical model described US28-induced STAT3 activation and 
IL-6 secretion. Using this model it is clear that IL-6/STAT3 signaling has the poten-
tial to generate a positive feedback loop that has the potential to run out of con-
trol. Moreover, once a certain critical amount of cells is producing IL-6, the positive 
feedback loop may force the production of the cytokine in the whole (cancerous) 
tissue creating an inflamed region. It should be noted that STAT3-signaling may be 
induced with multiple ligands. For example, IL-5 was found to be over-expressed in 
HCMV-infected cells to the same extent as IL-6 (11). Such other factors may be able 
to induce a positive feedback loop on their own, or facilitate one for another factor. 
Naturally, several mechanisms, which have been discussed in Chapter 2, are in play 
to prevent such a runaway feedback loop from happening. The Silencers Of Cyto-
kine Signaling (SOCS), in particular, are important negative regulators of STAT-sig-
naling (12). An exogenous factor such as US28 may disturb the balance between 
positive feedback and negative feedback for signaling networks like the STAT3 con-
trolled pathway(s). An important question rises however, why does HCMV induce 
IL-6 production and what role does it play in the viral life cycle. At a first glance, 
it seems counter-intuitive for a virus to induce pro-inflammatory signaling in the 
156
Discussion and future perspectives
cells it infects. However, activation of STAT3 signaling by IL-6 also has anti-apoptot-
ic effects (13) which may be beneficial to the virus. Additionally, since HCMV can 
infect macrophages (14) and monocytes (15), increased IL-6 secretion may act as 
a bait to attract new cells for HCMV to infect as IL-6 induces chemotaxis in both 
macrophages and monocytes (16). Under normal circumstances, increased IL-6 sig-
naling would have no severe effects by virtue of the negative regulation of STAT3 
activation. However, if a cell has impaired regulation of STAT3, US28-induced IL-6 
signaling either in an autocrine or in a paracrine fashion may result in a prolifera-
tive phenotype like the one that is observed in the NIH-3T3 cells. HCMV-induced 
IL-6 production itself is correlated with aberrant angiogenesis (17, 18). Of course, 
dysregulation of angiogenesis in the right context is in itself a potent mediator of 
tumorigenesis (19).
In conclusion, US28-induced IL-6 production may create a favorable microenviron-
ment for proliferation of HCMV. While US28 is solely responsible for HCMV-induced 
IL-6 production in the host cell at an early time-point of infection,   at later stag-
es during infection other viral factors may also induce IL-6 production.  One such 
factor may be UL33, which was shown in Chapter 7 to also constitutively activate 
STAT3. In Chapter 7, UL33 is further described to be expressed at later time points 
in infection. UL33 has earlier been described to be present on the virus particle 
(20). Yet, the amount of UL33 at early time points may be too little to result in ap-
preciable signaling. In this light it would be interesting to investigate whether UL33 
conditioned medium can induce STAT3 phosphorylation in other cells. Additionally, 
it would be interesting to analyze UL33-induced secretion of proteins. This can be 
done in two ways, one focusing on angiogenic factors with an approach using an an-
tibody array. This approach is sensitive enough for detecting low levels of proteins 
in the medium, but is biased towards angiogenic factors. The second approach en-
tails using mass-spectrometry to identify factors from the supernatant. While this 
approach is less sensitive it is unbiased and will allow for a full characterization of 
factors whose production is induced by UL33.
8.2 US28 induces β-catenin activation  
In Chapter 5, constitutive activation of β-catenin signaling is described. The involve-
ment of this pathway in US28 signaling was first based on the same micro-array 
study where US28-induced COX-2 expression was detected (3). The micro-array 
data also indicated up-regulation of factors involved in Wnt/β-catenin signaling. 
Further investigation, using the TOP-Flash reporter gene revealed that US28 consti-
tutively induces β-catenin signaling to Tcf-Lef. This was further confirmed by means 
of Western-blot analysis, showing increased levels of non-phosphorylated β-caten-
in. Interestingly, US28 activates β-catenin signaling in a non-canonical manner in 
NIH-3T3. However, another model system, using transgenic mice expressing US28 
in the intestine shows canonical β-catenin activation (21). This clearly indicates that 
the mechanism by which US28 induces β-catenin signaling is very much dependent 
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on the cellular context.
As mentioned above, US28 induces β-catenin signaling via a non-canonical path-
way. In the canonical β-catenin signaling pathway Wnt/Frizzled is usually accompa-
nied with LRP6 phosphorylation. However, the signaling through β-catenin that is 
induced by US28 in NIH-3T3 is of a different nature. US28-induces signaling via Gaq 
and Ga12/13, which subsequently results in activation of Rho/ROCK signaling. Further 
downstream this leads to Tcf/Lef activation.
Further investigation, detailed in Chapter 6, suggests that in the NIH-3T3 back-
ground US28 inhibits Akt phosphorylation by activating Rho-associated protein ki-
nase (ROCK) via RhoA. Acting further downstream in this signaling route are two 
protein phosphatases, PP2A and PTEN. Both PP2A and PTEN have a key role in the 
regulation of different signaling routes, including oncogenic pathways. In the case 
of US28-induced signaling, where either or both PP2A and PTEN are activated by 
US28, which may result in decreased Akt activation.
Further downstream, the transcriptional regulator Chibby (Cby) has been identi-
fied as an important factor in regulating b-catenin signaling (22). Interestingly, Cby’s 
antagonistic function is counteracted by TC1 (23). Moreover, TC1 is reported to be 
overexpressed in thyroid cancer (23) and metastatic colon cancer (24). In the case 
of colon cancer, increased TC1 expression is correlated with poor prognosis. This 
observation fits well with our current understanding of the molecular mechanisms 
by which Cby asserts its influence on β-catenin signaling. Indeed, US28 may have 
a similar effect as TC1 on Cby/β-catenin interaction albeit via another mechanism. 
Besides the difference in the mechanisms by which US28 and TC1 accomplish func-
tional inhibition of Cby, in both cases it results in a removal of the ‘brakes’ on β-cat-
enin signaling. It is unlikely that inhibiting Cby will directly result in transforma-
Figure 2. Schematic depiction of Lgr5 expression in humans. Data analyzed by the Atlas project from EMBL shows 
studies reporting over-expression in red and under-expression in blue. Most expression data is available about the 
brain and the digestive system.
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tion of cells. But in a cell where β-catenin signaling is already hyperactivated, loss 
of Cby’s antagonistic function will exacerbate the transformed phenotype. It will 
therefore be interesting to express US28 in a cellular background in which β-catenin 
signaling is already aberrant (eg. APC-mutants or knock-outs). One could imagine 
that US28-related interference with Cby functioning may add to canonical signaling 
and thus result in extra activation of B-catenin signaling. 
The pathway identified in NIH-3T3 and the canonical Wnt/β-catenin pathway, thus 
seem to be mutually exclusive, due to the differences in regulation of GSK3b phos-
phorylation. However, ‘unlocking’ of b-catenin by US28 may render cells more re-
sponsive to b-catenin signaling, resulting in a hyper response to otherwise normal 
triggers. Treating those cells with an agonist, such as Wnt, should then result in 
higher activation as measured, for instance, with the Tcf-Lef reporter system that 
was utilized in Chapter 5. If US28 does impart increased sensitivity to Wnt-activa-
tion, it may be an explanation of the observed tumor formation in transgenic mice 
(21).
In the US28-expressing transgenic mice expression is driven by the murine villin 
promoter. This results in high expression levels throughout the intestinal epitheli-
um. The intestinal epithelium is constantly replaced with new cells, which originate 
from the intestinal crypts. At the bottom of these crypts reside the intestinal stem 
cells that give rise to all the different epithelial cells, these cells express the GPCR 
Lgr5 and are defined as Lgr5+ cells (25). In the case of the transgenic mice men-
tioned above, US28 is also expressed by the Lgr5+ cells. Since deletion of APC in 
these cells results in rapid formation of adenomas (26), the presence US28 in Lgr5+ 
cells may be part of the mechanism that results in the formation of tumors in these 
mice.  Interestingly, Lgr5+ cells can autonomously form intestinal crypt structures; 
these structures have been termed organoids. The presence of Paneth cells increas-
es the efficiency of this process (27, 28). Lgr5+ cells are not only present in the 
intestine, Lgr5 is expressed in various tissues as shown in Figure 1. Organoids have 
been successfully cultured from Lgr5+ cells obtained from the stomach (29). Espe-
cially Lgr5 expression in the brain is interesting, considering the presence of US28 in 
glioblastoma that was described in Chapter 3. The LGR5 gene was found to be am-
plified in recurrent glioblastomas. (30). Moreover, knock-down of Lgr5 in brain cells 
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Figure 2. CCL5 and CX3CL1 have no effect on US28-in-
duced proliferation. For this experiments NIH-3T3 
cells were subjected to a similar proliferation exper-
iment as detailed in Chapter 2. Briefly, the cells were 
incubated for 24 hours with either CCL5 or CX3CL1 in 
medium containing [3H]-thymidine. The concentration 
used for either chemokines was 10-7 M.
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with a cancer-stem cell profile induces apoptosis (31). Recently, cancer stem cells 
have been shown to play a pivotal role in tumor maintenance in murine models for 
intestinal tumors and glioblastoma (32, 33). This raises the question whether US28 
is also expressed in cancer stem cells in patients suffering from HCMV-associated 
cancers. 
Since Lgr5+ cells are dependent on a variety of factors among which Wnt3a, it will 
be interesting to see whether Lgr5+ cells that express US28 will exhibit a different 
phenotype compared to wild-type organoids. To further study the tentative link be-
tween US28 and Lgr5+ stem cells, and their role in HCMV-associated cancers, it 
will be necessary to show combined US28 and Lgr5 expression in these cancers. 
While US28 expression has been shown in glioblastomas, analyzing Lgr5 expression 
in these tumors will be difficult as there is no reliable antibody yet. An alternative 
method would be to perform in situ RNA hybridizations to detect other stem cell 
markers such as Olfm4 or Ascl2. Both these genes have been successfully used as 
markers in mice and appear to be very specific (28, 34). Whether this is also the 
case in humans remains to be seen, but the fact that both these genes are highly 
conserved suggests that this may be the case.
In conclusion, US28 induces β-catenin activation via two possible signaling routes. 
A canonical route that was described in the transgenic mouse model (21) and a 
non-canonical route, through Rho and ROCK, whose increased activity results in 
increased Tcf/Lef activity. Our data in Chapter 6 suggests that US28-induced activa-
tion of Rho and ROCK results in dysregulation of Akt-regulated phosphorylation of 
Cby and b-catenin. To what extent induction of β-catenin by US28 is responsible for 
the induction of HCMV associated cancers remains to be clarified. It will be inter-
esting to see whether β-catenin activation by US28, like STAT3, can be correlated in 
glioblastoma. Especially since β-catenin over-expression is associated with glioblas-
toma growth (35, 36). Even more interesting, targeting the β-catenin in these can-
cers results in the down-regulation of several other signaling factors among which 
STAT3 (2). This suggests that there may be interplay between these two pathways.
8.3 Role of ligand-induced US28 signaling
 
In general, constitutive signaling appears to be a hallmark for US28. However, CCL5 
and CX3CL1 which both bind to US28 can influence signaling to a certain extent (1, 
37). While CCL5 generally acts as an agonist, potentiating calcium release induced 
by US28 (38), it has no effect of inositol phosphate accumulation (1). Moreover, 
CCL5 and CCL2 are both capable of inducing chemotaxis in vascular smooth muscle 
cells (39), which is a clear indication of ligand-dependent pathways controlled by 
US28. CX3CL1, on the other hand, acts in some cases as an inverse agonist on US28, 
inhibiting inositol phosphate accumulation. In the context of calcium signaling, 
however, it acts as an agonist (1, 37). Furthermore, CCL5 can increase US28-induced 
Tcf/Lef activity. It is likely that the reponse of US28 to a ligand is dependent on the 
cellular context. The clinical data presented in Chapter 3 indicates that US28-ex-
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pression appears to be localized in a specific subset of cells. This possibly highlights 
the importance of cellular context, and the need for a relevant model system for 
in vitro studies. Despite these concerns, the data presented in this thesis, as well 
as data from earlier studies indicate that ligand-induced signaling is not critical for 
US28-induced proliferation. In Figure 2, this is further demonstrated in a thymidine 
incorporation experiment. However, the fact that ligands do not seem to play a 
direct role in US28-induced proliferative signaling does not exclude a role for them 
in tumorigenesis. Especially considering the recent data from Bongers et al., where 
CCL2 over-expressing mice were crossed with mice expressing US28 in the intestine. 
This crossing exacerbated tumor formation in these mice (21). The vascular smooth 
muscle cell migration mentioned earlier may be an indication for a role of US28 in 
tumor angiogenesis.
 8.4 To what extent is UL33 mirroring US28 signaling?
In Chapter 7 signaling by another HCMV encoded chemokine receptor homolog is 
explored in further detail. Earlier research had already shown that, like US28, UL33 
signals in a constitutive manner through NF-κB (40). Besides this data, not much 
was known about UL33’s signaling. The discovery of US28’s propensity for induc-
ing proliferation in NIH-3T3 cells together with the fact that both proteins display 
constitutive activity prompted us to investigate UL33’s oncomodulatory properties. 
Moreover, immunohistochemistry staining of glioblastoma tumor samples shows 
presence of UL33 in these tumors. In contrast with the US28 stainings shown in 
Chapter 3, UL33 appears to be present in large portions of the tumor. Double stain-
ing for US28 and UL33 may give further insights in the role that either receptor plays 
in the tumor biology of glioblastoma. 
Our data show that there is a large degree of overlap between signaling by US28 and 
UL33, which may indicate that both receptors can take over each other signaling. 
This could provide HCMV with a degree of redundancy. However, arguing against 
redundancy, US28 is present at early stages of infection, whereas UL33 is present 
only at 96 hours post infection. Alternatively, UL33 and US28 may potentiate each 
others signaling. Work by Tschische et al. has shown that UL33 and UL78 can form 
heterodimers with US28, and may influence the constitutive signaling displayed by 
US28 (41). Considering the differences in temporal expression of both US28 and 
UL33 this may represent a way for HCMV to regulate signaling of both molecules.
One of the attractive features of UL33 is that, unlike US28, there is a mouse cyto-
megalovirus (MCMV) homolog, M33. Moreover, deletion of M33 from the MCMV 
genome results in a virus that displays impaired dissemination as well as attenuated 
infection of the spleen and pancreas (42). Reactivation was also negatively affected 
in the M33 deletion strain (38). Recently, complementation experiments using a 
strain of MCMV in which the gene encoding M33 is deleted (MCMV ΔM33) have 
shown that both US28 and UL33 can both functionally replace M33 in MCMV ΔM33 
(43). It will be interesting to see whether US28 and UL33 in this model can have on-
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comodulatory effects. To answer this question, these recombinant viruses may be 
used in combination with existing mouse models for different cancers.
8.5 Mathematical modeling of US28’s modulation of the STAT3 signaling pathway
Cellular responses are the result of the integration of multiple signaling events that 
are relayed through different signal transduction routes. To add to the complexity 
of signaling many pathways also engage in crosstalk with each other. The relatively 
new field of systems biology seeks to describe, model, and ultimately predict these 
signaling networks. In Chapter 4 US28-induced signaling through the IL-6/STAT3 
axis is described in great detail. Because of its paracrine nature, induction of the 
IL-6/STAT3 axis by an external factor was modeled. This model shows that STAT3 sig-
naling has the potential to become engaged in a positive feedback loop. The model 
also reveals that STAT3 signaling needs to be tightly controlled, as it is prone to 
enter a positive feedback loop. One can imagine that it is reasonable for a rapid re-
sponse system to exhibit such behavior. Experiments corroborated this model and 
showed that picomolar concentrations of IL-6 can already trigger a STAT3 response 
in cells. Moreover, the same experiments show that treatment with IL-6 induces the 
expression of IL-6 and prolonged STAT3 phosphorylation.
Considering that US28 induces IL-6 production via NF-kB, these data suggest that 
US28 may significantly influence the external milieu even when the amount of 
cells that actually express US28 is very small. It should be noted though, that STAT3 
signaling is normally tightly controlled by several negative feedback mechanisms, 
amongst which are the SOCS proteins as discussed in Chapter 2. It is known that in 
many cancers the STAT3 pathway is affected, either by mutations in STAT3 itself or 
by mutations in the associated receptors and regulatory proteins. Mutations that 
render STAT3 constitutively active have been shown to be able to induce angiogen-
esis (44), although such mutations remain to be demonstrated in patient samples. 
Another level at which IL-6/STAT3 signaling can be altered is at the IL-6 receptor. 
Mutations in the transactivating gp130 subunit of the IL-6 receptor can result in 
constitutive activation of the IL-6/STAT3 pathway that, in turn, results in increased 
production of IL-6. Such mutations have been described in hepatocellular tumors, 
which interestingly are always accompanied by mutations in β-catenin signaling 
proteins (45). Regulation of IL-6 expression itself can also be affected as was shown 
by Iliopoulis et al. where they demonstrated that transient activation of NF-kB can 
result in permanent downregulation of Let7 miRNAs. Let7 is an inhibitory factor 
of IL-6 expression, which thus results in increased IL-6 levels (46). Finally, overex-
pression of SOCS3 has been reported to inihibit growth of human non-small cell 
lung cancer cells as well as rendering them more sensitive to radiation (47). Also, 
epigenetic silencing of SOCS3 has been reported in several cancers (48-50). These 
data all indicate the effect of changes in signaling through the IL-6/STAT3 axis are 
dependent on the cellular context.
While the model proposed in Chapter 4 certainly has predictive value, its real use-
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fulness will become apparent when it can be linked to the other pathways engaged 
by US28. Until now, we have mainly described how the different pathways are acti-
vated via the viral receptors. However, if the signaling through the different routes 
can be integrated into one model that would greatly increase our understanding of 
US28 signaling and perhaps even allow for predictions in what kind of cells or tissue 
US28 may exert its oncomodulatory effects.
8.6 What new insights does the US28 signalosome offer?
Although the efforts described in this thesis as well as those of others have shed 
light on several important facets of US28 signaling, there are still significant caveats 
in our understanding of US28-induced signaling. In order to gain more understand-
ing of US28-induced signaling, we analyzed the US28 signalosome in Chapter 6. 
The proteins that interact with a receptor and mediate its signaling are referred 
to as the signalosome. To be able to isolate this subset of proteins a methodology 
for isolating US28 with its interacting partners had to be developed. As described 
in Chapter 6, a modified immuno-precipitation protocol was used to perform pull-
downs of US28 and its interacting partners, using anti-HA conjugated agarose and 
N-terminally HA-tagged US28. The co-precipitating proteins were then identified by 
way of liquid chromatography tandem mass-spectrometry.
While such an approach is immensely powerful, one major drawback is that the 
shear amount of data obtained by these analyses can be daunting. For now, this 
limits the use of proteomics for understanding cellular signaling. Of course, this is 
partly due to the fact that most experimental setups for analyzing cellular signaling 
by mass-spectrometry have been in the development phase for the last few years. 
As the techniques mature and the data analysis is standardized, it will be possible 
to assign reliability scores to the different datasets instead of the current practice of 
collecting all proteomics results regardless of data quality.
The 14-3-3 proteins are overrepresentated in the US28 signalsome. Because of the 
important role these proteins have in cellular signaling, this may result in aberrant 
signaling across many signaling pathways. An example of this was discussed ear-
lier in Chapter 6 where the binding of 14-3-3s by US28 is proposed to interfere 
with β-catenin regulation by Cby. Several factors that are normally associated with 
mitochondrial function were also found to co-precipitate with US28. This was a 
surprising finding, which suggests an important role for intracellular US28 in the 
alteration of cellular signaling and may also be indicative for a role for US28 in the 
HCMV-induced shift from oxidative phosphorylation to glycolysis by cytosolic lactic 
acid fermentation (also known as the Warburg effect) (51).
The current technique for co-immunoprecipitation of the US28 signalosome has 
proven to be reliable and reproducible. However, this analysis cannot distinguish 
between the different cellular compartments. An analysis of the differences be-
tween intracellular versus the US28 that is present on the plasma membrane would 
shed light on which of the US28 populations is responsible for the different signal-
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ing pathways. In order to address this issue a methodology for isolating the dif-
ferent US28 populations needs to be developed. We have explored two different 
approaches. First a classical biochemical approach using sucrose gradients to sepa-
rate the different cellular compartments was employed. The main advantage of this 
approach is that it allows for analysis of the different compartments using the same 
preparation. However, while it was no problem to isolate US28 from the plasma 
membrane compartment as well as from other compartments, we found that it was 
difficult to obtain enough protein for mass-spectrometry analysis. Furthermore, re-
producibility was also an issue using this approach. Therefore an alternative meth-
od, using selective biotinylation of plasma membrane proteins with NHS-SS-biotin 
was explored. This method takes advantage of the fact that NHS-SS-biotin cannot 
cross the plasma membrane leading to biotinylation of only extracellular lysines. 
Following biotinylation the cells expressing HA-tagged US28 can be subjected to the 
established co-immunoprecipitation method. Subsequently, the eluted US28 with 
their associated proteins are subjected to a biotin pull-down, using streptavidin. 
The resulting protein fraction will consist of biotinyated US28 and its associated 
proteins. Initial experiments have shown that it is possible using this method to not 
only purify biotinylated US28 (Figure 3A), but also associated proteins as shown 
by silverstaining of the resulting protein mixture (Figure 3B). Another promising 
technique involves the use of the lectin concanavalin A to isolate the plasma mem-
brane compartment. Concanavalin A binds to the α-D-glucose and α-D-mannose of 
glycosylated membrane proteins (52). Lee and colleagues have developed a meth-
od using concanavalin A bound to magnetic beads that can be used to quickly and 
reliably purify the plasma membrane fraction. Hence, using the above mentioned 
techniques, the signalosomes of plasma membrane bound US28 and intracellular 
US28 can be analyzed which may result in an increased understanding how US28 
redirects cellular signaling.
Mock US28 Mock US28 Mock US28
Lysate HA-IP Streptavidin
A B
Mock US28
Figure 3. (A) Western-blot analysis showing successful isolation of HA-US28 from HEK293T cells  transfected with 
DNA encoding HA-US28. (B) A silverstaining showing co-precipitating proteins that are co-isolated with US28, while 
some proteins are isolated in a non-specific manner as shown in the Mock sample, the majority of proteins are 
specifically co-precipitating with US28.
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8.7 Pharmaceutical intervention strategies, target US28 and UL33 or its pathways?
Considering that a significant portion of the population is HCMV sero-positive, US28 
may have an important impact on tumor biology in general. We have shown for 
the first time that in at least one type of cancer, glioblastoma, US28-associated sig-
naling has a significant effect on tumor progression and patient survival. Efforts to 
target US28 signaling with inverse agonists have been made (53-55). While these 
compounds are useful research tools, their potential as drugs is limited due to poor 
water solubility and low potency.
Considering the knowledge we now have of US28-induced signaling, it may actually 
be more advantageous to target the pathways that are induced by US28 instead of 
the receptor itself. Especially considering the paracrine effects that US28 has on 
surrounding cells. For example, treatment with STAT3 inhibitors may be a viable way 
of interfering with US28-mediated STAT3 activation. One drawback of targeting the 
signal transduction pathway instead of the receptor is the potential loss of specific-
ity since these pathways are present in many different cells. 
Systems biology approaches will play an important role in addressing the first issue 
of specificity. By understanding how the different signal transduction routes inter-
act which each other, the models can be predictive and provide insight how to tar-
get these pathways to get the desired cellular response (eg. death of a tumor cell).
Another HCMV-encoded GPCR, UL33, was found to have similar tumorigenic prop-
erties as US28. In Chapter 7 the way UL33 induces a proliferative phenotype is sim-
ilar to US28. Moreover, both US28 and UL33 can be found in glioblastoma tumor 
samples. The fact that these two proteins are expressed at similar times during 
infection (albeit that US28 is also expressed at early stages of infection) suggests 
that US28 and UL33 can act as back-up for each other. Therefore, a pharmacolog-
ical intervention strategy aimed at inhibiting HCMV-induced proliferative signaling 
should take into account both US28 and UL33.
To this end, the work described in this thesis has contributed to understanding the 
way viral GPCRs like US28 and UL33 induce oncomodulatory behavior and which 
may result in new strategies for treating HCMV-related cancers like glioblastoma.
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Nederlandse samenvatting
Het omleiden van signaaltransductie routes door HCMV-gecodeerde GPCRs
G-eiwit gekoppelde receptoren (GPCRs) vormen een grote groep membraan recep-
toren die gekarakteriseerd worden door de aanwezigheid van 7 transmembraan 
domeinen. GPCRs kunnen door een grote verscheidenheid aan liganden kunnen 
worden geactiveerd, variërend van licht tot aan eiwitten. Analoog aan de grote ver-
scheidenheid aan liganden, leidt de activatie van GPCRs tot uiteenlopende respon-
sen in de cel. De activatie van rhodopsine-receptoren op het netvlies door licht leidt 
bijvoorbeeld tot een elektrisch signaal dat naar de hersenen wordt gestuurd, terwi-
jl activatie van chemokine-receptoren chemotaxis (migratie van cellen) tot gevolg 
heeft.
Een groot deel van de bevolking is besmet met het Humaan cytomegalovirus 
(HCMV). Een HCMV besmetting heeft normaal gesproken geen ernstige gevolgen, 
en zal in de meeste mensen een latent bestaan leiden. In mensen met een niet 
goed werkend immuun systeem (bijvoorbeeld kankerpatienten) kan een HCMV 
besmetting echter tot complicaties leiden, zoals pneumonitis (ontsteking van de 
longblaasjes) en retinitis (ontsteking van het netvlies). Ook wordt HCMV in verband 
gebracht met verschillende kankers, zoals glioblastoma en colon kanker. Dit ver-
band is niet noodzakelijk rechtstreeks en men spreekt dan ook van een oncomodu-
lair in plaats van een oncogeen effect. Het feit dat zo’n groot deel van de bevolking 
HCMV-positief is duidt erop dat HCMV zeer goed aangepast is om het immuun-
systeem van zijn gastheer te omzeilen. Daartoe zijn er een aantal GPCRs ‘gekaapt’ 
uit het menselijk genoom, waaronder US28 en UL33, die afstammen van humane 
chemokine receptoren. Deze virale GPCRs (vGPCRs) verschillen op een aantal punt-
en van de humane chemokine receptoren. Een belangrijk verschil is dat US28 en 
UL33, in tegenstelling tot chemokine receptoren, constitutieve activiteit vertonen. 
Verder bindt US28 een aantal verschillende chemokines, waaronder CCL2, CCL5 en 
CX3CL1. Doordat US28 deze chemokines bindt en internaleert, worden de de lokale 
concentratie van deze chemokines verlaagt. Dit effect wordt ook wel een ‘chemo-
kine-sink’ genoem, hetgeen mogelijk bijdraagt aan de ontwijking van een immuun 
respons. Eerder onderzoek heeft uitgewezen dat constitutief actieve vGPCRs on-
cogene eigenschappen kunnen hebben. Eén van de eerste voorbeelden hiervan is 
de oncogene activiteit van ORF74, een vGPCR die door het Kaposi sarcoma herpes 
virus (KSHV) tot expressie wordt gebracht. Verscheidene onderzoeken hebben laten 
zien dat expressie van ORF74 leidt tot veranderingen in signaal transductie die tot 
oncogene transformatie kunnen leiden. Expressie van ORF74 in transgene muizen 
leidt tot laesies die erg lijken op laesies die worden gezien in Kaposi sarcoma. Er is 
ook gekeken of de vGPCRs gecodeerd door het HCMV dit soort effecten kunnen in-
duceren. In vitro studies hebben laten zien dat expressie van US28 in NIH-3T3 cellen 
versnelde celdeling en een verlies van contact inhibitie veroorzaakt. Net zoals in het 
geval van ORF74 zijn er ook in vivo experimenten met US28 uitgevoerd. Een eerste 
in vivo experiment behelsde xenograft experimenten waarbij er NIH-3T3 cellen die 
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US28 tot expressie brengen in de flank van muizen waren geïnjecteerd. Deze injec-
ties leidde tot de vorming van tumoren op de plek van injectie. Een later onderzoek 
liet zien dat expressie van US28 in de het darmepitheel van transgene muizen tot 
de vorming van adenomas leidt.
Het doel van dit proefschrift is om de moleculaire mechanismen die achter dit on-
comodulaire gedrag van US28 zitten te ontrafelen. Tevens is er gekeken naar het on-
cogene/oncomodulaire potentieel van een andere vGPCR, namelijk UL33. In hoofd-
stuk 1 en 2 wordt de huidige kennis betreffende vGPCRs en een aantal oncogene 
signaaltransductie routes beschreven. Hoofdstuk 1 is een introductie rond (virale) 
GPCRs, waarbij eerst de eigenschappen van GPCRs en chemokine receptoren in het 
bijzonder worden behandeld. Daarna worden de kenmerken van verschillende vG-
PCRs van verschillende herpesvirussen besproken. Daarbij wordt de nadruk gelegd 
op de signaaltransductie routes die door de verschillende vGPCRs worden geac-
tiveerd en de gevolgen van activatie van deze routes door vGCPRs. In hoofdstuk 2 
worden er een aantal oncogene signalering routes beschreven, waaronder activatie 
en regulatie van STAT-, Wnt/b-catenin- en VEGF-signalering die in latere hoofdstuk-
ken terug komen. 
Hoofdstuk 3 beschrijft hoe US28 de IL-6/STAT3-as activeert in NIH-3T3 en HEK293T 
cellen. Door middel van experimenten met verschillende specifieke inhibitors on-
trafelen we hoe US28 deze signaal transductie route activeert. Daarbij zien we dat 
US28 in NIH-3T3 cellen IL-6 productie induceert. Dezelfde experimenten laten ook 
zien dat US28-afhankelijke STAT3 activatie via JAKs verloopt. De betrokkenheid van 
JAK duidt op een rol van de IL-6 receptor. Experimenten met geconditioneerd medi-
um van cellen die US28 tot expressie brengen laten vervolgens zien dat deze cellen 
IL-6 aanmaken, wat vervolgens leidt tot STAT3 activatie. Dit kan worden onderbro-
ken door middel van IL-6 neutraliserende antilichamen en met een inhibitor die op 
de IL-6-receptor werkt. Verder zien we dat inhibitie van STAT3 US28-afhankelijke 
VEGF activatie remt. Experimenten met recombinante virussen laten zien dat we 
deze observaties in een virale context kunnen dupliceren. Ook waren we in staat 
om voor het eerst de aanwezigheid van US28 aan te tonen in tumor monsters van 
glioblastoma patiënten. Belangrijker nog, we konden STAT3 activatie in dezelfde re-
gio’s van deze tumoren laten zien en de mate van STAT3 activatie correleren aan de 
hevigheid van dit type kanker.
In hoofdstuk 4 wordt verder ingegaan op de eigenschappen van de US28-gerela-
teerde activatie van de IL-6/STAT3-as. Hierbij wordt er een eerste poging gedaan 
om US28-geinduceerde IL-6 productie en de daar bijhorende activatie van STAT3 
te vatten in een wiskundig model. Hierbij zien we dat US28-geinduceerde activatie 
van STAT3 via IL-6 een bistabiel systeem lijkt te zijn waarbij er 2 steady-state toe-
standen zijn. Hierbij kan er een positieve terugkoppeling ontstaan wanneer er een 
minimum concentratie van IL-6 wordt overschreden. Dit resulteert erin dat het sys-
teem de hoge steady-state waarde aanneemt. Als deze minimum concentratie niet 
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wordt bereikt zal het systeem de lage steady-state waarde aannemen en zal er geen 
positief terugkoppelings effect worden bereikt. In dit hoofdstuk worden ook een 
aantal eerste experimenten beschreven waarbij er is geprobeerd om dit model te 
verifiëren. Hoewel de eerste experimenten redelijk overeen lijken te komen met het 
model moet er nog meer werk worden verricht. Vooral het feit dat er voorbij wordt 
gegaan aan de negatieve regulatie van STAT3 is belangrijk en dit zal zeker worden 
meegenomen in toekomstige modellen van STAT3 signalering.
In de hoofdstukken 5 en 6 wordt activatie van Tcf-Lef signalering via de Wnt/b-cat-
enin route behandeld. In hoofdstuk 5 zien we dat US28 Tcf-Lef signalering activeert 
en dat dit gepaard gaat met  b-catenin activatie. Verdere experimenten laten echter 
zien dat er geen sprake is van LRP6 fosforylatie, hetgeen wel het geval zou zijn indi-
en er sprake is van de standaard activatie van Tcf-Lef door Wnt/b-catenin. Verdere 
experimenten laten zien dat G-eiwit signalering via Rho-ROCK tot Tcf-Lef activatie 
leidt. Hoe activatie van Rho-ROCK Tcf-Lef activiteit kan op reguleren is nog niet 
duidelijk, en een reden dat in hoofdstuk 6 het US28 signalosoom wordt geanal-
yseerd. Hierbij is het US28 signalosoom opgezuiverd door middel van co-immu-
no-precipitatie en massaspectrometrie. Vervolgens is er gekeken welke groepen 
van eiwitten op basis van ontologie over-gerepresenteerd zijn in de dataset. Daarbij 
viel de aanwezigheid van de 14-3-3 eiwitten op. Deze eiwitten spelen een belangri-
jke rol in het faciliteren van veel processen in de cel. Eén van deze processen is het 
binden van Cby aan b-catenin. Cby heeft normaal gesproken een remmende werk-
ing op b-catenin, maar om deze functie te kunnen uitvoeren is het belangrijk dat 
Cby wordt gefosforyleerd door Akt zodat 14-3-3 eiwitten kunnen binden aan Cby 
en b-catenin. Aangezien ROCK de activiteit van Akt indirect kan beïnvloeden door 
negatieve regulators van Akt te activeren, kan de controlerende functie van Cby op 
die manier worden opgeheven. Om te zien of Cby ook echt bindt aan 14-3-3 zijn er 
Bioluminiscence Resonance Energy Transfer (BRET) experimenten uitgevoerd waa-
rbij deze interactie kon worden aangetoond. Als de interactie van 14-3-3 met cli-
ent-eiwitten wordt gestabiliseerd met fusicoccin wordt Tcf-Lef signalering geremd. 
Hierbij moet wel worden opgemerkt dat dit niet noodzakelijk het gevolg hoeft te 
zijn van een stabilisatie van de interactie tussen 14-3-3 en Cby.
Hoofdstuk 7 beschrijft een eerste karakterisatie van de oncogene eigenschappen 
van UL33, een ander vGPCR die door HCMV tot expressie wordt gebracht. UL33 lijkt 
erg op US28 omdat het ook een constitutief actieve vGPCR is. In tegenstelling tot 
US28, bindt UL33 geen chemokines. Desondanks activeert UL33 vergelijkbare sig-
naleringsroutes als US28 en induceert het een verhoogde celgroei in vitro en tumor 
vorming in vivo. Verder wordt de aanwezigheid van UL33 in glioblastoma tumoren 
aangetoond. In de virale levens cyclus komt UL33 later dan US28 tot expressie maar 
is er wel sprake van grote overlap en zijn beide receptoren voor een groot deel van 
de tijd beiden aanwezig op de celmembraan. Hierbij is het mogelijk dat beide recep-
toren met elkaar dimeriseren en elkaars activiteit beïnvloeden. Ook is het mogelijk 
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dat US28 en UL33 in bepaalde gevallen elkaars functie kunnen overnemen.
Zowel US28 als UL33 leiden signaaltransductie routes om zodat het virus beter kan 
overleven. Deze activiteit is echter ook verantwoordelijk voor het oncomodulaire 
gedrag van HCMV. In dit proefschrift worden de moleculaire mechanismen die US28 
aanwendt om 2 belangrijke oncogene signaaltransductie routes te activeren bes-
chreven. In het geval van IL-6/STAT3 activatie door US28 is er een begin gemaakt 
met een systeem biologische benadering door het opzetten van een eerste model 
dat probeert te beschrijven hoe US28 de IL-6/STAT3-as activeert. Activatie van Tcf-
Lef door US28 lijkt op een niet-standaard manier te gebeuren en de analyse van het 
US28 signalosoom heeft belangrijke informatie opgeleverd over het mechanisme 
wat daar mogelijk achter zit. Ook is er een begin gemaakt met het beschrijven van 
de oncomodulaire eigenschappen van UL33.
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Final words/Dankwoord
Hier is het dan, het proefschrift na 4 jaar bloed, zweet en tranen als AIO op de 
VU en 1,5 jaar op afstand als post-doc-achtige in New York. Het dankwoord is 
natuurlijk een van de belangrijkste (en ieder geval meest gelezen) delen van een 
proefschrift. Zes jaar geleden begon ik als promovendus aan dit project. Ik had 
destijds vooral ervaring met microbiologisch onderzoek, en vrijwel geen ervaring 
met het kweken van zoogdiercellen. Die microbiologische ervaring kwam later 
goed van pas met het spotten van besmetting (gelukkig niet te vaak).
Allereerst wil ik graag mijn promoter Martine en co-promoter Marco bedanken. 
Martine, bedankt voor alle hulp en ondersteuning en ook met het helpen real-
iseren van mijn avontuur in New York. Ik kon altijd bij je terecht met vragen, en 
ook manuscripten kwamen altijd snel terug met goede suggesties. Marco, jij was 
een belangrijke bron van inspiratie en altijd bereid om naar mijn soms ‘crazy plans’ 
te luisteren. Onze brainstorm sessies, soms na een paar biertjes op een borrel, 
hebben soms tot mooie ideeën geleid. De signaaltransductie trip naar Aken was 
ook een mooie ervaring compleet met een record brekende rit naar Amsterdam. 
En natuurlijk was de metro rit naar huis op het einde van de dag een mooi mo-
ment om de dag even door te spreken. Wat meer op afstand, maar zeker niet 
minder belangrijk, was de grote baas Rob. Jij hield ons altijd scherp met goed com-
mentaar op presentaties en manuscripten en zonder jouw input had dit boekje er 
nooit gekomen.
Science doe je nooit alleen en ik ben geen uitzondering daarop. De praktische en 
morele ondersteuning van mijn collega’s op de VU was altijd erg belangrijk. Ik heb 
een aantal lab- en kantoorgenoten gehad op mijn tocht door verschillende werk-
kamers en labs. 
David, you were a great help with getting me started in the lab and my first 
kantoor-mate. You taught me the basics of cell culture and we were co-authors 
on several good papers. Andreas, thank you for all your help with the virus ex-
periments. I still remember the time that we were walking with our recombinant, 
radioactive viruses in the RNC. You also taught me how to work with viruses, and 
told me about the existence of Ibidi slides, which saved me a lot of frustration 
with trying to get my cells to move onto a glass slide. Also thanks for the company 
during my drive to Italy (and the free breakfast near Ulm), and of course for invit-
ing me for your marriage and later the skiing trip in Oberstdorf. Both were great 
experiences! I hope that the tulips are still doing well. Ellen, samen met Andreas, 
David en mij vormden we het vGPCR team, en ik ben blij dat we een mooi verhaal 
in PLoS ONE hebben kunnen publiceren. Hopelijk volgt het UL33 verhaal snel!
Jib, Anne en Herman thank you for being such good labmates and I hope that I 
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wasn’t too much of annoyance with my sometimes somewhat dirty bench. Jib and 
Herman, we shared our office space for a while until one (Jib) left the lab and the 
other (Herman) moved to another room. Thank you for the fun moments even if it 
was for only a short time. Kim, jij was mijn wat langere termijn kantoorgenoot en 
we hebben altijd veel lol gehad in ons kantoortje. Hoewel we allebei een andere 
tak van wetenschapssport beoefenen konden we het altijd goed met elkaar vinden 
en heb ik veel aan jouw tips en trucs gehad. Ken, you were the last addition to 
our office. Thank you for the fun and for bringing sometimes strange candy, also 
thanks for teaching me how to swear in Cantonese.
Verder wil ik Jan-Paul, Saskia, Obbe en Leontien bedanken voor hun geweldige 
ondersteuning van het lab zowel op technisch gebied als op sociaal gebied. Zonder 
goede analisten kan geen enkel lab draaien en jullie waren/zijn geweldig.
Mijn AIO generatiegenoten: Anne, Danny en Petra moet ik natuurlijk ook opnoe-
men. Danny, de metro rit met jou en Marco was zoals eerder gezegd een mooi 
einde van de dag. Petra, onze jaarlijkse carpool naar de FIGON dagen was op het 
einde bijna een traditie aan het worden. Ook de warme chocolade melk voor 
Sinterklaas was een leuk initiatief. Anne, wij hebben lange tijd N249 (ik hoop dat ik 
het kamer nummer goed heb) gedeeld en konden altijd prima met elkaar opschi-
eten, hoewel ik soms wel jaloers was op jouw keurig nette bench.
De next gen AIOs Azra, Sabrina en Saskia. Het was leuk om jullie te zien door-
stromen van de laatste fases van jullie studie naar een AIO plek. De lunches en 
koffiepauzes waren altijd gezellig, helemaal met de baklava van Azra. Veel geluk 
met het afronden van jullie promoties!
De rest van de collega’s: Dennis, Henry, Sven, Marola, Anitha, Iwan, Maikel, Chris, 
Luc, Rogier, Mark, Oscar, Ewald, Andrea, Laura, Cindy en wie ik verder nog mogelijk 
ben vergeten, bedankt voor gezelligheid tijdens de koffie, lunch en borrels. 
Cecilia and Maral, thank you for the hospitality in Stockholm. Although I was there 
for only one week, we made sure it counted and the data we obtained was instru-
mental for the STAT3 paper.
Ik heb behoorlijk wat studenten in de loop der tijd begeleid en die wil ik graag alle-
maal bedanken. Ik hoop dat ik niemand vergeet, maar mocht dat zo zijn dan alvast 
mijn excuses. Dewy, Loes, Laura, Robert-Jan, Francisca, Mark, Martin, Hanneke, 
Claire, Selina, Maaike, Mirjam, en Ilse. Bedankt voor jullie inzet en bijdrages, waar-
van er een aantal uiteindelijk in papers of dit proefschrift terecht zijn gekomen. Ik 
heb op mijn beurt veel van jullie geleerd over leiding en lesgeven.
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Although it was not a part of my Phd, I would like to thank the people that I 
worked with during my time at Mount Sinai in New York. Sergio, thank you for 
giving me the opportunity to work in your lab and for encouraging me to be more 
organized, which truth be told I could definitely use sometimes. I learned a lot of 
techniques which will really help me a lot in the rest of my scientific career. I had a 
great time living and working in New York, which was a great professional and per-
sonal experience. Glaucia, Michelle, Luciana, Monique, Lily, Alice, and Alan thank 
you for all the help and fun in and outside of the lab. I will most definitely come 
visit New York again as a tourist. Gerold, ook jij heel erg bedankt voor de hulp toen 
ik net was gearriveerd. Ik hoop dat je het nog lang naar je zin hebt in New York en 
ik zie je vast nog wel eens in Nederland of in New York.
Zonder ondersteuning van het thuisfront had ik het natuurlijk nooit gered en 
daarom wil graag Daniel, Bas, Jeroen en Jelger bedanken. Jullie zijn al sinds lange 
tijd goede vrienden en de avonden uit, korte vakanties en vis avonturen zijn altijd 
fantastisch geweest om even te ontspannen. Dat heb ik zeker gemist tijdens mijn 
tijd in Amerika en moeten we zeker inhalen de komende tijd.
Als laatste bedank ik mijn ouders en mijn broertje natuurlijk. Pap, Mam en Bart, 
bedankt voor jullie ondersteuning ook al was het soms lastig uit te leggen wat 
ik nou precies deed. Zonder jullie steun had ik dit nooit kunnen doen, heel erg 
bedankt daarvoor!
